(19)

(12)





C07K 14/46 (2006.01)

(11) **EP 3 782 465 A1**

EUROPEAN PATENT APPLICATION

(51) Int Cl.:

(72) Inventors:

A01K 67/027 (2006.01)

SEYFRIED, Salim

13127 Berlin (DE)

• RÖDEL, Claudia Jasmin

Kurfürstendamm 54/55

10707 Berlin (DE)

(74) Representative: Hertin und Partner

Rechts- und Patentanwälte PartG mbB

14469 Potsdam (DE)

- (43) Date of publication: 24.02.2021 Bulletin 2021/08
- (21) Application number: 19193235.9
- (22) Date of filing: 23.08.2019
- (84) Designated Contracting States:
 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States:
 BA ME Designated Validation States:
 KH MA MD TN
- (71) Applicant: Universität Potsdam 14469 Potsdam (DE)

(54) TRANSGENIC FISH MODEL FOR STROKE

(57) The invention relates to a transgenic fish lacking at least one endogenous functional protein required for a functional CCM complex, comprising an exogenous nucleic acid encoding a functional version of said at least one protein under the transcriptional control of an endocardium-specific genetic system, wherein said at least one protein required for a functional CCM complex can be selected from the group comprising CCM1 (KRIT1), CCM2, CCM3, and Heg1. In embodiments, the transgenic fish comprises a cardiovascular system with a heart that produces blood flow, and develops vascular lesions in cerebellar blood vessels, in particular in lowly perfused cerebellar blood vessels. The invention also relates to a method for measuring a pharmacological effect of a drug, comprising contacting a transgenic fish according to any one of claims 1 to 10 with a drug, and measuring a pharmacological effect of the drug, wherein the effect of the drug may be an effect on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke. Furthermore, the invention comprises various uses of the transgenic fish of the invention.

Printed by Jouve, 75001 PARIS (FR)

Description

[0001] The invention relates to a transgenic fish lacking at least one endogenous functional protein required for a functional CCM complex, comprising an exogenous nucleic acid encoding a functional version of said at least one protein under the transcriptional control of an endocardium-specific genetic system, wherein said at least one protein required for a functional CCM complex can be selected from the group comprising CCM1 (KRIT1), CCM2, CCM3, and Heg1. In embodiments, the transgenic fish comprises a cardiovascular system with a heart that produces blood flow, and develops

vascular lesions in cerebellar blood vessels, in particular in lowly perfused cerebellar blood vessels. The invention also

relates to a method for measuring a pharmacological effect of a drug, comprising contacting a transgenic fish according to any one of claims 1 to 10 with a drug, and measuring a pharmacological effect of the drug, wherein the effect of the drug may be an effect on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke. Furthermore, the invention comprises various uses of the transgenic fish of the invention.

BACKGROUND

15

5

[0002] Stroke is a major unresolved medical problem. Therefore, assays that can contribute to the elucidation of the mechanisms and enable the testing of active substances, for example, are urgently required. Since strokes are usually caused by multiple factors, the production of such animal models is very difficult.

- [0003] Cerebral cavernous malformation (CCM) is a vascular disease with a prevalence of 0.4 to 0.5 percent of the total population. The familiar form of the disease is caused by a two-hit mechanism (Knudson, 1971) in which heterozygous carriers with a heterozygous germline mutation in one of the genes CCM1/KRIT1 (Duboysky et al., 1995), CCM2/MGC4607 or CCM3/PDCD10 (Craig et al., 1998) acquire another somatic mutation in the other allele (Akers et al., 2009). The CCM defects occur mainly within the cerebral capillary vasculature and are characterized by a mulberry-like appearance. Clinical symptoms range from neuronal defects such as seizures and headaches to hemorrhagic strokes
- ²⁵ (Spiegler et al., 2018). Symptomatic cavernomas can be surgically resected, but this is not always possible due to the location and accessibility of the lesion. Other therapeutic measures are not available.
 [0004] Hemodynamic forces play an important role in the development of the entire circulatory system. The biomechanical effect of the blood flow plays a central role here. Blood flow gradually decreases with distance to the heart. Thus, endothelial cells of different vascular beds are exposed to different graduations of biomechanical stress induced
- ³⁰ by blood flow. Endothelial cells therefore respond to different biomechanical demands and activate signal transduction pathways which have effects on cell orientation, migration and proliferation (Baeyens et al., 2016a). Pathological changes in biomechanical signal transduction pathways and abnormal patterns of blood flow have already been associated with etiologies of various blood vessel diseases (Baeyens et al., 2016b), including cerebral cavernous malformations (CCM) (Macek Jilkova et al., 2014; Mleynek et al., 2014; Renz et al., 2015).
- ³⁵ **[0005]** Several indications suggest a central role of blood flow in the etiology of CCMs: i) CCM lesions mostly occur in venous vessels that are predominantly weakly supplied with blood (Chohan et al., 2018). ii) The loss of CCM protein function causes upregulation of blood flow sensitive factors KLF2 and KLF4, which act as mediators of biomechanical signals in endothelial cells (Renz et al., 2015;). iii) Switching off the Klf2a/b expression causes a rescue of cardiovascular defects in zebrafish CCM mutants (Renz et al., 2015). iv.) In conditional endothelial CCM/ or CCM2 knock-out mice, the
- formation of cerebrovascular lesions is suppressed by KLF2/4 knock-outs (Zhou et al., 2015; Cuttano et al., 2016; Zhou et al., 2016). v.) The blood pressure regulating substance propanolol reduces CCM lesion exposure in patients (Reinhard et al., 2016; Zabramski et al., 2016) and suppresses the *ccm2* mutant embryonic phenotype in zebrafish (Offen et al., 2018).
- [0006] In the zebrafish animal model of cerebral cavernomas, a complete loss of CCM protein function causes developmental defects in the entire cardiovascular system (Mably et al., 2006; Kleaveland et al., 2009; Renz et al., 2015). These defects lead, among other things, to the loss of cardiac function and thus the blood flow is missing as an essential stimulus for normal development of the cardiovascular system. According to this, it has not been possible to reproduce blood flow-dependent hemorrhagic conditions in zebrafish as they occur in CCM patients. However, this is an essential prerequisite for a comprehensive investigation of CCM protein-deficient endothelial cells and their defects and the causes of CCM-related cerebral hemorrhages.

[0007] In the CCM animal model of the mouse, conditionally induced knock-outs can be used to generate post-natal lesions in the cerebral vasculature. However, due to the high workload and costs involved, the mouse is not a suitable model for systematically screening for new active substances for the cure or treatment of CCM. In comparison the Zebrafish is clearly more advantageous. In zebrafish, large quantities of experimental embryos can be created and examined in parallel at relatively low cost.

[0008] Accordingly, there remains a strong need in the art for the provision of a suitable animal model that can be used for investigating the pathological mechanisms leading to stroke and related diseases, such as the formation of vascular lesions and the development of cerebellar cavernous malformation, as well as for testing or measuring the

effect of drug candidates for the treatment of stroke or related diseases.

SUMMARY OF THE INVENTION

⁵ **[0009]** In light of the prior art the technical problem underlying the present invention is the provision of an improved animal model for studying stroke and related diseases including vascular malformations. This problem is solved by the features of the independent claims. Preferred embodiments of the present invention are provided by the dependent claims.

Embodiments relating to a transgenic fish of the invention

10

50

[0010] The invention therefore relates to a transgenic fish lacking at least one endogenous functional protein required for a functional CCM complex, comprising an exogenous nucleic acid encoding a functional version of said at least one protein under the transcriptional control of an endocardium-specific genetic system.

- **[0011]** In embodiments, the transgenic fish of the invention is a zebrafish.
- ¹⁵ **[0012]** The transgenic fish of the invention can be used as a model system for studying stroke and other diseases involving vascular lesions. For example, the transgenic fish can be used as a tool in the search for drugs or active substances to be used in stroke patients, for example for treatment of prevention of stroke. The invention represents a genetic animal model, for example in the zebrafish embryos, in which pathological changes and hemorrhagic bleeding occurs in the vasculature and serves as a model for stroke and other diseases associated with vascular lesions, such
- as CCM. Due to its small size of only a few millimeters and its extrauterine development, the zebrafish embryo is excellently suited for pharmacological drug discovery. This animal model can be used for the targeted investigation and/or testing of drugs that have an effect on the formation of vascular lesions and potentially suppress hemorrhagic stroke.

[0013] The invention is based on the entirely surprising finding that the expression of a functional protein required for

- the formation of a functional CCM complex, such as a CCM protein (such as CCM1, CCM2, CCM3 or Heg1, for example) in the endocardium of a mutant that lacks the respective endogenous functional protein required for a functional CCM complex, restores heart development and leads to establishment of apparently normal blood flow. However, in such transgenic fish and embryos bleeding in the cerebral blood vessels, which are deficient in CCM protein, can be detected. The phenotype occurring in the transgenic fish of the present invention with cerebellar hemorrhage resembles to the
- 30 phenotype of hemorrhagic stroke and other disease associated with vascular lesions, in particular cerebral vascular lesions.

[0014] In the transgenic fish described herein, pharmacological or genetic investigations on the development of strokes as well as possibilities for the prevention and treatment of hemorrhagic stroke can be carried out.

- [0015] In addition, the transgenic fish described herein, can be used to study the formation of vascular malformations and to study the interactions between endothelial cells with neighboring cells including cells of the immune system, pericytes, and vascular smooth muscle cells. These interactions can also be subjected to pharmacological or genetic investigations to elucidate potential roles of cell-cell communication in the development of strokes as well as to assess possibilities for the prevention and treatment of hemorrhagic stroke or vascular malformations.
- [0016] In further embodiments of the invention, the at least one protein required for a functional CCM complex is selected from the group comprising CCM1 (KRIT1), CCM2, CCM3, and Heg1.
- **[0017]** The term "protein required for a functional CCM complex" relates to any protein that needs to be present and functional for the formation of a functional CCM complex. Such proteins have been described in the art, as for example by Kleaveland et al. (Nat Med. 2009 Feb;15(2):169-76. doi: 10.1038/nm.1918. Epub 2009 Jan 18), among others, and is therefore a clearly defined term as understood by a skilled person, as will be explained in the detailed description below.
- 45 [0018] Furthermore, in the context of the invention the at least one protein required for a functional CCM complex is CCM1. Additionally, the fish lacking at least one endogenous functional protein required for a functional CCM complex may be a zebrafish carrying a loss-of-function allele of *krit1*, such as a *krit1^{ty219c}* allele, preferably a zebrafish homozygously carrying a loss-of-function allele of *krit1*, such as a *krit1^{ty219c}* allele.

[0019] Loss-of-function alleles of *krit1* that can be used in the context of the invention comprise ty219c, m775, s234,s610,t26458 and sa44926.

[0020] In embodiments of the transgenic fish, lack of the least one endogenous functional protein required for a functional CCM complex is due to a knock down of expression by an antisense oligonucleotide, preferably an antisense oligonucleotide Morpholino, or another method of inactivating the gene function known to the person skilled in the art. **[0021]** In the context of the invention, the endocardium-specific genetic system can comprise a Gal4-UAS system,

⁵⁵ wherein the Gal4-UAS system comprises a Gal4 gene, preferably Gal4ff, under the control of an endocardium-specific transcriptional regulator, such as an endocardium-specific promoter, and a nucleic acid sequence encoding said functional protein required for a functional CCM complex under the control of a UAS region. The use of the Gal4-UAS system is particularly advantageous, since established Gal4-lines can be combined with newly developed lines expressing the

gene for transgenic expression under the control of a UAS element. Such lines can be crossed to the Gal4-line and lead to specific conditional gene expression.

[0022] As used herein, the use of the term "endocardium-specific" in the context of a genetic system, a transcriptional regulator, a promoter, an enhancer, a promoter/enhancer combination or the like relates to a genetic element that drives

- ⁵ or activates gene expression in endocardial cells, whereas it is not activated and does not drive gene expression in (other) endothelial cells or other cells of the cardiovascular system. Endocardial cells as used herein can be regarded as a specific subtype of endothelial cells, that differ from endothelial cells by expression of certain endocardial-specific genes.
- [0023] In embodiments, the endocardium-specific genetic system can comprise or consist of a endocardium-specific
 promoter or a genetic element that directly drives expression of said functional protein required for a functional CCM complex.

[0024] For example, in embodiments comprising a Gal4-UAS system the endocardium-specific expression of the Gal4 gene can be driven by an nfatc1 promoter. Furthermore, in the context of the invention endocardium-specific expression of the said functional protein required for a functional CCM complex can be driven directly by an *nfatc1* promoter. Further

- promoters that can be used in the context of the invention for endocardium-specific expression comprise the *spp1*-promoter and/or genetic elements controlling *spp1* in a fish, such as a zebrafish.
 [0025] In embodiments of the invention, the functional version of said at least one protein is a fusion protein of the at least one functional protein and a reporter protein, such as a fluorescent reporter protein, such as for example mCherry, EGFP or any other fluorescent or chemiluminescent or otherwise traceable protein suitable for fusion to said protein
 - [0026] Accordingly, the nucleic acid sequence encoding the functional version of said at least one protein can be fused to a nucleic acid sequence of a reporter gene encoding a reporter protein. The resulting expression of a fusion protein of the at least one functional protein and a reporter protein may represent a function version of protein required for a
- functional CCM complex.
 [0027] The transgenic fish of the invention is preferably characterized in that it comprises a cardiovascular system with a heart that produces blood flow, and wherein said fish develops vascular lesions in cerebellar blood vessels, in particular in lowly perfused cerebellar blood vessels.

[0028] In embodiments, the transgenic fish comprises a functional cardiovascular system with a heart that produces blood flow within an endothelium, functional endothelial cells of the lateral dorsal aorta and/or lumenized intersegmental

30 vessels, and wherein said fish develops vascular lesions in cerebellar blood vessels, in particular in lowly perfused cerebellar blood vessels.

[0029] In the context of the invention, the vascular lesions developed by the transgenic fish can be visualized. Preferably, the transgenic lesions can be visualized by a traceable reagent injected into the cardiovascular system of said transgenic fish, such as a traceable dye or labeled nanobeads, such as a fluorescent dyes or fluorescent nanobeads, for example by microangiography.

[0030] Furthermore, the lesions may be visualized by using a transgenic fish additionally expressing fluorescentlylabelled blood proteins or blood cells. For example transgenes expressing fluorescently-labelled vitamin D-binding protein (VDBP), such as a green fluorescent protein (GFP)-tagged VDBP. Furthermore, the transgenic zebrafish line Tg(gata1 a:DsRed) or similar lines expressing fluorescently labelled blood cells may be used and can be selected by a skilled

- 40 person. Further methods of visualizing vascular lesions in a transgenic fish are known to a person skilled in the art. [0031] In the context of the invention, the transgenic fish can be at a stage of development selected from the group consisting of an embryo stage, a larva stage, and an adult stage.
 - Embodiments relating to use of a transgenic fish of the invention and methods employing a transgenic fish of the invention

[0032] The invention further relates to a method for measuring a pharmacological effect of a drug, comprising

- contacting a transgenic fish of the present invention with a drug, and
- ⁵⁰ measuring a pharmacological effect of the drug.

20

35

45

[0033] In the context of the method for measuring (or testing) a pharmacological effect of a drug as disclosed herein, the pharmacological effect of the drug is an effect on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke.

⁵⁵ **[0034]** In this context, the pharmacological effect of the drug can be measured by comparing the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke in the transgenic fish contacted with the drug to the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of cerebellar cavernous malformation and/or the development of stroke in a transgenic fish of the invention not contacted with said drug.

[0035] As used herein, the term "drug" relates to any compound, such as a biological or chemical molecule, such as a small molecule, a protein, a nucleic acid or any other compound that can be envisioned to be used as a drug in the treatment of a patient.

[0036] In the context of the invention, "contacting" a transgenic fish with a drug or compound comprises incubation of

5 the fish in a suitable medium comprising said compound, but also any other form of administration of said compound to the transgenic fish comprising feeding/oral administration and injection, such as injection into a body cavity or into the blood stream or into a tissue. Suitable routes of administration are known to a skilled person.

[0037] The invention further relates to use of a transgenic fish of the present invention as a model for the treatment and/or prevention of vascular lesions, cerebellar cavernous malformation and/or stroke.

- 10 [0038] Furthermore, the invention comprises the use of a transgenic fish of the invention in a method of screening a compound for an effect on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke, the method comprising
 - contacting said transgenic fish to a compound and
- 15
- measuring the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke.
- [0039] In the method of screening a compound for an effect on the formation of vascular lesions, the development of 20 cerebellar cavernous malformation and/or the development of stroke the measuring of the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke may comprise comparing the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke in the transgenic fish contacted with the compound to the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke in a transgenic fish of the invention not contacted with said 25
- compound.

[0040] Further uses of the transgenic fish of the invention can be envisioned by the person skilled in the art. This includes use of the transgenic fish for various research purposes such as studying the mechanisms leading to the development of vascular lesions.

[0041] The various embodiments and features of the transgenic fish of the invention disclosed herein also apply to 30 the various embodiments of the methods and uses employing such a transgenic fish presented herein, and vice versa.

DETAILED DESCRIPTION OF THE INVENTION

[0042] All cited documents of the patent and non-patent literature are hereby incorporated by reference in their entirety.

35 [0043] The present invention relates to a transgenic fish, methods involving said transgenic fish and the use of said transgenic fish of the invention.

[0044] As used herein, "transgenic fish" refers to fish, or progeny of a fish, into which an exogenous nucleic acid (which may also be referred to as an exogenous construct in the context of the invention) has been introduced. A fish into which a construct has been introduced includes fish which have developed from embryonic cells into which the construct has

- 40 been introduced. As used herein, an exogenous construct can be a nucleic acid that is artificially introduced, or was originally artificially introduced, into an animal. The term artificial introduction is intended to exclude introduction of a construct through normal reproduction or genetic crosses. That is, the original introduction of a gene or trait into a line or strain of animal by cross breeding is intended to be excluded. However, fish produced by transfer, through normal breeding, of an exogenous construct (that is, a construct that was originally artificially introduced) from a fish containing
- 45 the construct are considered to contain an exogenous construct. Such fish are progeny of fish into which the exogenous construct has been introduced. As used herein, progeny of a fish are any fish which are descended from the fish by sexual reproduction or cloning, and from which genetic material has been inherited. In this context, cloning refers to production of a genetically identical fish from DNA, a cell, or cells of the fish. The fish from which another fish is descended is referred to as a progenitor fish. As used herein, development of a fish from a cell or cells (embryonic cells, for example),
- 50 or development of a cell or cells into a fish, refers to the developmental process by which fertilized egg cells or embryonic cells (and their progeny) grow, divide, and differentiate to form an adult fish. [0045] The invention relates to any type of fish suitable for transgenic manipulation and introduction of exogenous nucleic acids. As used herein, fish refers to any member of the classes collectively referred to as pisces. It is preferred that fish belonging to species and varieties of fish of commercial or scientific interest be used. Such fish include salmon,
- 55 trout, tuna, halibut, catfish, zebrafish, medaka, carp, tilapia, goldfish, and loach. [0046] A preferred fish for use with the disclosed constructs and methods is zebrafish, Danio rerio. Zebrafish are a popular experimental animal since they have many of the advantages of popular invertebrate experimental organisms, and include the additional advantage that they are vertebrates. Another significant advantage of zebrafish for the study

of development and cell lineages is that, like *Caenorhabditis*, they are largely transparent (Kimmel, Trends Genet 5:283-8 (1989)). The generation of thousands of zebrafish mutants (Driever et al., Development 123:37-46 (1996); Haffter et al., Development 123:1-36 (1996)) provides abundant raw material for transgenic study of these animals. General zebrafish care and maintenance is described by Streisinger, Natl. Cancer Inst. Monogr. 65:53-58 (1984).

- [0047] Zebrafish embryos are easily accessible and nearly transparent. Given these characteristics, a transgenic zebrafish embryo, carrying a construct encoding a reporter protein and tissue-specific expression sequences, can provide a rapid real time *in vivo* system for analyzing spatial and temporal expression patterns of developmentally regulated genes. In addition, embryonic development of the zebrafish is extremely rapid. In 24 hours an embryo develops rudiments of all the major organs, including a functional heart and circulating blood cells (Kimmel, Trends Genet 5:283-8 (1989)).
 Other fish with some or all of the same desirable characteristics are also preferred.
- [0048] As used herein, "nucleic acid" shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids or modified variants thereof. An "exogenous nucleic acid" or "exogenous genetic element" or "exogenous construct" relates to any nucleic acid introduced into the cell, which is not a component of the cells "original" or "natural" genome or transcriptome. Exogenous nucleic acids may be integrated or non-integrated in the genetic material of the transition of the cells for the integrated to the transition of the cells.
- ¹⁵ target cell of the fish of the invention, or relate to stably transduced nucleic acids. [0049] Any given suitable delivery method for providing exogenous nucleic acids to cells of fish of the invention is encompassed by the invention. The transgenic fish of the invention can be produced by introducing a transgenic construct into cells of a the fish, such as a zebrafish, preferably embryonic cells, and most preferably in a single cell embryo, essentially as described in Meng et al. (1998). The transgenic construct is preferably integrated into the genome of the
- 20 zebrafish, however, the construct can also be constructed as an artificial chromosome. [0050] The exogenous nucleic acids, which may be recombinant constructs, can be introduced into fish, preferably embryonic fish cells, using any suitable technique known in the art or later developed for the introduction of transgenic constructs. For example, microinjection, electroporation, liposomal delivery and particle gun bombardment can all be utilized to effect transgenic construct delivery to embryonic cells as well as other methods standard in the art for delivery
- of nucleic acids to zebrafish embryos or embryonic cells. Further included are microinjection (described by, for example, Culp et al. (1991) Proc Natl Acad Sci USA 88, 7953-7957), electroporation (described by, for example, Inoue et al. (1990), Cell. Differ. Develop. 29, 123-128; Muller et al. (1993), FEBS Lett. 324, 27-32; Murakami et al. (1994), J. Biotechnol. 34, 35-42; Muller et al. (1992), Mol. Mar. Biol. Biotechnol. 1, 276-281; and Symonds et al.(1994), Aquaculture 119, 313-327), particle gun bombardment (Zelenin et al. (1991), FEBS Lett. 287, 118-120), retroviral vectors (Lu et al (1997).
- Mol Mar Biol Biotechnol 6, 289-95), and the use of liposomes (Szelei et al. (1994), Transgenic Res. 3,116-119).
 [0051] Zebrafish embryos can be obtained by mating adult zebrafish in specially designed mating tanks. Eggs are usually laid in the morning and are collected immediately so that they can be microinjected at the one cell stage. Embryonic cells can be obtained from zebrafish as described by Fan et al. (2004). Zebrafish containing a transgene can be identified by numerous methods such as probing the genome of the zebrafish for the presence of the transgene construct by
- ³⁵ Northern or Southern blotting. Polymerase chain reaction techniques can also be employed to detect the presence of the transgene.

[0052] In one embodiment, a transgenic fish of the present invention is one whose somatic and germ cells contain at least one genomically integrated copy of a recombinant construct of the invention. In another embodiment, the exogenous construct (exogenous nucleic acid) may not be integrated into the genome of the fish. The invention further provides a

- 40 transgenic fish gamete, including a transgenic fish egg or sperm cell, a transgenic fish embryo, and any other type of transgenic fish cell or cluster of cells, whether haploid, diploid, triploid or other zygosity, having at least one copy of an exogenous nucleic acid of the present invention, which may be genomically integrated. [0053] The "Tol2 transposon system" to generate transgenic zebrafish is known in the art (Kawakami, K. Genome
- Biol.; 8(Suppl 1): S7 (2007)). The medaka fish Tol2 element is an autonomous transposon that encodes a fully functional
 transposase. The transposase protein can catalyze transposition of a transposon construct that has 200 and 150 base
 pairs of DNA from the left and right ends of the Tol2 sequence, respectively. These sequences contain essential terminal
 inverted repeats and subterminal sequences. DNA inserts of fairly large sizes (as large as 11 kilobases) can be cloned
 between these sequences without reducing transpositional activity.
- [0054] As used herein, the term "fish" comprises the embryo stage, larva stage and adult stage of the fish. The term "embryo" includes a single cell fertilized egg (i.e., a zygote) stage of the organism. In particular, the recombinant construct is integrated into the fish's somatic and germ cells such that it is stable and inheritable (is stably transmitted through the germ line). The transgenic fish or fish cell preferably contains a multiplicity exogenous nucleic acids or constructs, which may be genomically integrated.
- [0055] Progeny of the transgenic fish of the invention, and transgenic fish derived from a transgenic fish egg, sperm, embryo or other fish cell of the present invention, are also included in the present invention. A fish is "derived from" a transgenic fish egg, sperm cell, embryo or other cell if the transgenic fish egg, sperm cell, embryo or other cell contributes DNA to the fish's genomic DNA. For example, a transgenic embryo of the present invention can develop into a transgenic fish of the present invention; a transgenic egg of the present invention can be fertilized to create a transgenic embryo

of the present invention that develops into a transgenic fish of the present invention; a transgenic sperm cell of the present invention can be used to fertilize an egg to create a transgenic embryo of the present invention that develops into a transgenic fish of the present invention; and a transgenic cell of the present invention can be used to clone a transgenic fish of the present invention. In some embodiments of the present invention, the transgenic fish is sterile.

⁵ The present invention further includes a cell line derived from a transgenic fish embryo or other transgenic fish cell of the present invention, which contains at least one copy of a recombinant construct of the present invention. Methods of isolating such cells and propagating them are conventional. **100561** In one embediment, the disclosed transgenic fish of the present invention are produced by introducing a recombinant construct of the present invention.

[0056] In one embodiment, the disclosed transgenic fish of the present invention are produced by introducing a recombinant construct of the present invention into cells of a fish, particularly into embryonic cells, and more particularly into a single cell embryon. Where the transports construct is introduced into embryonic cells, and more particularly

- ¹⁰ into a single cell embryo. Where the transgene construct is introduced into embryonic cells, the transgenic fish is obtained by allowing the embryo to develop into a fish. Introduction of constructs into embryonic cells of fish, and subsequent development of the fish, are simplified by the fact that embryos develop outside of the parent fish. [0057] Embryos or embryonic cells can generally be obtained by collecting eggs immediately after they are laid. It is generally preferred that the eggs be fertilized prior to or at the time of collection. This is particularly accomplished by
- ¹⁵ placing a male and female fish together in a tank that allows egg collection under conditions that stimulate mating. After collecting eggs, one technique is that the embryo be exposed for introduction of genetic material by removing the chorion. This can be done manually or, particularly, by using a protease such as pronase. A fertilized egg cell prior to the first cell division is considered a one-cell embryo, and the fertilized egg cell is thus considered an embryonic cell. [0058] After introduction of the transgene construct, the embryo is allowed to develop into a fish. This generally need
- 20 involve no more than incubating the embryos under the same conditions used for incubation of eggs. However, the embryonic cells can also be incubated briefly in an isotonic buffer. If appropriate, expression of an introduced transgene construct can be observed during development of the embryo.

[0059] Fish harboring a transgene can be identified by any suitable means. For example, the genome of potential transgenic fish can be probed for the presence of construct sequences. To identify transgenic fish actually expressing

- the transgene, the presence of an expression product can be assayed. Several techniques for such identification are known and used for transgenic animals and most can be applied to transgenic fish. Probing of potential or actual transgenic fish for nucleic acid sequences present in or characteristic of a transgene construct can be accomplished by Southern or Northern blotting. Also, detection can be achieved using polymerase chain reaction (PCR) or other sequencespecific nucleic acid amplification techniques. Furthermore, the transgenic constructs/exogenous nucleic acids intro-
- ³⁰ duced into the fish of the invention may comprise reporter genes, such as fluorescent reporter genes, which are expressed in visible locations of the fish, as for example the eye. Examples of such tissue specific reporter genes for identification of transgenic fish are known to the person skilled in the art, such as for example cryaa:EGFP, where the fluorescent reporter protein EGFP is expressed under the control of the lens specific promoter of the cryaa gene of zebrafish. [0060] After "founder" transgenic fish are identified, one can mate them to wild type fish to identify those fish which
- 25 comprise the transgene in their germ cells. Transgenic fish of the present invention can be either male or female. A transgenic fish of the present invention can be hemizygous for the transgene, which is a particular state for maintenance of transgenic fish lines. Alternatively, hemizygous fish can be crossed with each other to produce homozygous fish or fish lines.

[0061] The transgenic fish of the invention lack at least one endogenous functional protein required for a functional CCM complex.

[0062] Cerebral cavernous malformations (CCMs) are a common vascular malformation with a prevalence of 0.1%-0.5% in the human population. CCMs arise primarily in the brain as thin-walled, dilated blood vessels that cause seizures, headaches and stroke in midlife, often in association with focal hemorrhage. Familial CCM shows an autosomal dominant pattern of inheritance and is caused by loss-of-function mutations in three genes: KRIT1 (also known as CCM1), CCM2

- (also known as malcalvernin and osm) and PDCD10 (also known as CCM3). The CCM proteins are putative adaptor proteins that interact biochemically leading to the formation of a CCM complex and participate in a signaling pathway that is not yet fully characterized. A clue to the role of CCM protein signaling in the cardiovascular system comes from genetic studies in zebrafish, which reveal that loss of krit1, ccm2 or heg1 (encoding the type I transmembrane receptor heart of glass) results in a dilated heart phenotype early in development. This phenotype is characterized by heart failure
- ⁵⁰ associated with enlarged cardiac chambers in which the endocardium is covered by a thin layer of myocardial cells. Heg1 has been shown to also interact with the CCM complex comprising CCM1, CCM2 and/or CCM3 and functional Heg1 is required for a functional CCM complex. Expression of heg1, krit1 and ccm2 mRNA has been detected in the endocardium, but not the myocardium, of zebrafish embryos, suggesting that these proteins operate in an endothelial cell-autonomous signaling pathway. The involvement of CCM1-3 and Heg1 in the formation of a CCM phenotype and
- ⁵⁵ the formation of a functional CCM complex has been describe in detail in the literature, for example by Kleaveland et al. (Nature Medicine, VOLUME 15, NUMBER 2, FEBRUARY 2009, pp. 169-176) and Spiegeler et al. (Mol Syndromol 2018;9:60-69).

[0063] Signaling through the HEG1 receptor and the CCM proteins of the CCM complex is required to regulate en-

dothelial cell-cell association during formation of the cardiovascular system and for its integrity thereafter. Accordingly, loss of function of at least one of Heg1, CCM1, CCM2 and CCM3 leads to a malfunction of the CCM complex and to malformation of the components of the cardiovascular system, such as failure of nascent endothelial cells, defects in the heart, the aorta, lymphatic vessels, abnormal endothelial cell junctions, dilated heart phenotype early in development,

- ⁵ heart failure associated with enlarged cardiac chambers in which the endocardium is covered by a thin layer of myocardial cells. In the context of the present invention, a protein required for a functional CCM complex includes Heg1, CCM1, CCM2 and CCM3 and any other protein known by the skilled person or that will be identified as being required for a functional CCM1 complex.
- [0064] CCM3 is encoded by two paralog genes ccm3a (pdcd10a) and ccm3b (pdcd10b) encoding the corresponding protein versions CCM3a and CCM3b. The paralog genes ccm3a and ccm3b have 83 % sequence homology and protein function of CCM3a and CCM3b are redundant. Accordingly, in case of a lack of a functional endogenous CCM3, both versions of the protein have are lacking, for example due to inactivation of both genes ccm3a and ccm3b.
- [0065] In this context, a "functional" version of a protein is understood as any version of a protein that can fulfill a specific function. Accordingly, a functional protein or a functional version of a protein required for a functional CCM complex, such as for example a functional CCM1, relates to any version of a CCM1 protein that can support the function of the CCM complex. This may include mutated or truncated versions of the respective protein, for example CCM1, or version of the protein that have been fused to other proteinaceous components, such as a reporter protein.
- [0066] In cases where the functional protein required for a functional CCM complex is a fusion protein of for example a function CCM1 protein and a reporter protein, a suitable linker sequence can be used. A skilled person is aware of such linkers and can design linker sequences that enable flexibility between the components of the fusion protein and do not interfere with the function of the components.

[0067] In the context of the invention, an "endogenous" functional protein is a protein that is encoded by an endogenous nucleic acid of the cell of the transgenic fish. Accordingly, an endogenous protein is not encoded by an exogenous nucleic acid of the transgenic fish, but can be encoded and expressed from nucleic acids occurring naturally in the fish,

²⁵ irrespective of the introduced genetic modification, such as from a genomic DNA sequence or a mRNA sequence generated from genomic DNA. A fish that lacks an endogenous functional protein can comprise a functional version of said protein that is encoded and expressed from an exogenous nucleic acid. **20.101**

[0068] A fish lacking a functional endogenous protein required for a functional CCM complex comprises a modification, such as a genetic mutation, preventing the expression of a functional protein required a functional CCM complex, such as a function CCM1, CCM2, CCM3 or Heg1, from an endogenous nucleic acid sequence. Such modification, for example genetic mutations of the corresponding endogenous gene, are known to the person skilled in the art and can also be introduced into the genome of a fish, such as a zebrafish, by the skilled person.

30

[0069] For example, in the case of CCM1, also known as Krit1, many mutations of the endogenous *krit1* gene leading to lack of a functional endogenous Krit1 protein are known, such as for example the following *krit1*-alleles: ty219c, ty219c,

- ³⁵ m775, s234,s610,t26458, sa44926. Further loss of function alleles of *krit1* leading to malfunction of the CCM complex are known or can be designed. Similarly, suitable alleles or modification of other proteins required for a functional CCM complex such as Heg1, CCM2 and CCM3 can be identified or designed/developed by a skilled person.
 [0070] Furthermore, the lack of at least one endogenous functional protein required for a functional CCM complex, such as CCM1 (KRIT1), CCM2, CCM3, and Heg1, can be induced by other means than alteration of the genomic DNA,
- ⁴⁰ such as knock down of mRNA by use of antisense RNA molecules, such as antisense oligonucleotide Morpholino mediated knockdown or any other method known to the skilled person for inactivating gene function. Alternatively, it may be possible to use specific inhibitors of the respective at least one endogenous protein, while using a transgenic version that is not inhibited by said inhibitor. Further suitable approaches leading to a lack of an endogenous functional protein can be developed or identified by a skilled person.
- 45 [0071] These methods can involve a tissue-specific knock-out through the targeted insertion of recombination elements (e.g. Cre/Lox-Recombination system), for example via CRISPR/Cas9-mediated genome engineering. Another more tedious method of generating such a disease model is cell transplantation of krit1 mutant cells into the wild-type host embryos. These mutant cells will, in some instances, generate mutant clones in regions of the vasculature susceptible to the formation of vascular lesions or vascular malformations.
- 50 [0072] Furthermore, the transgenic fish of the invention comprise an exogenous nucleic acid encoding a functional version of said at least one lacking endogenous protein required for a functional CCM complex. Said function version of the protein is under the control of a endocardium-specific genetic system, leading to expression of the functional protein from the exogenous nucleic acid in cells where the endocardium-specific genetic system gets activated. Accordingly, in such cells the lack or loss of the endogenous functional protein can be complemented by expression of the functional version of said protein form the exogenous nucleic acid.
- **[0073]** The following *Table 1* contains preferred protein sequence of functional proteins required for a functional CCM complex to be comprised by the transgenic fish of the invention. *Table 2* contains preferred nucleic acid sequences that can be comprised by the exogenous nucleic acid of the transgenic fish of the invention. The amino acid sequence of

Table 1 correspond to the wild-type sequences of CCM1, CCM2, CCM3 (paralog versions a and b as encoded by the corresponding paralog genes) and Heg1. The corresponding nucleic acid sequences encoding these proteins are listed in *Table 2*. Furthermore, *Table 2* includes further preferred nucleic acid sequence that can be used in the context of the present invention.

5

 Table 1. Preferred amino acid sequences of the present invention.

	SEQ ID NO.	Amino Acid Sequence	Description
10	SEQ ID	MMGNQELEEVFVAVIRPKNTTSLNSKEYRAKSYEILLIEV	protein sequence of CCM1 (KRIT1)
	NO 1	PLEGKEKKRKKVLLGTKIHADSDRTKSILEFVDETTKPISN	
		NQGIIGKRVVHMRKFLLDGDSGGKEASLFIVPINVKDNSK	
		SVHHPGSPSFYCLQDIMRVCSETSAHFSSSTSKMLLALD	
15		KWLAEQHTVPHAIPALFRPAPVDRVKTNVSNPAYAVEKQ	
		TDGTLHMGYTALEIKSKLMSLEKADLCIQNPLYGSDLQYT	
		NRVDKVIINPYFGLGAPDYSKIQIPKRDKWQHSMTSVTED	
		KERQWVDDFPLHRSACEGDTELLSKLLDGGFSVKQLDS	
20		DHWAPIHYACWHGKVEATKLLLEKGNCNPNLLNGQLSS	
		PLHFAAIGGHAEIVQLLLQHPEIDRHIEDQQKRSPLQVCE	
		ENKQNNWEETVNLLQQASNKPYEKVRIYRMDGSYRSVE	
		LKHGNNTTVQQIMEGMRLSQETQQYFTIWICSENLSLQL	
25		KPYHKPLQHLRMWSEIVTDLTALDPQRESPQLFLRRDVR	
		LPLEVEKKVEDPLSILILFDEARHCLLKGFLSTSDNKLITLA	
		SLLLQIIYGNYDSKKHKQGFLNEENLKSIVPISKVKSKAHH	
20		WTNRILHEYKSLSTSEGVSKEMHHLQRLFLQNCWDIPTY	
30		GAAFFTGQVFTKASSSTHKVIRVYVGVNTKGLHLMNMET	
		KVLHLSLEYGTFMWQLGQADQYVQIHSLENKKNFVVHTK	
		QAGLIVKLLMKLSGQIAPNDRAVSDKYAYG	
35	SEQ ID	MEEDVKKVKKPGIVSPFKRVFLKGEKGRDKKALEKSTER	protein sequence of CCM2
	NO 2	RALHTFSLSLPDHRIDPDILLNDYIEKEVKYLGQLTSVPGY	
		LNPSSRTEVLQLIDNARKSHQLAGQLTSEQDAVVSLSAY	
		NVKLVWRDGEDIILRVPIHDIAAVSYIRDDSLHLVVLKTAQ	
40		EPGGSPCHSTEMSKSPTLSSLSESGAVLVEVCCLLVLAV	
		DNKAAAEELCLLLSQVFQIVYTESTIDFLDRAIFDGATTPT	
		RHLSIYSEDSSSKVDVKDVFEAEASTFSFQSSLEAGHSS	
		SPSPTSAPASPQTKTASESELSTTAAELLQDYMTTLRTKL	
45		SSKEIQQFATLLHEYRNGASIHEFCINLRQLYGDSRKFLLL	
		GLRPFIPEKDSQHFENFLETIGVKDGRGIITDSFGRYKRTT	
		SSASDSTTNGNGAAGGSDEGTATSEGDEWDRMISDISN	
		DIEALGSSMDQDGVPS	
50	SEQ ID	MTMEEMKNEADATSMVSMTLYAVMYPVFNELESVNLSA	protein sequence of Pdcd10a
	NO 3	AQTLRAAFKKAEKENPGLTQDIIMKILEKKNVEINFTESLL	(Ccm3a)
		RMAADDVEEYMIDRPEREFQDLNERARALKQILSKIPDEI	
		NDRVRFLQTIKDIASAIKELLDTVNNVFKKYQYQNRRALE	
55		HQKKEFVKHSKSFSDTLKTYFKDGKAINVFASANRLIHQT	
		NLILQTFKTVA	

(continued)

	SEQ ID NO.	Amino Acid Sequence	Description
5	SEQ ID	MTMEEMKNEAEPNSIVSMTLYAVMYPVFNELGRINPSAA	protein sequence of Pdcd10b
	NO 4	QTLRAAFVKAEKENPGLTQDIIMKILEKKNVEINFTESLLR	(Ccm3b)
		MAADDVEEYMIKRPEQEFQDLNEKARALKHILSKIPDEIN	
10		DRVRFLQTIKDIASAIKELLDTVNNVFRKYQYQNRRALEH	
10		QKKEFVKYSKSFSDTLKTYFKDGKAINVFISANRLIHQTNL	
		ILQTFKTVA	
	SEQ ID	MMETCARRVLFTAALLVLSTVIAETFSTDSDTDNPLSTET	protein sequence of Heg1
15	NO 5	FYSRTSGLKQTSSWPGREATATAVDLSSGLGEMTEIPAS	
		VSITAAREGHSPKPLQTSTNAADWKTSMTSDETTEHLQS	
		DTELTHNATAQWESPSSASHSITSHHPVTETRTVRDVTD	
		LIDMDTTDSVSHTDSTYISTTNRVGERTLLSVISNSTFAYT	
20		QNSSISDAESQTSPWEEKTSGATQVNEETEETVSTVSEQ	
		TDPTFEDRNITSATLETGRSTLFQGTESQTGQPSVTGQT	
		AKEVTDIDNPNSTPPLTVTSRDVEETDATSVSSETSYTQT	
		SSDSASSILPFTSSERNVTSTSQESHNSTLIYSTNTGGST	
25		EFSTGSVSSTAHEETERSSTQIVDETTLHDVTSAPPVLED	
		VATTIDDSLSKFPSGQSPTIPKTDDQTNTQVVPTSTHRPQ	
		VTDEATDEVSTVYSSTTTLTTTPSVTTRQLQPHHTTVET	
		QTQHTTIVTTDIIQVLRTTPSTAHHVPTSTTSGPQAPSTAD	
30		SSDVTTLHLETSTATPGNTTAHGGRATTPFSKSSPSRTT	
		VVVTTGHLTDKSTTETGSATTQMPLRTSASPGHVCGPKT	
		CANGGHCVRSAEGSYYCQCLSAWTGPFCTEDVDECVN	
		SPCPQGSVCVNTGGSFSCECDLGFDLEDGRSCTQVKTF	
35		LGTFTVNNSLHLRNLGLHELHREIQQLLNASLSIFHGYRR	
		FTLGKRDGQGVQIPVVSMFSLSSNVTSADVFNSIQMSLN	
		NCSRTYSHCPIKLQHQLSYHVESLCMAQKTKCDVQYSD	
40		CSDISGIPNCQCLPGYFKRNPEDMTCRDCGDGLKLVNG	
40		KCVECMFGFGGFNCNNFYKLIAVVVSPAGGALLLIVVIALI	
		VTCCKKDKNDINKIIFKSGELQMSPYAEFPKSNRVSMEW	
		GRETIEMQENGSTKNLLQMTDIYYSPALRNSDLERNGLY	
45		PFSGLPGSRHSCIYPAQWNPSFLSDDSRRRDYF	

50

	SEQ	Nucleic Acid Sequence	Description
	ID NO.		
5	SEQ	ATGATGGGAAACCAAGAGCTAGAGGAGGTGTTTGTTG	Coding nucleotide sequence of ccm1
	ID NO	CTGTTATCCGACCAAAAAACACAACCAGCCTCAACTCC	(krit1)
	0	AAAGAATACCGTGCTAAATCCTATGAGATTTTACTTATC	
10		GAAGTTCCCCTGGAGGGAAAAGAGAAAAAGCGGAAGA	
		AAGTGCTGCTTGGGACTAAAATCCACGCCGACAGTGA	
		CCGGACAAAGTCAATTCTGGAGTTTGTGGATGAAACCA	
		CCAAGCCCATATCCAATAACCAGGGCATAATAGGGAA	
15		GCGTGTCGTGCACATGAGGAAGTTCCTGTTAGATGGA	
		GACAGTGGAGGAAAAGAGGCCTCGTTATTTATTGTGC	
		CAATTAATGTCAAAGACAACAGCAAGTCCGTGCATCAC	
		CCTGGGAGCCCCAGTTTCTACTGCCTTCAGGACATCAT	
20		GCGTGTGTGTAGTGAAACCAGTGCTCATTTCTCCTCCA	
		GCACCTCAAAGATGCTGCTCGCTCTCGACAAGTGGTT	
		AGCGGAGCAGCACACTGTGCCTCACGCTATTCCTGCT	
		CTGTTCCGGCCGGCTCCGGTGGACCGTGTGAAAACTA	
25		ACGTGAGTAACCCGGCGTACGCAGTGGAGAAGCAGA	
		CAGACGGGACGCTGCACATGGGCTACACGGCTCTGG	
		AGATCAAGAGTAAACTGATGTCTCTGGAGAAAGCAGAT	
		CTGTGCATCCAGAACCCGCTGTACGGCTCAGATCTGC	
30		AGTACACCAACAGAGTGGACAAAGTCATCATCAACCCT	

Table 2. Nucleic acid sequence of the present invention.

	SEQ	Nucleic Acid Sequence	Description
5	ID NO.		
		TACTTTGGCTTGGGAGCTCCAGATTACTCCAAAATCCA	
		GATTCCAAAGAGAGACAAATGGCAGCACAGCATGACC	
		AGCGTCACCGAAGACAAAGAGCGCCAGTGGGTGGAT	
10		GATTTCCCTCTGCACCGAAGCGCCTGTGAGGGAGACA	
		CTGAGCTTTTGTCTAAATTGCTGGATGGCGGATTCTCA	
		GTCAAACAGCTGGACAGCGACCATTGGGCACCCATTC	
		ATTATGCATGCTGGCATGGGAAGGTGGAGGCCACTAA	
15		ACTGCTGCTGGAGAAAGGCAACTGTAACCCCAACCTG	
		CTGAACGGCCAGCTGAGCTCTCCTTTACACTTCGCAG	
		CTATCGGCGGTCATGCAGAAATCGTGCAGCTCCTCCT	
		GCAGCACCCAGAGATCGACAGACACATCGAGGACCAG	
20		CAGAAACGATCGCCGCTTCAAGTATGTGAAGAAAACAA	
		GCAGAACAACTGGGAGGAAACCGTGAATCTCCTTCAA	
		CAAGCCAGCAATAAACCATACGAGAAGGTGAGGATTT	
		ACCGTATGGATGGATCGTACCGCTCTGTGGAGCTGAA	
25		GCATGGGAACAACACCACCGTGCAGCAGATCATGGAG	
		GGCATGAGATTATCACAGGAGACCCAGCAGTATTTTAC	
		CATCTGGATCTGCTCCGAAAACCTTAGTCTGCAGCTGA	
		AGCCGTACCACAAGCCCTTGCAGCACTTACGGATGTG	
30		GAGCGAGATCGTGACGGATCTCACTGCTCTGGATCCA	
		CAGAGAGAAAGTCCACAGCTCTTCCTGCGCAGAGACG	
		TTCGGCTGCCTTTAGAGGTCGAGAAAAAGGTTGAAGA	
		TCCGCTGTCCATCCTCATCCTATTTGATGAAGCTCGTC	
35		ACTGCCTCCTTAAAGGTTTCCTCTCGACGTCAGATAAC	
		AAGCTAATCACGCTCGCAAGCCTCCTCCTGCAGATCAT	
		CTACGGAAACTACGACAGCAAGAAGCACAAACAGGGC	
10		TTTCTAAATGAGGAAAACCTGAAATCCATAGTTCCCATT	
40		TCAAAGGTCAAGAGCAAAGCACATCACTGGACTAACA	
		GGATACTTCACGAGTACAAGAGTCTGAGCACTAGTGA	
		GGGTGTGAGTAAAGAAATGCATCACCTCCAGAGGCTC	
45		TTCCTGCAGAACTGCTGGGATATTCCTACTTATGGTGC	
		AGCGTTTTTCACAGGACAGGTCTTCACTAAAGCCAGCT	
		CCAGCACACAAGGTGATCCGCGTGTATGTGGGCGT	
		CAACACCAAAGGCCTGCATCTGATGAACATGGAGACA	
50		AAAGTGCTTCACCTCAGTCTGGAGTATGGGACATTTAT	
		GTGGCAGCTGGGTCAGGCTGATCAATACGTGCAAATC	
		CACAGTCTGGAGAACAAGAAGAACTTTGTCGTTCACAC	
		CAAACAGGCTGGTCTTATCGTGAAGCTGCTGATGAAG	
55		CTGAGTGGACAAATTGCACCAAACGACAGAGCTGTGT	
		CTGATAAATATGCGTATGGGTAA	

(continued)

	SEQ	Nucleic Acid Sequence	Description
5	ID NO.		
	SEQ	ATGGAGGAGGATGTAAAGAAAGTCAAAAAGCCAGGTA	Coding nucleotide sequence of ccm2
	ID NO	TCGTGTCTCCGTTCAAGCGGGTGTTTCTGAAAGGGGA	
	1	GAAGGGTAGGGATAAGAAGGCTCTGGAGAAGTCCACT	
10		GAACGCAGGGCCCTCCACACCTTCTCTCTCTCTCC	
		CAGACCACCGTATCGACCCAGATATTCTGCTCAATGAC	
		TACATCGAGAAGGAAGTTAAGTATCTGGGACAGCTGA	
		CCTCAGTTCCTGGATACCTGAATCCCTCCAGCCGCACT	
15		GAAGTTCTGCAGCTCATTGACAATGCCAGGAAGTCTCA	
		TCAGTTGGCTGGGCAGCTGACCTCAGAGCAGGATGCT	
		GTTGTCAGTTTATCAGCGTACAATGTGAAGCTTGTGTG	
		GCGTGATGGAGAGGACATCATTCTGCGCGTACCCATC	
20		CACGACATTGCAGCTGTGTCCTACATCAGAGACGACT	
		CGCTTCATCTAGTGGTGCTAAAAACAGCTCAGGAGCC	
		CGGAGGTTCCCCATGTCATAGTACAGAGATGTCGAAA	
		TCTCCCACTCTGAGCTCTCTATCTGAGAGTGGGGGCTGT	
25		GCTGGTGGAGGTCTGCTGTCTGCTTGTGCTGGCTGTT	
		GACAACAAGGCTGCAGCAGAGGAGCTCTGTCTTCTAC	
		TCAGTCAAGTCTTCCAGATCGTCTATACCGAGTCCACC	
20		ATCGACTTCCTAGACAGGGCCATCTTTGATGGAGCCA	
30		CAACACCCACCAGGCATCTCTCAATCTATAGTGAAGAC	
		TCCTCAAGTAAAGTTGATGTCAAAGATGTGTTTGAGGC	
		CGAGGCAAGCACATTCTCGTTCCAGAGTTCTCTAGAG	
25		GCGGGACATTCCTCTAGCCCCTCCCCCACCTCGGCCC	
55		CGGCCTCGCCACAAACCAAAACAGCCAGTGAGAGCGA	
		ACTGAGCACAACAGCTGCTGAACTGCTGCAAGACTAC	
		ATGACCACATTGAGGACAAAGCTTTCGTCCAAAGAGAT	
40		CCAGCAGTTTGCCACACTGTTACATGAATACAGAAACG	
40		GCGCCTCCATCCATGAGTTCTGTATCAACCTGCGGCA	
		GCTTTATGGAGACAGCAGGAAGTTCCTTCTCCTCGGA	
		CTGCGGCCGTTCATCCCCGAGAAGGACAGCCAGCATT	
45		TTGAGAACTTTCTGGAGACCATCGGCGTGAAGGATGG	
		CCGCGGAATCATCACAGACAGTTTCGGCCGTTATAAG	
		CGCACGACGAGCTCTGCGTCTGACTCCACCACGAACG	
		GAAACGGTGCTGCGGGCGGATCAGATGAGGGAACAG	
50		CCACCTCTGAGGGCGACGAATGGGACCGCATGATTTC	
		AGACATAAGCAATGACATTGAAGCCTTAGGAAGCAGC	
		ATGGATCAAGACGGCGTGCCATCTTGA	

(continued)

	SEQ	Nucleic Acid Sequence	Description
5	NO.		
	SEQ	ATGACAATGGAAGAGATGAAGAATGAAGCGGACGCGA	Coding nucleotide sequence of
	ID NO	CCTCCATGGTATCCATGACCCTCTACGCCGTGATGTAC	pdcd10a (ccm3a)
	0	CCGGTGTTCAATGAGCTGGAGAGTGTAAATCTGTCTG	
10		CGGCACAGACTCTGCGAGCTGCTTTCAAAAAGGCAGA	
		GAAGGAAAACCCAGGACTGACTCAGGACATTATCATG	
		AAAATACTGGAGAAGAAGAACGTGGAGATCAACTTCAC	
		CGAGTCTTTATTACGCATGGCTGCTGATGATGTTGAGG	
15		AGTACATGATTGACAGGCCCGAGCGGGAGTTCCAGGA	
		CCTGAATGAAAGAGCTCGCGCGCTGAAACAGATCCTC	
		AGCAAAATCCCAGACGAAATTAATGACCGAGTCCGATT	
		CCTGCAGACAATCAAAGATATAGCCAGTGCCATAAAAG	
20		AGCTGCTGGACACAGTGAACAACGTCTTCAAGAAATAT	
		CAGTACCAGAACAGAAGGGCACTTGAGCATCAGAAGA	
		AAGAGTTTGTGAAACATTCGAAAAGCTTCAGCGACACT	
25		CTGAAAACATACTTCAAAGACGGAAAGGCAATAAACGT	
25		GTTTGCCAGTGCCAACCGGCTCATCCACCAAACCAAC	
		TTGATACTGCAGACCTTCAAAACTGTCGCATAG	
	SEQ	ATGACAATGGAAGAGATGAAGAATGAAGCTGAGCCAA	Coding nucleotide sequence of
30	ID NO 9	ATTCAATAGTCTCTATGACATTGTACGCAGTCATGTATC	pdcd10b (ccm3b)
	Ŭ	CAGTCTTCAATGAGTTGGGGAGGATAAACCCGTCAGC	
		AGCACAGACATTGCGGGCAGCATTTGTCAAAGCAGAG	
		AAGGAGAACCCAGGGCTCACTCAAGATATCATTATGAA	
35		GATACTGGAGAAGAAGAATGTGGAGATCAACTTCACA	
		GAGTCACTACTGCGCATGGCTGCAGATGATGTGGAGG	
		AGTACATGATTAAGAGACCTGAACAGGAGTTCCAGGA	
		CCTGAATGAGAAAGCACGAGCTCTAAAACATATCCTGA	
40		GTAAAATCCCAGATGAGATCAACGACAGAGTGCGCTT	
		CCTACAGACTATCAAAGACATCGCCAGTGCTATAAAGG	
		AGCTGCTGGACACAGTCAACAATGTTTTTAGGAAGTAT	
		CAGTACCAGAATCGCAGGGCACTTGAACACCAAAAGA	
45		AGGAGTTTGTGAAGTACTCCAAAAGCTTCAGTGATACG	
		CTGAAAACATACTTCAAAGACGGAAAGGCAATAAACGT	
		CTTTATCAGTGCCAACAGGCTTATCCACCAAACTAACT	
		TGATACTGCAGACCTTCAAAACCGTCGCCTAG	

50

(continued)	
-------------	--

5	SEQ ID NO.	Nucleic Acid Sequence	Description
	SEQ	ATGATGGAAACGTGCGCTCGCCGTGTGCTTTTCACGG	Coding nucleotide sequence of heg1
	ID NO	CCGCTCTGCTCGTCCTCAGTACTGTGATAGCGGAAAC	
	10	TTTCTCCACAGACTCGGACACCGATAATCCACTGAGTA	
10		CAGAAACTTTTTATAGCCGAACAAGTGGCTTGAAACAA	
		ACCTCCTCCTGGCCAGGGAGAGAGGCCACTGCCACA	
		GCCGTGGATCTATCGAGCGGACTGGGAGAGATGACG	
		GAGATTCCCGCCAGTGTATCCATCACTGCAGCCCGAG	
15		AGGGACATTCACCAAAACCTTTACAAACCTCTACAAAT	
		GCAGCGGATTGGAAGACCAGTATGACCTCAGATGAGA	
		CAACAGAACATCTTCAATCTGACACTGAGCTTACCCAT	
		AATGCGACCGCCCAATGGGAGAGTCCATCATCAGCAT	
20		CTCACAGCATTACCAGCCACCATCCAGTAACAGAGAC	
		ACGAACCGTGCGAGATGTAACAGATCTGATAGACATG	
		GACACCACAGACTCAGTCTCCCACACTGATAGCACCT	
25		ACATTTCCACAACCAACCGAGTTGGAGAACGCACACT	
25		GCTCTCAGTGATCTCCAACAGCACCTTTGCGTACACCC	
		AGAACTCAAGCATCTCTGATGCAGAGTCTCAAACGTCC	
		CCATGGGAGGAGAAGACATCAGGAGCCACCCAAGTCA	
30		ATGAGGAAACTGAAGAAACTGTGTCAACAGTGTCCGA	
		ACAGACTGATCCCACTTTTGAAGACCGCAATATCACCA	
		GTGCAACTCTGGAGACTGGGCGGTCAACATTATTCCA	
		AGGCACTGAGTCACAGACAGGACAACCTAGTGTCACA	
35		GGACAGACCGCTAAGGAGGTGACTGATATCGACAATC	
		CAAATTCAACACCGCCTCTCACAGTAACCAGTAGGGAT	
		GTTGAGGAAACAGATGCCACATCAGTGAGCAGTGAGA	
		CATCTTATACACAAACCAGCAGTGACTCTGCCTCCTCA	
40		ATCTTGCCTTTTACTTCTAGTGAACGCAATGTCACTAG	
		CACGTCCCAAGAGAGCCATAATTCCACACTCATTTATT	

SEQ	Nucleic Acid Sequence	Description
, NO.		
	CCACAAATACTGGTGGTTCCACTGAGTTTTCGACTGGA	
	TCAGTGAGCTCTACCGCCCATGAAGAAACTGAACGGT	
	CTTCAACTCAAATAGTAGATGAGACAACCCTTCATGAT	
<u>_</u>	GTTACTTCTGCACCCCAGTGCTTGAAGATGTAGCCAC	
0	AACTATCGATGACTCGCTTTCCAAGTTCCCTTCCGGCC	
	AATCGCCTACCATCCCTAAAACCGATGACCAAACCAAC	
	ACACAAGTGGTGCCAACATCAACTCATAGGCCACAGG	
	TTACAGATGAAGCCACCGATGAGGTGTCTACAGTTTAC	
5	AGTTCTACCACTACTTTAACTACCACAACTCCTTCTGTC	
	ACCACTAGACAACTCCAACCACACCACCACAGTGG	
	AAACCCAAACACAACACACTACCATTGTTACCACCGAT	
	ATCATTCAGGTACTGCGAACGACACCTTCTACAGCCCA	
_	TCATGTGCCTACATCGACTACCAGTGGACCACAGGCT	
0	CCAAGTACAGCTGATTCTTCTGACGTCACCACATTGCA	
	CTTGGAAACCAGCACAGCCACGCCGGGGAACACTACG	
	GCGCACGGTGGACGTGCAACAACGCCTTTTAGCAAGA	
	GCAGCCCGAGTAGAACAACTGTGGTAGTGACCACTGG	
5	ACATCTCACTGACAAAAGCACTACAGAGACAGGAAGC	
	GCAACCACGCAGATGCCTCTTAGAACATCAGCATCAC	
	CAGGTCATGTATGTGGACCTAAAACCTGTGCAAATGGA	
	GGTCATTGTGTTAGATCAGCTGAAGGAAGTTACTACTG	
	TCAGTGTCTCTCCGCATGGACCGGACCCTTCTGCACT	
0	GAAGATGTGGACGAGTGTGTGAACAGTCCATGTCCTC	
	AGGGTTCAGTGTGTGTCAACACAGGTGGTTCTTTCAGC	
	TGTGAATGTGACCTGGGCTTTGACCTGGAGGATGGCC	
	GCAGTTGTACACAAGTCAAGACATTTTTGGGCACTTTC	
5	ACAGTCAACAACTCTCTTCATCTCAGAAATTTAGGTCT	
	GCACGAGCTACACAGAGAGATCCAACAGCTGCTCAAT	
	GCTTCTCTCCCATCTTCCATGGTTATAGACGCTTTAC	
	CCTGGGTAAAAGAGATGGACAAGGTGTGCAAATCCCA	
	GTGGTGAGCATGTTTTCACTCTCCTCCAATGTGACCAG	
0	CGCGGATGTTTTCAACAGCATCCAGATGTCCCTTAACA	
	ACTGCAGCCGGACATACTCGCACTGTCCCATTAAACTT	
	CAGCACCAGCTCTCCTATCACGTGGAGAGCCTGTGCA	
	TGGCCCAGAAGACCAAGTGTGATGTGCAGTACTCAGA	
5	TTGCTCGGATATTAGCGGGATTCCCAACTGTCAGTGCC	
	TTCCTGGGTACTTTAAAAGGAACCCAGAAGACATGACC	
	TGCAGAGACTGTGGAGATGGACTCAAGCTTGTTAATG	
	GCAAATGTGTCGAATGCATGTTTGGATTTGGAGGTTTC	
	AACTGCAATAATTTCTATAAGCTGATAGCCGTGGTGGT	
0	CTCGCCTGCTGGAGGAGCTCTTCTGTTGATTGTGGTC	
	ATTGCTCTTATTGTCACCTGCTGCAAAAAAGACAAAAA	
	CGACATCAACAAGATCATCTTCAAAAGTGGAGAGCTTC	
	AGATGTCGCCATACGCAGAGTTTCCTAAGAGCAATCG	
5	CGTGTCCATGGAGTGGGGTAGAGAGACTATCGAGATG	
	CAGGAGAACGGCAGTACAAAAAACCTCCTGCAAATGA	
	CTGACATTTATTACTCGCCTGCACTGAGAAACTCCGAC	
	CTGGAGCGTAATGGTCTGTATCCATTCTCGGGCCTTCC	

(00)	ntinu	(hou
(00)	IIUIIU	ieu)

5	SEQ ID NO.	Nucleic Acid Sequence	Description
		TGGTTCAAGGCATTCCTGCATCTATCCGGCTCAGTGGA	
		ACCCTTCCTTCTTAAGCGACGATTCACGCCGAAGAGA	
		СТАСТТТТБА	

15			
20			
25			
30			
35			
40			
45			
50			
55			

	SEQ ID	Nucleic Acid Sequence	Description
5	NO.		
	SEQ	TACCACCTAAATTGTAAGCGTTAATATTTTGTTAAAATT	Plasmid Sequenz of pDestTol2_UAS:
	ID NO 11	CGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCA	mCherry-Krit1,alpha-cry:EGFP used in
		ATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAG	the examples of the invention
10		AATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGG	
		AACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGT	
		CAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCA	
		CTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTC	
15		GAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGG	
		AGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCG	
		AACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA	
		GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG	
20		CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGC	
		CGCTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCG	
		CAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCG	
		CTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAA	
25		GGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTC	
		ACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAA	
		TACGACTCACTATAGGGCGAATTGGGTACCAAATAGTA	
		GGAATTACCCACCTGTACAAGTGCTGAAAACTTGGATG	
30		AATAAGCCCGTTTGCCATTTTCTACTGCTATTTTAAATC	
		TTTTCTGTATTTGTCTGCATTTGTCTTTACCCTTGAATA	
		AATGTTTTAGTTGTTTTTTTCAATTATGACTGTGTTTAA	
		CAGACATTATTACAATAATATGTAATAGTAGTACACACT	
35		ATTATTATGTAATAGTACTTGTTGACTGTATTTGAGAAC	
		TGGACCGAGTGAGTGTTACGTCACCCATTCAAAATGAC	
		TTACTTCTGGCTCCAACAAAATGAAGTTAATTCAGTTG	
		CCATTTTTCACTGTATGGACATCGCCGTGTTGGAGCTA	
40		GACGTCGCCAATAAGCAAGAAAGAGCCGAGATGCGTC	
		GAGTCTGAGTCACCGTTCCTATGGCAACCCCTCTAACC	
		AATCAGAAGTAAGCTTGTTGGAAGTCCACAGCCTACCA	
		CTTGAAAGCGGGCTGCACAAAATCTGTCAAACGTTTTG	
45		AACGTTGGATGTGAGAGCACATACTTTTATTAAGGCAT	
		CTGGTTGGTCAGTTTATAATATCAACAACTTGGGCTAC	
		AGAAAAGAAAAGTTATTACAGAAATTATGATTAACAAGT	
		ACATGTTAAATAAAGATTTTAATATGAATGCCACCACTG	
50		GAGCATTCATGCCATTTGGAGCTTCTTCCTGTTTGGAT	
		CACTAGAAGGAGGAGGTCACTCATTACAGTTCTCATAT	
		ACAGTCGTTGGTTGGTTGGTTGGTTGGTTGGTA	
		GATTGATTGATTGATTGATTGATTGATTGATTGAT	
55		TGATTGATTGATTGATTGATTGATTGATTGATTGA	
		TTGATTGATTGATTGATTGATTGGTAGTCAAAATA	
		AGAAATAATTTCCACAGATTCATTACAGAAATGATTAAA	
		TGCATACATAAAAAACTGGGGGGGGGGGGGGATACAACA	

Γ	SEQ	Nucleic Acid Sequence	Description
	ID		
5	NO.		
		ACACACTTAAGTCACATTTGCCTACGTAAAGAAAAGTA	
		AAGAAAATCAATAGCTATATTTTACATCTCCTTTTTTG	
		CTGTCTTTTAATTAGCCTTGTTTTGCTGTTATCTTGATT	
10		GAAACTGTAACTTCTTCACCTGCTTCTTTCTTTGTAGG	
		TTTTGCCAGCCCAGAAACAGGCATGGCTGTGCAAGGC	
		CAGAGCACCATGCACAATGCGCTGCATGTCTTCATGA	
		ACGGCTCAATGTCCTCAGTCCAGGGCTCAGCCAACGA	
		CCCCATCTTCCTCCTTCACCATGCTTTCATTGACAGGT	
15		AACAAACACGTCATGACATTAGACTGCACAGTTTTTGA	
		CAAAGTTCATACAATCTGTTGTTTATAGCTGCTACAATT	
		AGTGAAGTTTGTGAATGTACTTGGATGAGCAGCGAAA	
		GATCAATTGAGATCAATTGTTAGAGTTTGGTTGCCCTG	
20		CAGAGCAAAGAACAAAAAATAATCTGGTGGCTTTACTG	
20		CGTGAGGTTATTATTGGTGGAATAGAAACACAAAACAT	
		AATTGCATTTATTTGTTTAATTTTTTATCTTATCTTAACTT	
		TCATCTTGCATATTTGTTTCTTACATCATTTCTAGCATCT	
		TTGAGCGCTGGCTAAGAACTCATCAGCCTCCCCGGTC	
25		CATCTACCCACGTACCAATGCACCAATTGGCCACAATG	
		ACGGCTACTACATGGTGCCATTCCTTCCTCTTTATAGG	
		AATGGAGACTACCTCCTGTCCAACAAGGCTCTTGGATA	
		CGAGTACGCCTACCTGTTGGACCCAGGTCATTGCACA	
		ACACCAGAAATGCCCTCTGATCTGCAAAAGACGTGAAT	
30		ATCTGTTCAGACACCCATATCCACTCTGTTCCACACAG	
		GTCAGAGGTTTGTCCAGGAGTTCTTGACAGAGGTGTA	
		AAAAGTACTCAAAAATTTTACTCAAGTGAAAGTACAAGT	
		ACTTAGGGAAAATTTTACTCAATTAAAAGTAAAAGTATC	
35		TGGCTAGAATCTTACTTGAGTAAAAGTAAAAAGTACT	
		CCATTAAAATTGTACTTGAGTATTAAGGAAGTAAAAGTA	
		AAAGCAAGAAAGAAAACTAGAGATTCTTGTTTAAGCTT	
		TTAATCTCAAAAAACATTAAATGAAATGCATACAAGGTT	
		TTATCCTGCTTTAGAACTGTTTGTATTTAATTATCAAACT	
40		ATAAGACAGACAATCTAATGCCAGTACACGCTACTCAA	
		AGTTGTAAAACCTCAGATTTAACTTCAGTAGAAGCTGA	
		TTCTCAAAATTGTTAGTGTCAAGCCTAGCTCTTTTGGG	
		GCTGAAAAGCAATCCTGCAGTGCTGAAAAGCCTCTCA	
45		CAGGCAGCCGATGCGGGAAGAGGTGTATTAGTCTTGA	
		TAGAGAGGCTGCAAATAGCAGGAAACGTGAGCAGAGA	
		CTCCCTGGTGTCTGAAACACAGGCCAGATGGGCCCTC	
		GAGCAGGAAACAGCTATGACCATGATTACGCCAAGCT	
		ATCAACTTTGTATAGAAAAGTTGGTAATACGACTCACTA	
50		TAGGGCGAATTGGGTACCGGGCCCCCCCCGAGGTC	
		GACGGTATCGATAAGCTTAGGCCTCCAAGGCGGAGTA	
		CTGTCCTCCGGGCTGGCGGAGTACTGTCCTCCGGCAA	
		GGTCGGAGTACTGTCCTCCGACACTAGAGGTCGGAGT	
55		ACTGTCCTCCGACGCAAGGCGGAGTACTGTCCTCCGG	
		GCTGGCGGAGTACTGTCCTCCGGCAAGGTCGGAGTA	
		CTGTCCTCCGACACTAGAGGTCGGAGTACTGTCCTCC	
		GACGCAAGGCGGAGTACTGTCCTCCGGGCTGGCGGA	

S	EQ	Nucleic Acid Sequence	Description
ID	C		
5 N	0.		
		GTACTGTCCTCCGGCAAGGGTCGACTCTAGAGGGTAT	
		ATAATGGATCCCATCGCGTCTCAGCCTCACTTTGAGCT	
		CCTCCACACGAATTCCTGCAGCCCGGGGGGATCCACTA	
10		GTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGC	
		TTTTGTTCCCTTTAGTGAGGGTTAATTCAAGTTTGTACA	
		AAAAAGCAGGCTCATGGCATGGTGAGCAAGGGCGAG	
		GACGACAACATGGCCATCATCAAGGAGTTCATGCGCTT	
		CAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGA	
15		GTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTA	
		CGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAA	
		GGGCGGCCCCTGCCCTTCGCCTGGGACATCCTGTC	
		CCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAG	
		CACCCCGCCGACATCCCCGACTACTTGAAGCTGTCCT	
20		TCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTT	
		CGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTC	
		CTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAG	
		CTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAA	
25		TGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCG	
		AGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCG	
		AGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCC	
		ACTACGACGCCGAGGTCAAGACCACCTACAAGGCCAA	
		GAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAA	
30		CATCAAGCTGGACATCACCTCCCACAACGAGGACTAC	
		ACCATCGTGGAACAGTACGAGCGCGCCGAGGGCCGC	
		CACTCCACCGGCGGCATGGACGAGCTGTACAAGGGA	
		GGCGCTGCAGGAGGCTCTAGAATGGGAAACCAAGAG	
35		CTAGAGGAGGTGTTTGTTGCTGTTATCCGACCAAAAAA	
		CACAACCAGCCTCAACTCCAAAGAATACCGTGCTAAAT	
		CCTATGAGATTTTACTTATCGAAGTTCCCCTGGAGGGA	
		AAAGAGAAAAAGCGGAAGAAAGTGCTGCTTGGGACTA	
		AAATtCACGCCGACAGTGACCGGACAAAGTCAATTCTG	
40		GAGTTTGTGGATGAAACCACCAAGCCCATATCCAATAA	
		CCAGGGCATAATAGGGAAGCGTGTtGTGCACATGAGG	
		AAGTTCCTGTTAGATGGAGACAGTGGAGGAAAAGAGG	
		CCTCGTTATTTATTGTGCCAATTAATGTCAAAGACAACA	
15		GCAAGTCCGTGCATCACCCTGGGAGCCCCAGTTTCTA	
70		CTGCCTTCAGGACATCATGCGTGTGTGTGTGTGAAACC	
		AGTGCTCATTTCTCCTCCAGCACCTCAAAGATGCTGCT	
		CGCTCTCGACAAGTGGTTAGCGGAGCAGCACACTGTG	
		CCTCACGCTATTCCTGCTCTGTTCCGGCCGGCTCCGG	
50		TGGACCGTGTGAAAACTAACGTGAGTAACCCGGCGTA	
		CGCAGTGGAGAAGCAGACAGACGGGACGCTGCACAT	
		GGGCTACACGGCTCTGGAGATCAAGAGTAAACTGATG	
		TCTCTGGAGAAAGCAGATCTGTGCATCCAGAACCCGC	
		TGTACGGCTCAGATCTGCAGTACACCAACAGAGTGGA	
00		CAAAGTCATCATCAACCCTTACTTTGGCTTGGGAGCTC	
		CAGATTACTCCAAAATCCAGATTCCAAAGAGAGACAAA	
		TGGCAGCACAGCATGACCAGCGTCACCGAAGACAAAG	

SEQ	Nucleic Acid Sequence	Description
5 ID 5 NO .		
	AGCGCCAGTGGGTGGATGATTTCCCTCTGCACCGAAG	
	CGCCTGTGAGGGAGACACTGAGCTTTTGTCTAAATTGC	
	TGGATGGCGGATTCTCAGTCAAACAGCTGGACAGCGA	
	CCATTGGGCACCCATTCATTATGCATGCTGGCATGGG	
10	AAGGTGGAGGCCACTAAACTGCTGCTGGAGAAAGGCA	
	ACTGTAACCCCAACCTGCTGAACGGCCAGCTGAGCTC	
	TCCTTTACACTTCGCAGCTATCGGCGGTCATGCAGAAA	
	TCGTGCAGCTCCTCCTGCAGCACCCAGAGATCGACAG	
15	ACACATCGAGGACCAGCAGAAACGATCGCCGCTTCAA	
	GTATGTGAAGAAAACAAGCAGAACAACTGGGAGGAAA	
	CCGTGAATCTCCTTCAACAAGCCAGCAATAAACCATAC	
	GAGAAGGTGAGGATTTACCGTATGGATGGATCGTACC	
	GCTCTGTGGAGCTGAAGCATGGGAACAACACCACCGT	
20	GCAGCAGATCATGGAGGGCATGAGATTATCACAGGAG	
	ACCCAGCAGTATTTTACCATCTGGATCTGCTCCGAAAA	
	CCTTAGTCTGCAGCTGAAGCCGTACCACAAGCCCTTG	
	CAGCACTTACGGATGTGGAGCGAGATCGTGACGGATC	
25	TCACTGCTCTGGATCCACAGAGAGAAAGTCCACAGCT	
	CTTCCTGCGCAGAGACGTTCGGCTGCCTTTAGAGGTC	
	GAGAAAAAGGTTGAAGATCCGCTGTCCATCCTCATCCT	
	ATTTGATGAAGCTCGTCACTGCCTCCTTAAAGGTTTCC	
	TCTCGACGTCAGATAACAAGCTAATCACGCTCGCAAG	
30	CCTCCTCCTGCAGATCATCTACGGAAACTACGACAGC	
	AAGAAGCACAAACAGGGCTTTCTAAATGAGGAAAACCT	
	GAAATCCATAGTTCCCATTTCAAAGGTCAAGAGCAAAG	
	CACATCACTGGACTAACAGGATACTTCACGAGTACAAG	
35	AGTCTGAGCACTAGTGAGGGTGTGAGTAAAGAAATGC	
	ATCACCTCCAGAGGCTCTTCCTGCAGAACTGCTGGGA	
	TATTCCTACTTATGGTGCAGCGTTTTTCACAGGACAGG	
	TCTTCACTAAAGCCAGCTCCAGCACACACAAGGTGATC	
	CGCGTGTATGTGGGCGTCAACACCAAAGGCCTGCATC	
40	TGATGAACATGGAGACAAAAGTGCTTCACCTCAGTCTG	
	GAGTATGGGACATTTATGTGGCAGCTGGGTCAGGCTG	
	ATCAATACGTGCAAATCCACAGTCTGGAGAACAAGAAG	
	AACTTTGTCGTTCACACCAAACAGGCTGGTCTTATCGT	
45	GAAGCTGCTGATGAAGCTGAGTGGACAAATTGCACCA	
	AACGACAGAGCTGTGTCTGATAAATATGCGTATGGGTA	
	AACCCAGCTTTCTTGTACAAAGTGGAATTCACTAGTGA	
	TTTAATAGTGTGCATTCAGTGCAGGATGTTATGTATTTA	
	TTTTCTGTAGTGCAAACTTTTTCAAAGAATTTTCCAGTC	
50	TAAGCTTTTCAGTCAAGAAAAAAAAAGGCGTCTGATTA	
	TCTGTGATATTTTAAATAATTAGCTCTTAAATCTGGTGA	
	ACCAAGTGGCCACAACACATTAAATACTGACGTTCTAC	
	AGCCATGTAGCTTCATCTGGTCTGGTTTGTTTTGGCAG	
55	GCACTTATTTTCCGGTGATAGTTGGCCACAAGAGTATT	
	GTCTGAGCCATTCAGTGCTAGACTGTCATTCTCAGGTC	
	AGAATCCACCCCACTGATTCTGCTGACAACACTGTTCC	
	CACCATGAGATAATGCCATTCCAGAGAGATCCATTTGT	

SEQ	Nucleic Acid Sequence	Description
5 NO.		
	AAGCCCCTCTTTCTGCAGCACAGGTATATAACCAGGG	
	CTCTGCCTCCACTAAGGCCGGCACACATCATTTGGGG	
	ATCTTTGTACTGTACTAGCCTCTATTAGCCTCCTACTTG	
•	CGTTCAGTTCACATCTTTTGTTCATCAGGTGCAATAAGT	
0	TACAGTAAGGAGTTACCAGGTCTGACATTAATCGAATT	
	CCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCG	
	GGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACG	
	TAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCG	
5	AGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTT	
	CATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCC	
	ACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCT	
	TCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT	
	CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAG	
0	CGCACCATCTTCTTCAAGGACGACGGCAACTACAAGA	
	CCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGG	
	TGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGA	
	GGACGGCAACATCCTGGGGCACAAGCTGGAGTACAAC	
5	TACAACAGCCACAACGTCTATATCATGGCCGACAAGCA	
	GAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCAC	
	AACATCGAGGACGGCAGCGTGCAGCTCGCCGACCAC	
	TACCAGCAGAACACCCCCATCGGCGACGGCCCCGTG	
	CTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCG	
0	CCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACAT	
	GGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACT	
	CTCGGCATGGACGAGCTGTACAAGGGCGGTGGAAGA	
	TCTGGGAATTCAAGGCCTCTCGAGCCTCTAGATTCTGC	
5	AGCCCTATAGTGAGTCGTATTACGTAGATCCAGACATG	
	ATAAGATACATTGATGAGTTTGGACAAACCACAACTAG	
	AATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGA	
	TGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAA	
	ACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCA	
0	GGTTCAGGGGGAGGTGTGGGAGGTTTTTTCCAACTTT	
	ATTATACATAGTTGATAATTCACTGGCCGTCGTTTTACA	
	TCGATGATGATCCAGACATGATAAGATACATTGATGAG	
	TTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATG	
5	CTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTA	
-	ACCATTATAAGCTGCAATAAACAAGTTAACAACAACAAT	
	TGCATTCATTTTATGTTTCAGGTTCAGGGGGGGGGGGGG	
	GGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTG	
	GTATGGCTGATTATGATCCTCTAGATCAGATCTGCGAA	
0	GATACGGCCACGGGTGCTCTTGATCCTGTGGCTGATT	
	TTGGACTGTGCTGCTCGCAGCTGCTGATGAATCACATA	
	CTTCCTCCATTTTCTTCCACTGATTGACTGTTATAATTT	
	CCCTAATTTCCAGGTCAAGGTGCTGTGCATTGTGGTAA	
5	TAGATGTGACATGACGTCACTTCCAAAGGACCAATGAA	
-	CATGTCTGACCAATTTCATATAATGTGAAAACGATTTTC	
	ATAGGCAGAATAAATAACATTTAAATTAAACTGGGCAT	
	CAGCGCAATTCAATTGGTTTGGTAATAGCAAGGGAAAA	

SE	Nucleic Acid Sequence	Description
ID		
5 NO		
	TAGAATGAAGTGATCTCCAAAAAATAAGTACTTTTTGAC	
	TGTAAATAAAATTGTAAGGAGTAAAAAGTACTTTTTTT	
	CTAAAAAAATGTAATTAAGTAAAAGTAAAAGTATTGATT	
10	TTTAATTGTACTCAAGTAAAGTAAAAATCCCCAAAAATA	
	ATACTTAAGTACAGTAATCAAGTAAAATTACTCAAGTAC	
	TTTACACCTCTGGTTCTTGACCCCCTACCTTCAGCAAG	
	CCCAGCAGATCCACTAGTTCTAGAGCGGCCGCCACCG	
	CGGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGTT	
15	AATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTC	
	CTGTGTGAAATTGTTATCCGCTCACAATTCCACACAAC	
	ATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTG	
	CCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGC	
20	TCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCC	
20	AGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAG	
	GCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCT	
	CACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGA	
	GCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTAT	
25	CCACAGAATCAGGGGATAACGCAGGAAAGAACATGTG	
	AGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG	
	GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC	
	CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAG	
	GTGGCGAAACCCGACAGGACTATAAAGATACCAGGCG	
30	TTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC	
	GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTC	
	CCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCT	
	GTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAA	
35	GCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGAC	
	CGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAA	
	CCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCC	
	ACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCG	
	GTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGG	
40	CTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGC	
	TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCT	
	TGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT	
	TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA	
45	GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTC	
	TGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTT	
	TGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATC	
	CTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTA	
	TATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTA	
50	ATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCG	
	TTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAA	
	CTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGC	
	TGCAATGATACCGCGAGACCCACGCTCACCGGCTCCA	
55	GATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCG	
	AGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCAT	
	CCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTA	
	GTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATT	

(continued)

5	SEQ ID NO.	Nucleic Acid Sequence	Description
		GCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTA	
		TGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCG	
		AGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTA	
10		GCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTG	
		GCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGC	
		ATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTT	
		CTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAA	
15		TAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGT	
		CAATACGGGATAATACCGCGCCACATAGCAGAACTTTA	
		AAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAA	
		ACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGA	
20		TGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCT	
		TTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGG	
		AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACA	
		CGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATAT	
25		TATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGG	
		ATACATATTTGAATGTATTTAGAAAAATAAACAAATAGG	
		GGTTCCGCGCACATTTCCCCGAAAAGTG	

(continued)

5	SEQ ID NO.	Nucleic Acid Sequence	Description
	SEQ	TACCACCTAAATTGTAAGCGTTAATATTTTGTTAAAATT	Plasmid Sequenz of pDestTol2_UAS:
	ID NO	CGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCA	EGFP -Krit1,alpha-cry:EGFP used in
	12	ATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAG	the examples of the invention
10		AATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGG	
		AACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGT	
		CAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCA	
		CTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTC	
15		GAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGG	
		AGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCG	
		AACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA	
•••		GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACG	
20		CTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGC	
		CGCTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCG	
		CAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCG	
25		CTATTACGCCAGCTGGCGAAAGGGGGGATGTGCTGCAA	
25		GGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTC	
		ACGACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAA	
		TACGACTCACTATAGGGCGAATTGGGTACCAAATAGTA	
30		GGAATTACCCACCTGTACAAGTGCTGAAAACTTGGATG	
		AATAAGCCCGTTTGCCATTTTCTACTGCTATTTTAAATC	
		TTTTCTGTATTTGTCTGCATTTGTCTTTACCCTTGAATA	
		AATGTTTTAGTTGTTTTTTTCAATTATGACTGTGTTTAA	
35		CAGACATTATTACAATAATATGTAATAGTAGTACACACT	
		ATTATTATGTAATAGTACTTGTTGACTGTATTTGAGAAC	
		TGGACCGAGTGAGTGTTACGTCACCCATTCAAAATGAC	
		TTACTTCTGGCTCCAACAAAATGAAGTTAATTCAGTTG	
40		CCATTTTTCACTGTATGGACATCGCCGTGTTGGAGCTA	
		GACGTCGCCAATAAGCAAGAAGAGCCGAGATGCGTC	

	SEQ ID	Nucleic Acid Sequence	Description
5	NO.		
		GAGTCTGAGTCACCGTTCCTATGGCAACCCCTCTAACC	
		AATCAGAAGTAAGCTTGTTGGAAGTCCACAGCCTACCA	
		CTTGAAAGCGGGCTGCACAAAATCTGTCAAACGTTTTG	
		AACGTTGGATGTGAGAGCACATACTTTTATTAAGGCAT	
0		CTGGTTGGTCAGTTTATAATATCAACAACTTGGGCTAC	
		AGAAAAGAAAAGTTATTACAGAAATTATGATTAACAAGT	
		ACATGTTAAATAAAGATTTTAATATGAATGCCACCACTG	
		GAGCATTCATGCCATTTGGAGCTTCTTCCTGTTTGGAT	
5		CACTAGAAGGAGGAGGTCACTCATTACAGTTCTCATAT	
-		ACAGTCGTTGGTTGGTTGGTTGGTTGGTTGGTA	
		GATTGATTGATTGATTGATTGATTGATTGATTGAT	
		TGATTGATTGATTGATTGATTGATTGATTGATTGA	
		TTGATTGATTGATTGATTGATTGGTAGTCAAAATA	
20		AGAAATAATTTCCACAGATTCATTACAGAAATGATTAAA	
		TGCATACATAAAAAACTGGGGGGGGGGGGGGGATACAACA	
		ACACACTTAAGTCACATTTGCCTACGTAAAGAAAAGTA	
		AAGAAAATCAATAGCTATATTTTACATCTCCTTTTTTG	
25		CTGTCTTTTAATTAGCCTTGTTTTGCTGTTATCTTGATT	
.0		GAAACTGTAACTTCTTCACCTGCTTCTTTCTTTGTAGG	
		TTTTGCCAGCCCAGAAACAGGCATGGCTGTGCAAGGC	
		CAGAGCACCATGCACAATGCGCTGCATGTCTTCATGA	
		ACGGCTCAATGTCCTCAGTCCAGGGCTCAGCCAACGA	
80		CCCCATCTTCCTCCTTCACCATGCTTTCATTGACAGGT	
		AACAAACACGTCATGACATTAGACTGCACAGTTTTTGA	
		CAAAGTTCATACAATCTGTTGTTTATAGCTGCTACAATT	
		AGTGAAGTTTGTGAATGTACTTGGATGAGCAGCGAAA	
		GATCAATTGAGATCAATTGTTAGAGTTTGGTTGCCCTG	
15		CAGAGCAAAGAACAAAAAATAATCTGGTGGCTTTACTG	
		CGTGAGGTTATTATTGGTGGAATAGAAACACAAAACAT	
		AATTGCATTTATTTGTTTAATTTTTTATCTTATCTTAACTT	
		TCATCTTGCATATTTGTTTCTTACATCATTTCTAGCATCT	
0		TTGAGCGCTGGCTAAGAACTCATCAGCCTCCCCGGTC	
		CATCTACCCACGTACCAATGCACCAATTGGCCACAATG	
		ACGGCTACTACATGGTGCCATTCCTTCCTCTTTATAGG	
		AATGGAGACTACCTCCTGTCCAACAAGGCTCTTGGATA	
-		CGAGTACGCCTACCTGTTGGACCCAGGTCATTGCACA	
15		ACACCAGAAATGCCCTCTGATCTGCAAAAGACGTGAAT	
		ATCTGTTCAGACACCCATATCCACTCTGTTCCACACAG	
		GTCAGAGGTTTGTCCAGGAGTTCTTGACAGAGGTGTA	
		AAAAGTACTCAAAAATTTTACTCAAGTGAAAGTACAAGT	
50		ACTTAGGGAAAATTTTACTCAATTAAAAGTAAAAGTATC	
		TGGCTAGAATCTTACTTGAGTAAAAGTAAAAAGTACT	
		CCATTAAAATTGTACTTGAGTATTAAGGAAGTAAAAGTA	
		AAAGCAAGAAAGAAAACTAGAGATTCTTGTTTAAGCTT	
_		TTAATCTCAAAAAACATTAAATGAAATGCATACAAGGTT	
5		TTATCCTGCTTTAGAACTGTTTGTATTTAATTATCAAACT	
		ATAAGACAGACAATCTAATGCCAGTACACGCTACTCAA	
		AGTTGTAAAACCTCAGATTTAACTTCAGTAGAAGCTGA	

SI	EQ	Nucleic Acid Sequence	Description
ID)		
5 N	0.		
		TTCTCAAAATTGTTAGTGTCAAGCCTAGCTCTTTTGGG	
		GCTGAAAAGCAATCCTGCAGTGCTGAAAAGCCTCTCA	
		CAGGCAGCCGATGCGGGAAGAGGTGTATTAGTCTTGA	
10		TAGAGAGGCTGCAAATAGCAGGAAACGTGAGCAGAGA	
		CTCCCTGGTGTCTGAAACACAGGCCAGATGGGCCCTC	
		GAGCAGGAAACAGCTATGACCATGATTACGCCAAGCT	
		ATCAACTTTGTATAGAAAAGTTGGTAATACGACTCACTA	
		TAGGGCGAATTGGGTACCGGGCCCCCCCCGAGGTC	
15		GACGGTATCGATAAGCTTAGGCCTCCAAGGCGGAGTA	
		CTGTCCTCCGGGCTGGCGGAGTACTGTCCTCCGGCAA	
		GGTCGGAGTACTGTCCTCCGACACTAGAGGTCGGAGT	
		ACTGTCCTCCGACGCAAGGCGGAGTACTGTCCTCCGG	
20		GCTGGCGGAGTACTGTCCTCCGGCAAGGTCGGAGTA	
20		CTGTCCTCCGACACTAGAGGTCGGAGTACTGTCCTCC	
		GACGCAAGGCGGAGTACTGTCCTCCGGGCTGGCGGA	
		GTACTGTCCTCCGGCAAGGGTCGACTCTAGAGGGTAT	
		ATAATGGATCCCATCGCGTCTCAGCCTCACTTTGAGCT	
25		CCTCCACACGAATTCCTGCAGCCCGGGGGGATCCACTA	
		GTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGC	
		TTTTGTTCCCTTTAGTGAGGGTTAATTCAAGTTTGTACA	
		AAAAAGCAGGCTATGGTGAGCAAGGGCGAGGAGCTGT	
20		TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACG	
30		GCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGA	
		GGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT	
		GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCC	
		TGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGC	
35		AGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCA	
		CGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC	
		CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACT	
		ACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACA	
10		CCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTT	
40		CAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGA	
		GTACAACTACAACAGCCACAACGTCTATATCATGGCCG	
		ACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGAT	
		CCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGC	
45		CGACCACTACCAGCAGAACACCCCCATCGGCGACGG	
		CCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACC	
		CAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGC	
		GATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCG	
		GGATCACTCTCGGCATGGACGAGCTGTACAAGGGAGG	
50		CGCTGCAGGAGGCTCTAGAATGGGAAACCAAGAGCTA	
		GAGGAGGTGTTTGTTGCTGTTATCCGACCAAAAAACAC	
		AACCAGCCTCAACTCCAAAGAATACCGTGCTAAATCCT	
		ATGAGATTTTACTTATCGAAGTTCCCCTGGAGGGAAAA	
55		GAGAAAAAGCGGAAGAAAGTGCTGCTTGGGACTAAAA	
		TtCACGCCGACAGTGACCGGACAAAGTCAATTCTGGAG	
		TTTGTGGATGAAACCACCAAGCCCATATCCAATAACCA	
		GGGCATAATAGGGAAGCGTGTtGTGCACATGAGGAAG	

SEQ ID	Nucleic Acid Sequence	Description
5 NO .		
	TTCCTGTTAGATGGAGACAGTGGAGGAAAAGAGGCCT	
	CGTTATTTATTGTGCCAATTAATGTCAAAGACAACAGC	
	AAGTCCGTGCATCACCCTGGGAGCCCCAGTTTCTACT	
	GCCTTCAGGACATCATGCGTGTGTGTGTGTGAAACCAG	
0	TGCTCATTTCTCCTCCAGCACCTCAAAGATGCTGCTCG	
	CTCTCGACAAGTGGTTAGCGGAGCAGCACACTGTGCC	
	TCACGCTATTCCTGCTCTGTTCCGGCCGGCTCCGGTG	
	GACCGTGTGAAAACTAACGTGAGTAACCCGGCGTACG	
5	CAGTGGAGAAGCAGACAGACGGGACGCTGCACATGG	
	GCTACACGGCTCTGGAGATCAAGAGTAAACTGATGTC	
	TCTGGAGAAAGCAGATCTGTGCATCCAGAACCCGCTG	
	TACGGCTCAGATCTGCAGTACACCAACAGAGTGGACA	
	AAGTCATCATCAACCCTTACTTTGGCTTGGGAGCTCCA	
0	GATTACTCCAAAATCCAGATTCCAAAGAGAGACAAATG	
	GCAGCACAGCATGACCAGCGTCACCGAAGACAAAGAG	
	CGCCAGTGGGTGGATGATTTCCCTCTGCACCGAAGCG	
	CCTGTGAGGGAGACACTGAGCTTTTGTCTAAATTGCTG	
5	GATGGCGGATTCTCAGTCAAACAGCTGGACAGCGACC	
5	ATTGGGCACCCATTCATTATGCATGCTGGCATGGGAA	
	GGTGGAGGCCACTAAACTGCTGCTGGAGAAAGGCAAC	
	TGTAACCCCAACCTGCTGAACGGCCAGCTGAGCTCTC	
0	GTGCAGCTCCTCCTGCAGCACCCAGAGATCGACAGAC	
	ATGTGAAGAAAACAAGCAGAACAACTGGGAGGAAAACC	
	GTGAATCTCCTTCAACAAGCCAGCAATAAACCATACGA	
-	GAAGGTGAGGATTTACCGTATGGATGGATCGTACCGC	
5	TCTGTGGAGCTGAAGCATGGGAACAACACCACCGTGC	
	TTAGTCTGCAGCTGAAGCCGTACCACAAGCCCTTGCA	
0	GCACTTACGGATGTGGAGCGAGATCGTGACGGATCTC	
	GAAAAAGGTTGAAGATCCGCTGTCCATCCTCATCCTAT	
_	TTGATGAAGCTCGTCACTGCCTCCTTAAAGGTTTCCTC	
5	TCGACGTCAGATAACAAGCTAATCACGCTCGCAAGCC	
	TCCTCCTGCAGATCATCTACGGAAACTACGACAGCAA	
	GAAGCACAAACAGGGCTTTCTAAATGAGGAAAACCTG	
	AAATCCATAGTTCCCATTTCAAAGGTCAAGAGCAAAGC	
0		
	GTCTGAGCACTAGTGAGGGTGTGAGTAAAGAAATGCA	
	TCACCTCCAGAGGCTCTTCCTGCAGAACTGCTGCGGAT	
	ATTCCTACTTATGGTGCAGCGTTTTTCACAGGACAGGT	
5	CGCGTGTATGTGGGCGTCAACACCAAAGGCCTGCATC	
	TGATGAACATGGAGACAAAAGTGCTTCACCTCAGTCTG	
	GAGTATGGGACATTTATGTGGCAGCTGGGTCAGGCTG	

SEQ	Nucleic Acid Sequence	Description
NO.		
	ATCAATACGTGCAAATCCACAGTCTGGAGAACAAGAAG	
	AACTTTGTCGTTCACACCAAACAGGCTGGTCTTATCGT	
	GAAGCTGCTGATGAAGCTGAGTGGACAAATTGCACCA	
	AACGACAGAGCTGTGTCTGATAAATATGCGTATGGGTA	
	AACCCAGCTTTCTTGTACAAAGTGGAATTCACTAGTGA	
	TTTAATAGTGTGCATTCAGTGCAGGATGTTATGTATTTA	
	TTTTCTGTAGTGCAAACTTTTTCAAAGAATTTTCCAGTC	
	TAAGCTTTTCAGTCAAGAAAAAAAAGGCGTCTGATTA	
5	TCTGTGATATTTTAAATAATTAGCTCTTAAATCTGGTGA	
	ACCAAGTGGCCACAACACATTAAATACTGACGTTCTAC	
	AGCCATGTAGCTTCATCTGGTCTGGTTTGTTTTGGCAG	
	GCACTTATTTTCCGGTGATAGTTGGCCACAAGAGTATT	
_	GTCTGAGCCATTCAGTGCTAGACTGTCATTCTCAGGTC	
0	AGAATCCACCCACTGATTCTGCTGACAACACTGTTCC	
	CACCATGAGATAATGCCATTCCAGAGAGATCCATTTGT	
	AAGCCCCTCTTTCTGCAGCACAGGTATATAACCAGGG	
	CTCTGCCTCCACTAAGGCCGGCACACATCATTTGGGG	
5	ATCTTTGTACTGTACTAGCCTCTATTAGCCTCCTACTTG	
	CGTTCAGTTCACATCTTTTGTTCATCAGGTGCAATAAGT	
	TACAGTAAGGAGTTACCAGGTCTGACATTAATCGAATT	
	CCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCG	
	GGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACG	
0	TAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCG	
	AGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTT	
	CATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCC	
	ACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCT	
5	TCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT	
	CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAG	
	CGCACCATCTTCTTCAAGGACGACGGCAACTACAAGA	
	CCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGG	
	TGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGA	
0	GGACGGCAACATCCTGGGGCACAAGCTGGAGTACAAC	
	TACAACAGCCACAACGTCTATATCATGGCCGACAAGCA	
	GAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCAC	
	AACATCGAGGACGGCAGCGTGCAGCTCGCCGACCAC	
5	TACCAGCAGAACACCCCCATCGGCGACGGCCCCGTG	
	CTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCG	
	CCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACAT	
	GGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACT	
_	CTCGGCATGGACGAGCTGTACAAGGGCGGTGGAAGA	
ע	TCTGGGAATTCAAGGCCTCTCGAGCCTCTAGATTCTGC	
	AGCCCTATAGTGAGTCGTATTACGTAGATCCAGACATG	
	ATAAGATACATTGATGAGTTTGGACAAACCACAACTAG	
	AATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGA	
5		
	ACAAGIIAACAACAACAATTGCATTCATTTTATGTTTCA	
	GGTTCAGGGGGAGGTGTGGGGAGGTTTTTTCCAACTTT	
	ATTATACATAGTTGATAATTCACTGGCCGTCGTTTTACA	

	SEQ ID	Nucleic Acid Sequence	Description
5	NO.		
		TCGATGATGATCCAGACATGATAAGATACATTGATGAG	
		TTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATG	
		CTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTA	
		ACCATTATAAGCTGCAATAAACAAGTTAACAACAACAACAAT	
0		TGCATTCATTTTATGTTTCAGGTTCAGGGGGGGGGGGGG	
		GGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTG	
		GTATGGCTGATTATGATCCTCTAGATCAGATCTGCGAA	
		GATACGGCCACGGGTGCTCTTGATCCTGTGGCTGATT	
5		TTGGACTGTGCTGCTCGCAGCTGCTGATGAATCACATA	
		CTTCCTCCATTTTCTTCCACTGATTGACTGTTATAATTT	
		CCCTAATTTCCAGGTCAAGGTGCTGTGCATTGTGGTAA	
		TAGATGTGACATGACGTCACTTCCAAAGGACCAATGAA	
		CATGTCTGACCAATTTCATATAATGTGAAAACGATTTTC	
0		ATAGGCAGAATAAATAACATTTAAATTAAACTGGGCAT	
		CAGCGCAATTCAATTGGTTTGGTAATAGCAAGGGAAAA	
		TAGAATGAAGTGATCTCCAAAAAATAAGTACTTTTTGAC	
		TGTAAATAAAATTGTAAGGAGTAAAAAGTACTTTTTTT	
5		CTAAAAAAATGTAATTAAGTAAAAGTAAAAGTATTGATT	
•		ТТТААТТӨТАСТСААӨТАААӨТАААААТССССАААААТА	
		ATACTTAAGTACAGTAATCAAGTAAAATTACTCAAGTAC	
		TTTACACCTCTGGTTCTTGACCCCCTACCTTCAGCAAG	
		CCCAGCAGATCCACTAGTTCTAGAGCGGCCGCCACCG	
0		CGGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGTT	
		AATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTC	
		CTGTGTGAAATTGTTATCCGCTCACAATTCCACACAAC	
		ATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTG	
5		CCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGC	
0		TCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCC	
		AGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAG	
		GCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCT	
		CACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGA	
0		GCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTAT	
		CCACAGAATCAGGGGATAACGCAGGAAAGAACATGTG	
		AGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG	
		GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC	
5		CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAG	
0		GTGGCGAAACCCGACAGGACTATAAAGATACCAGGCG	
		TTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC	
		GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTC	
		CCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCT	
0		GTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAA	
		GCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGAC	
		CGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAA	
		CCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCC	
5		ACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCG	
J		GTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGG	
		CTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGC	
		TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCT	

(continued)

	SEQ ID	Nucleic Acid Sequence	Description
5	NO.		
		TGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT	
		TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA	
		GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTC	
10		TGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTT	
		TGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATC	
		CTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTA	
		TATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTA	
15		ATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCG	
		TTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAA	
		CTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGC	
		TGCAATGATACCGCGAGACCCACGCTCACCGGCTCCA	
20		GATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCG	
		AGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCAT	
		CCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTA	
		GTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATT	
25		GCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTA	
		TGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCG	
		AGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTA	
•••		GCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTG	
30		GCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGC	
		ATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTT	
		CTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAA	
25		TAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGT	
35		CAATACGGGATAATACCGCGCCACATAGCAGAACTTTA	
		AAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAA	
		ACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGA	
40		TGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCT	
40		TTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGG	
		AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACA	
		CGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATAT	
45		TATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGG	
40		ATACATATTTGAATGTATTTAGAAAAATAAACAAATAGG	
		GGTTCCGCGCACATTTCCCCGAAAAGTG	

50

(continued)	
-------------	--

5	SEQ ID NO.	Nucleic Acid Sequence	Description
10	SEQ ID NO 13	GTAATACGACTCACTATAGGGCGAATTGGGTACCGGG CCCCCCTCGAGGTCGACGGTATCGATAAGCTTAGGC CTCCAAGGCGGAGTACTGTCCTCCGGGCTGGCGGAG TACTGTCCTCCGGCAAGGTCGGAGTACTGTCCTCCGA CACTAGAGGTCGGAGTACTGTCCTCCGACGCAAGGCG GAGTACTGTCCTCCGGGCTGGCGGAGTACTGTCCTCC GGCAAGGTCGGAGTACTGTCCTCCGACACTAGAGGTC GGAGTACTGTCCTCCGACGCAAGGCGGAGTACTGTCC TCCGGGCTGGCGGAGTACTGTCCTCCGGCAAGGGTC GACTCTAGAGGGTATATAATGGATCCCATCGCGTCTCA	UAS promoter sequence, which can be used in a endocardium-specific genetic system of the invention
20		GCCTCACTTTGAGCTCCTCCACACGAATTCCTGCAGCC CGGGGGATCCACTAGTTCTAGAGCGGCCGCCACCGC GGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGTTA ATT	

	SEQ ID	Nucleic Acid Sequence	Description
5	NO.		
	SEQ	ATGGTGAGCAAGGGCGAGGAcGACAACATGGCCATCA	Coding nucleotide sequence of an
		TCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGG	mCherry-KRIT1 fusion protein including
	14	CTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGA	a linker sequence, which can be used as a functional Krit1/CCM1 protein in the
10		GGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGC	context of the invention.
		CAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTT	
		CGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGC	
		TCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCG	
15		ACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTG	
		GGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGT	
		GACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGA	
		GTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTC	
20		CCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGG	
20		GCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGG	
		ACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGA	
		AGCTGAAGGACGGCGGCCACTACGACGCCGAGGTCA	
		AGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCC	
25		CGGCGCCTACAACGTCAACATCAAGCTGGACATCACC	
		TCCCACAACGAGGACTACACCATCGTGGAACAGTACG	
		AGCGCGCCGAGGGCCGCCACTCCACCGGCGGCATGG	
		ACGAGCTGTACAAGGGAGGCGCTGCAGGAGGCTCTA	
30		GAATGGGAAACCAAGAGCTAGAGGAGGTGTTTGTTGC	
		TGTTATCCGACCAAAAAACACAACCAGCCTCAACTCCA	
		AAGAATACCGTGCTAAATCCTATGAGATTTTACTTATCG	
		AAGTTCCCCTGGAGGGAAAAGAGAAAAAGCGGAAGAA	
35		AGTGCTGCTTGGGACTAAAATtCACGCCGACAGTGACC	
00		GGACAAAGTCAATTCTGGAGTTTGTGGATGAAACCACC	
		AAGCCCATATCCAATAACCAGGGCATAATAGGGAAGC	
		GTGTtGTGCACATGAGGAAGTTCCTGTTAGATGGAGAC	
		AGTGGAGGAAAAGAGGCCTCGTTATTTATTGTGCCAAT	
40		TAATGTCAAAGACAACAGCAAGTCCGTGCATCACCCTG	
		GGAGCCCCAGTTTCTACTGCCTTCAGGACATCATGCG	
		TGTGTGTAGTGAAACCAGTGCTCATTTCTCCTCCAGCA	
		CCTCAAAGATGCTGCTCGCTCTCGACAAGTGGTTAGC	
45		GGAGCAGCACACTGTGCCTCACGCTATTCCTGCTCTG	
		TTCCGGCCGGCTCCGGTGGACCGTGTGAAAACTAACG	
		TGAGTAACCCGGCGTACGCAGTGGAGAAGCAGACAGA	
		CGGGACGCTGCACATGGGCTACACGGCTCTGGAGAT	
50		CAAGAGTAAACTGATGTCTCTGGAGAAAGCAGATCTGT	
		GCATCCAGAACCCGCTGTACGGCTCAGATCTGCAGTA	
		CACCAACAGAGTGGACAAAGTCATCATCAACCCTTACT	
		TTGGCTTGGGAGCTCCAGATTACTCCAAAATCCAGATT	
55		CCAAAGAGAGACAAATGGCAGCACAGCATGACCAGCG	
55		TCACCGAAGACAAAGAGCGCCAGTGGGTGGATGATTT	
		CCCTCTGCACCGAAGCGCCTGTGAGGGAGACACTGA	
		GCTTTTGTCTAAATTGCTGGATGGCGGATTCTCAGTCA	

(continued)

	SEQ ID	Nucleic Acid Sequence	Description
5	NO.		
		AACAGCTGGACAGCGACCATTGGGCACCCATTCATTA	
		TGCATGCTGGCATGGGAAGGTGGAGGCCACTAAACTG	
		CTGCTGGAGAAAGGCAACTGTAACCCCAACCTGCTGA	
10		ACGGCCAGCTGAGCTCTCCTTTACACTTCGCAGCTATC	
		GGCGGTCATGCAGAAATCGTGCAGCTCCTCCTGCAGC	
		ACCCAGAGATCGACAGACACATCGAGGACCAGCAGAA	
		ACGATCGCCGCTTCAAGTATGTGAAGAAAACAAGCAG	
15		AACAACTGGGAGGAAACCGTGAATCTCCTTCAACAAG	
		CCAGCAATAAACCATACGAGAAGGTGAGGATTTACCG	
		TATGGATGGATCGTACCGCTCTGTGGAGCTGAAGCAT	
		GGGAACAACACCACCGTGCAGCAGATCATGGAGGGC	
20		ATGAGATTATCACAGGAGACCCAGCAGTATTTTACCAT	
		CTGGATCTGCTCCGAAAACCTTAGTCTGCAGCTGAAG	
		CCGTACCACAAGCCCTTGCAGCACTTACGGATGTGGA	
		GCGAGATCGTGACGGATCTCACTGCTCTGGATCCACA	
25		GAGAGAAAGTCCACAGCTCTTCCTGCGCAGAGACGTT	
		CGGCTGCCTTTAGAGGTCGAGAAAAAGGTTGAAGATC	
		CGCTGTCCATCCTCATCCTATTTGATGAAGCTCGTCAC	
•••		TGCCTCCTTAAAGGTTTCCTCTCGACGTCAGATAACAA	
30		GCTAATCACGCTCGCAAGCCTCCTCCTGCAGATCATCT	
		ACGGAAACTACGACAGCAAGAAGCACAAACAGGGCTT	
		TCTAAATGAGGAAAACCTGAAATCCATAGTTCCCATTT	
25		CAAAGGTCAAGAGCAAAGCACATCACTGGACTAACAG	
35		GATACTTCACGAGTACAAGAGTCTGAGCACTAGTGAG	
		GGTGTGAGTAAAGAAATGCATCACCTCCAGAGGCTCT	
		TCCTGCAGAACTGCTGGGATATTCCTACTTATGGTGCA	
40		GCGTTTTTCACAGGACAGGTCTTCACTAAAGCCAGCTC	
40		CAGCACACACAAGGTGATCCGCGTGTATGTGGGCGTC	
		AACACCAAAGGCCTGCATCTGATGAACATGGAGACAA	
		AAGTGCTTCACCTCAGTCTGGAGTATGGGACATTTATG	
45		TGGCAGCTGGGTCAGGCTGATCAATACGTGCAAATCC	
		ACAGTCTGGAGAACAAGAAGAACTTTGTCGTTCACACC	
		AAACAGGCTGGTCTTATCGTGAAGCTGCTGATGAAGC	
		TGAGTGGACAAATTGCACCAAACGACAGAGCTGTGTC	
50		TGATAAATATGCGTATGGGTAA	

	SEQ ID	Nucleic Acid Sequence	Description
5	NO.		
	SEQ ID NO 15	ATGGTGAGCAAGGGCGAGGAcGACAACATGGCCATCA	Coding nucleotide sequence of an mCherry that can be used for encoding a fusion protein of the invention.
		TCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGG	
		CTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGA	
10		GGGCGAGGGCCGCCCTACGAGGGCACCCAGACCGC	
		CAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTT	
		CGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGC	
45		TCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCG	
15		ACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTG	
		GGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGT	
		GACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGA	
20		GTTCATCTACAAGGTGAAGCTGCGCGCGCACCAACTTC	
20		CCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGG	
		GCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGG	
		ACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGA	
25		AGCTGAAGGACGGCGGCCACTACGACGCCGAGGTCA	
		AGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCC	
		CGGCGCCTACAACGTCAACATCAAGCTGGACATCACC	
		TCCCACAACGAGGACTACACCATCGTGGAACAGTACG	
30		AGCGCGCCGAGGGCCGCCACTCCACCGGCGGCATGG	
		ACGAGCTGTACAAG	
	SEQ ID NO 16	GGAGGCGCTGCAGGAGGCTCTAGA	Coding nucleotide sequence of a linker that can be used for encoding a linker of a fusion protein of the invention.
35	SEQ	AATTCACTAGTGATTTAATAGTGTGCATTCAGTGCAGG	Nucleotide sequence of an alpha-
	ID NO	ATGTTATGTATTTATTTTCTGTAGTGCAAACTTTTTCAAA	crystallin promoter that can be used for
	17	GAATTTTCCAGTCTAAGCTTTTCAGTCAAGAAAAAAAAA	the invention.
40		GGCGTCTGATTATCTGTGATATTTTAAATAATTAGCTCT	
40		TAAATCTGGTGAACCAAGTGGCCACAACACATTAAATA	
		CTGACGTTCTACAGCCATGTAGCTTCATCTGGTCTGGT	
		TTGTTTTGGCAGGCACTTATTTTCCGGTGATAGTTGGC	
45		CACAAGAGTATTGTCTGAGCCATTCAGTGCTAGACTGT	
		CATTCTCAGGTCAGAATCCACCCCACTGATTCTGCTGA	
		CAACACTGTTCCCACCATGAGATAATGCCATTCCAGAG	
		AGATCCATTTGTAAGCCCCTCTTTCTGCAGCACAGGTA	
50		TATAACCAGGGCTCTGCCTCCACTAAGGCCGGCACAC	
		ATCATTTGGGGATCTTTGTACTGTACTAGCCTCTATTAG	
		CCTCCTACTTGCGTTCAGTTCACATCTTTTGTTCATCAG	
		GTGCAATAAGTTACAGTAAGGAGTTACCAGGTCTGACA	
55		TTAATCGAATT	

(continued)

5	SEQ ID NO.	Nucleic Acid Sequence	Description
10	SEQ ID NO 18	ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTG GTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAAC GGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGC GATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCT GCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCC TCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAG	Coding nucleotide sequence of an EGFP that can be used for encoding a fusion protein of the invention or as a marker of the presence of a transgenic construct.
15		CCGCTACCCCGACCACATGAAGCAGCACGACTTCTTC AAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGC ACCATCTTCTTCAAGGACGACGGCAACTACAAGACCC GCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGA	
20		ACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGA CGGCAACATCCTGGGGGCACAAGCTGGAGTACAACTAC AACAGCCACAACGTCTATATCATGGCCGACAAGCAGA AGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAA	
25		CATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTA CCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT GCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCC CTGAGCAAAGACCCCCAACGAGAAGCGCGATCACATGG TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCT	
30		CGGCATGGACGAGCTGTACAAG	
(continued)

	SEQ	Nucleic Acid Sequence	Description
5	ID NO.		
	SEQ	ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTG	Coding nucleotide sequence of an
	ID NO	GTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAAC	EGFP-KRIT1 fusion protein including a
	19	GGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGC	a functional Krit1/CCM1 protein in the
10		GATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCT	context of the invention.
		GCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCC	
		TCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAG	
		CCGCTACCCCGACCACATGAAGCAGCACGACTTCTTC	
15		AAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGC	
		ACCATCTTCTTCAAGGACGACGGCAACTACAAGACCC	
		GCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGA	
		ACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGA	
20		CGGCAACATCCTGGGGCACAAGCTGGAGTACAACTAC	
		AACAGCCACAACGTCTATATCATGGCCGACAAGCAGA	
		AGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAA	
25		CATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTA	
25		CCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT	
		GCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCC	
		CTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG	
30		TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCT	
		CGGCATGGACGAGCTGTACAAGGGAGGCGCTGCAGG	
		AGGCTCTAGAATGGGAAACCAAGAGCTAGAGGAGGTG	
		TTTGTTGCTGTTATCCGACCAAAAAACACAACCAGCCT	
35		CAACTCCAAAGAATACCGTGCTAAATCCTATGAGATTT	
		TACTTATCGAAGTTCCCCTGGAGGGAAAAGAGAAAAA	
		GCGGAAGAAAGTGCTGCTTGGGACTAAAATtCACGCC	
		GACAGTGACCGGACAAAGTCAATTCTGGAGTTTGTGG	
40		ATGAAACCACCAAGCCCATATCCAATAACCAGGGCATA	
		ATAGGGAAGCGTGTtGTGCACATGAGGAAGTTCCTGTT	
		AGATGGAGACAGTGGAGGAAAAGAGGCCTCGTTATTT	
		ATTGTGCCAATTAATGTCAAAGACAACAGCAAGTCCGT	
45		GCATCACCCTGGGAGCCCCAGTTTCTACTGCCTTCAG	
		GACATCATGCGTGTGTGTAGTGAAACCAGTGCTCATTT	
		CTCCTCCAGCACCTCAAAGATGCTGCTCGCTCTCGAC	
		AAGTGGTTAGCGGAGCAGCACACTGTGCCTCACGCTA	
50		TTCCTGCTCTGTTCCGGCCGGCTCCGGTGGACCGTGT	
		GAAAACTAACGTGAGTAACCCGGCGTACGCAGTGGAG	
		AAGCAGACAGACGGGACGCTGCACATGGGCTACACG	
		GCTCTGGAGATCAAGAGTAAACTGATGTCTCTGGAGA	
55		AAGCAGATCTGTGCATCCAGAACCCGCTGTACGGCTC	

(continued)

	SEQ	Nucleic Acid Sequence	Description
5	NO.		
		AGATCTGCAGTACACCAACAGAGTGGACAAAGTCATC	
		ATCAACCCTTACTTTGGCTTGGGAGCTCCAGATTACTC	
		CAAAATCCAGATTCCAAAGAGAGACAAATGGCAGCAC	
10		AGCATGACCAGCGTCACCGAAGACAAAGAGCGCCAGT	
		GGGTGGATGATTTCCCTCTGCACCGAAGCGCCTGTGA	
		GGGAGACACTGAGCTTTTGTCTAAATTGCTGGATGGC	
		GGATTCTCAGTCAAACAGCTGGACAGCGACCATTGGG	
15		CACCCATTCATTATGCATGCTGGCATGGGAAGGTGGA	
		GGCCACTAAACTGCTGCTGGAGAAAGGCAACTGTAAC	
		CCCAACCTGCTGAACGGCCAGCTGAGCTCTCCTTTAC	
		ACTTCGCAGCTATCGGCGGTCATGCAGAAATCGTGCA	
20		GCTCCTCCTGCAGCACCCAGAGATCGACAGACACATC	
		GAGGACCAGCAGAAACGATCGCCGCTTCAAGTATGTG	
		AAGAAAACAAGCAGAACAACTGGGAGGAAACCGTGAA	
		TCTCCTTCAACAAGCCAGCAATAAACCATACGAGAAGG	
25		TGAGGATTTACCGTATGGATGGATCGTACCGCTCTGTG	
		GAGCTGAAGCATGGGAACAACACCACCGTGCAGCAGA	
		TCATGGAGGGCATGAGATTATCACAGGAGACCCAGCA	
		GTATTTTACCATCTGGATCTGCTCCGAAAACCTTAGTC	
30		TGCAGCTGAAGCCGTACCACAAGCCCTTGCAGCACTT	
		ACGGATGTGGAGCGAGATCGTGACGGATCTCACTGCT	
		CTGGATCCACAGAGAGAAAGTCCACAGCTCTTCCTGC	
		GCAGAGACGTTCGGCTGCCTTTAGAGGTCGAGAAAAA	
35		GGTTGAAGATCCGCTGTCCATCCTCATCCTATTTGATG	
		AAGCTCGTCACTGCCTCCTTAAAGGTTTCCTCTCGACG	
		TCAGATAACAAGCTAATCACGCTCGCAAGCCTCCTCCT	
10		GCAGATCATCTACGGAAACTACGACAGCAAGAAGCAC	
40		AAACAGGGCTTTCTAAATGAGGAAAACCTGAAATCCAT	
		AGTTCCCATTTCAAAGGTCAAGAGCAAAGCACATCACT	
		GGACTAACAGGATACTTCACGAGTACAAGAGTCTGAG	
15		CACTAGTGAGGGTGTGAGTAAAGAAATGCATCACCTC	
40		CAGAGGCTCTTCCTGCAGAACTGCTGGGATATTCCTAC	
		TTATGGTGCAGCGTTTTTCACAGGACAGGTCTTCACTA	
		AAGCCAGCTCCAGCACACAAAGGTGATCCGCGTGTA	
50		TGTGGGCGTCAACACCAAAGGCCTGCATCTGATGAAC	
00		ATGGAGACAAAAGTGCTTCACCTCAGTCTGGAGTATG	
		GGACATTTATGTGGCAGCTGGGTCAGGCTGATCAATA	
		CGTGCAAATCCACAGTCTGGAGAACAAGAAGAACTTT	
55		GTCGTTCACACCAAACAGGCTGGTCTTATCGTGAAGCT	
-		GCTGATGAAGCTGAGTGGACAAATTGCACCAAACGAC	
		AGAGCTGTGTCTGATAAATATGCGTATGGGTAA	

[0074] The invention further relates to functionally analogous sequences of the respective functional versions of a protein required for a functional CCM complex. Protein modifications to the functional proteins required for a functional CCM complex of the present invention, which may occur through substitutions in amino acid sequence, and nucleic acid sequences encoding such molecules, are also included within the scope of the invention. Substitutions as defined herein

- ⁵ are modifications made to the amino acid sequence of the protein, whereby one or more amino acids are replaced with the same number of (different) amino acids, producing a protein which contains a different amino acid sequence than the primary protein. In some embodiments this amendment will not significantly alter the function of the protein. Like additions, substitutions may be natural or artificial. It is well known in the art that amino acid substitutions may be made without significantly altering the protein's function. This is particularly true when the modification relates to a "conservative"
- amino acid substitution, which is the substitution of one amino acid for another of similar properties. Such "conserved" amino acids can be natural or synthetic amino acids which because of size, charge, polarity and conformation can be substituted without significantly affecting the structure and function of the protein. Frequently, many amino acids may be substituted by conservative amino acids without deleteriously affecting the protein's function.
- [0075] In general, the non-polar amino acids Gly, Ala, Val, lie and Leu; the non-polar aromatic amino acids Phe, Trp and Tyr; the neutral polar amino acids Ser, Thr, Cys, Gin, Asn and Met; the positively charged amino acids Lys, Arg and His; the negatively charged amino acids Asp and Glu, represent groups of conservative amino acids. This list is not exhaustive. For example, it is well known that Ala, Gly, Ser and sometimes Cys can substitute for each other even though they belong to different groups.
- [0076] As explained herein, in the context of the invention functional versions of a protein required for a functional CCM complex may be provided in the form of an exogenous nucleic acids encoding the respective functional versions of a protein required for a functional CCM complex, which may comprise more than one protein, for example in case of CCM3, namely CCM3a and CCM3b.

[0077] Nucleic acid sequences of the invention include the nucleic acid sequences encoding a functional version of a protein required for a functional CCM complex of the invention. Protein sequences according to *Table 1* and functionally

²⁵ analogous sequences represent preferred sequences of functional proteins required for a functional CCM complex. Preferred nucleic acid sequence comprised by encoding an exogenous nucleic acid encoding a functional version of a protein required for a functional CCM complex are listed under *Table 2*.

[0078] The functional versions of a protein required for a functional CCM complex of the invention may include proteins tags that allow easy identification or binding of the provided protein through standard techniques, for example by using antibodies directed against the protein tag. A preferred protein-tag that can be encoded by a nucleic acid sequence of the invention is a V5-tag, myc-tag, HA-tag, HIS-tag or an antibody Fc-Fragment. Alternative tags, which are well known in the art and can be selected by a skilled person, may be used instead.

30

55

[0079] In another aspect, the invention encompasses functional versions of proteins required for a function CCM complex as disclosed herein as well as their use in the context of the methods disclosed herein. In particular, the invention also relates to nucleic acid molecules encoding a functional version of a protein required for a function CCM complex,

- and in particular one or more nucleic acid molecules encoding a functional version of a protein required for a function CCM complex, and in particular one or more nucleic acid molecules encoding a functional version of a protein required for a function CCM complex or parts thereof, selected from the group comprising:
- a) one or more nucleic acid molecules comprising a nucleotide sequence which encodes a functional version of a
 protein required for a function CCM complex;

b) one or more nucleic acid molecules which are complementary to the nucleotide sequences in accordance with a);

c) one or more nucleic acid molecules which undergo hybridization with the nucleotide sequences according to a)
 or b) under stringent conditions;

d) one or more nucleic acid molecules comprising a nucleotide sequence having sufficient sequence identity to be functionally analogous the nucleotide sequences according to a), b) or c);

e) one or more nucleic acid molecules which, as a consequence of the genetic code, are degenerated into nucleotide sequences according to a) through d); and

 f) one or more nucleic acid molecules according the nucleotide sequences of a) through e) which are modified by deletions, additions, substitutions, translocations, inversions and/or insertions and functionally analogous to a nucleotide sequence according to a) through e)

[0080] Accordingly, the invention encompasses nucleic acid molecules with at least 60%, preferably 70%, more preferably 80%, especially preferably 90% sequence identity to the nucleic acid molecule encoding a functional version of

a protein required for a function CCM complex.

[0081] Sequence variants of the claimed nucleic acids and/or proteins, for example defined by the provided % sequence identity, that maintain the said properties of the invention are also included in the scope of the invention. Such variants, which show alternative sequences, but maintain essentially the same properties, such as functionally complementing

the CCM complex present in the respective cell of the transgenic fish of the invention. Sequence identity relates to the percentage of identical nucleotides or amino acids when carrying out a sequence alignment, for example using software such as BLAST.

[0082] It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides

- ¹⁰ bear minimal homology or sequence identity to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Deletions, substitutions and other changes in sequence that fall under the described sequence identity are also encompassed in the invention. [0083] As used herein, a "reporter gene" may be a gene that encodes a "reporter protein" is any protein that can be specifically detected when expressed. Reporter proteins are useful for detecting or quantitating expression from expression.
- ¹⁵ sion sequences. For example, operatively linking nucleotide sequences encoding a reporter protein to a tissue specific expression sequence allows one to study lineage development, such as the development of the cardiovascular system or blood vessels. In such studies, the reporter protein serves as a marker for monitoring developmental processes, such as development of the heart, blood vessels and/or other aspects of the cardiovascular system. Many reporter proteins are known to one of skill in the art. These include, but are not limited to, beta-galactosidase, luciferase, and alkaline
- ²⁰ phosphatase that produce specific detectable products. Fluorescent reporter proteins can also be used, such as green fluorescent protein (GFP), cyan fluorescent protein (CFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP). Other examples include the green fluorescent protein from Aequorea coerelescens (AcGFP), DsRedExpress, and red coral fluorescent proteins (for example, AmCyan, ZsGreen, Zs Yellow, AsRed2, DsRed2, and HcRedI). For example, by utilizing GFP, fluorescence is observed upon exposure to light at 489 nm without the addition of a substrate.
- ²⁵ The use of a reporter protein that, like GFP, is directly detectable without requiring the addition of exogenous factors are preferred for detecting or assessing gene expression during zebraflsh embryonic development. Fluorescent proteins can be isolated from many different species, including but not limited to, Aequorea Victoria (Chalfie, et al., 1994), Zoanthus species (Matz, et al., 1999), Renilla reniformis (Ward and Cormier, 1979) and Aequorea coerelescens. Furthermore, the term reporter protein includes but is not limited to pigment proteins, fluorescent proteins, luminescent protein, enzymes
- ³⁰ and other detectable proteins. Specific examples include but are not limited to melanin (including eumalanin and pheomelanin), carotenoids, pteridines, cyan biocbromes, aequorin, luciferase, luciferin, blue fluorescent protein, red fluorescent protein, ds red fluorescent protein, cyan fluorescent protein, yellow fluorescent protein, and green fluorescent protein (including naturally occurring and mutant variants thereof). See, e.g., U.S. Pat. Nos. 7,034,141; 7,037,645; and 6,087,476. In some embodiments the visually detectable proteins such as the fluorescent or luminescent proteins are
- ³⁵ preferred. The foregoing is to be construed as inclusive of "enhanced" proteins, including but not limited to enhanced green fluorescent protein (eGFP), which are known in the art. A "reporter gene" is a nucleic acid encoding a reporter protein. "Fluorescent or luminescent" as used herein to describe an animal or fish phenotype means that at least a portion of the animal or fish is visibly fluorescent or luminescent to the ordinary human observer under usual conditions for observing fluorescence or luminescence (e.g., dimmed or reduced light, as in night-time or a darkened room, with
- or without the addition of supplemental illumination of the animal with an ultra-violet or "black" light). The phenotype may be exhibited as a pattern of fluorescence or luminescence on or through the skin of the animal, overall fluorescence or luminescence or or through the skin of the animal, and/or fluorescence or luminescence of the eyes of the animal, etc.
 [0084] The transgenic fish of the invention comprise an exogenous nucleic acid encoding a functional version of a protein required for a functional CCM complex under the transcriptional control of an endocardium-specific genetic
- ⁴⁵ system.

[0085] In the context of the invention, the term "transcriptional control" is used in the sense of regulation of gene expression or gene regulation and includes a wide range of mechanisms that are used by cells to increase or decrease the production of specific gene products (protein or RNA). Sophisticated programs of gene expression are widely observed in biology, for example to trigger developmental pathways, respond to environmental stimuli, or adapt to new food

- 50 sources. Such systems have been modified or adapted for use in biotechnological application and the control of transgenic genetic elements that may be introduced in cells and organisms, including transgenic fish. In molecular biology and genetics, transcriptional regulation is the means by which a cell regulates the conversion of DNA to RNA (transcription), thereby orchestrating gene activity. A single gene can be regulated in a range of ways, from altering the number of copies of RNA that are transcribed, to the temporal control of when the gene is transcribed. The regulation of transcription
- ⁵⁵ is a vital process in all living organisms. It is orchestrated by transcription factors and other proteins working in concert to finely tune the amount of RNA being produced through a variety of mechanisms. Important regulatory elements and aspects of transcriptional control that can form part of genetic systems controlling transcription of nucleic acid sequence include promoters, which are elements of DNA that may bind RNA polymerase and other proteins for the successful

initiation of transcription directly upstream of the gene, the chromatin state, transcription factors, and enhancer (or cisregulatory modules/elements (CRM/CRE)), which are on-coding DNA sequences containing multiple activator and repressor binding sites.

[0086] Expression sequences including promoters, enhancers, response elements and combinations thereof (some-

- times referred to as "regulatory elements") useful for producing the disclosed zebrafish are known. See, e.g., U.S. Pat. Nos. 6,730,822; 6,380,458; and 5,932,780. The expression sequences may be constitutively active or inducible (e.g., tissue-specific). Examples include but are not limited to the CMV promoter, beta-actin promoter, the RSV promoter, crystalline promoters such as the alpha and delta crystalline promoters, the mylz2 promoter, the PGK promoter, the myosin heavy chain promoter, the myosin light chain promoter, the cardiac myosin promoter, and the keratin promoter.
- See, e.g., U.S. Pat. Nos. 6,949,242; 6,897,045; and 6,784,289. In some embodiments crystalline promoters and/or enhancers, such as the delta crystalline promoter and/or enhancers, are preferably included in the expression sequence. [0087] A nucleic acid encoding the expression product (sometimes also referred to as a protein of interest) is operatively associated with the expression sequence to form what is sometimes referred to as an "expression cassette" in accordance with known techniques. If desired, insulators can be included upstream, downstream, or both upstream and downstream
- ¹⁵ from the expression sequence and associated nucleic acid encoding the expression product, in accordance with known techniques. See, e.g., U.S. Pat. Nos. 6,395,549; 6,229,070; 6,100,448; and 5,610,053. Also if desired, scaffold attachment regions can be included upstream, downstream, or both upstream and downstream from the expression sequence and associated nucleic acid encoding the expression product, in accordance with known techniques. See, e.g., U.S. Pat. Nos. 6,239,328; 6,100,448; 5,773,695; and 5,773,689.
- 20 [0088] As used herein, an "endocardium-specific genetic system" relates to any kind of regulatory nucleic acid element of sequence or combination of elements or sequences that lead to endocardium-specific expression of a nucleic acid sequence that is under the control of the said genetic system. For example, an endocardium-specific genetic system can be a endocardium-specific promoter that selectively activates expression of the controlled coding sequence in endocardial cells. Enhancers or promoter/enhancer combination are further examples of elements that can be comprised or can constitute a genetic system in the sense of the invention.
- or can constitute a genetic system in the sense of the invention.
 [0089] In the context of the invention, the term "endocardium-specific" used in the context of a genetic system, a transcriptional regulator, a transcriptional regulator, a promoter, an enhancer, a promoter/enhancer combination or the like relates to a genetic element that drives or activates gene expression in endocardial cells, whereas it is not activated and does not drive gene expression in endothelial cells or other cells of the cardiovascular system. In that sense, the
- 30 term "endocardium-specific" is not restricted to genetic elements that are exclusively expressed in endocardial cells, but to those who are capable of inducing expression in endocardial cells, while they are not active in other cells types, in particular not in endothelial cells. However, activity in other cell types, in particular in cell types that do not form part of the cardiovascular system and do not significantly influence development or function of the cardiovascular system, does not exclude a genetic system or element from falling under the term "endocardium-specific" as used herein.
- ³⁵ **[0090]** Examples of endocardium-specific promoters include, as non-limiting examples, the nfatc1 promoter, the spp1 promoter and the npr3 promoter.

[0091] The endocard or endocardium is the innermost layer of tissue that lines the chambers of the heart. Its cells are embryologically and biologically similar to the endothelial cells that line blood vessels and can be regarded as a specialized subset of endothelial cells. The endocardium also provides protection to the valves and heart chambers. The endocardium

40 underlies the much more voluminous myocardium, the muscular tissue responsible for the contraction of the heart. The endocardium controls certain aspects of myocardial function and therefore fulfills specialized functions that differentiate them from "normal" or "other" endothelial cells.

[0092] In embodiments of the invention, the term endocardium can include the endothelial cells of the myocardial capillaries and blood vessels, which are in closed contact to the cardiomyocytes (heart muscle cells), is involved in this modulatory role. In other embodiments of the invention, the term endocardium does not include the endothelial cells of

⁴⁵ modulatory role. In other embodiments of the invention, the term endocardium does not include the endothelial cells of the myocardial capillaries and blood vessels.

[0093] Endocardial cells are different from endothelial cells. The term "endothelium" refers to cells that line the interior surface of blood vessels and lymphatic vessels, forming an interface between circulating blood or lymph in the lumen and the rest of the vessel wall. It is a thin layer of simple, or single-layered, squamous cells called endothelial cells.

- ⁵⁰ Endothelial cells in direct contact with blood are called vascular endothelial cells, whereas those in direct contact with lymph are known as lymphatic endothelial cells.
 [0094] Vascular endothelial cells line the entire circulatory system, from the heart to the smallest capillaries. These cells have unique functions in vascular biology. These functions include fluid filtration, such as in the glomerulus of the kidney, blood vessel tone, hemostasis, neutrophil recruitment, and hormone trafficking.
- ⁵⁵ **[0095]** The endothelium of the interior surfaces of the heart chambers is called endocardium. As explained above, endocardial cells have specific functions which are due to their specific location in the heart and therefore have to be differentiated from endothelial cells that are not located in the heart and that do not line the heart chambers.

[0096] As used herein the term "endocardium-specific" therefore relates to all genes or genetic elements or genetic

systems that are specifically activated in endocardial cells but not in endothelial cells of other organs than the heart or endothelial cells that do not line the heart chambers or endothelial cells that are not located in the heart.

[0097] In the context of the present invention, the GAL4-UAS system is a preferred genetic system which can be used for endocardium-specific expression of the functional version of the protein required for a functional CCM complex from the exogenous nucleic acid.

5

[0098] The GAL4-UAS system is generally used to study gene expression and function in organisms such as the fruit fly or the zebra fish. It has also been adapted to study receptor chemical-binding functions in vitro in cell culture. The system has two parts: the Gal4 gene, encoding the yeast transcription activator protein Gal4, and the UAS (Upstream Activation Sequence), an enhancer to which GAL4 specifically binds to activate gene transcription.

- 10 [0099] For the different model organisms, in which the GAL4-UAS system is used, such as the zebrafish, several socalled GAL4 lines have been developed, each of which expresses GAL4 in some subset of the zebrafish's tissues or cell type. For example, some lines might express GAL4 only or predominantly in muscle cells, nerves, or endocardial cells. For zebrafish, there are many such lines, which express GAL4 in only a very specific subset of cells in the fish. The presence of GAL4, by itself, in these cells has little or no effect, since GAL4's main effect is to bind to a UAS region,
- ¹⁵ and zebrafish cells have no functional UAS regions. Since Gal4 by itself is not visible, and has little effect on cells, the other necessary part of this system are the "reporter lines". These are strains of zebrafish with the special UAS region next to a desired gene. These genetic instructions occur in every cell of the animal, but in most cells nothing happens since that cell is not producing GAL4. In the cells that are producing GAL4, however, the UAS is activated, the gene next to it is turned on, and it starts producing its resulting protein. This may report to the investigator which cells are
- 20 expressing GAL4, hence the term "reporter line", but genes intended to manipulate the cell behavior are often used as well. [0100] Gal4 is a modular protein consisting broadly of a DNA-binding domain and an activation domain. The UAS to which GAL4 binds is CGG-N11-CCG, where N can be any base. Although GAL4 is a yeast protein not normally present in other organisms it has been shown to work as a transcription activator in a variety of organisms such as Drosophila, zebrafish and human cells.
- ²⁵ **[0101]** For study in zebrafish, the GAL4 gene can be placed under the control of a native gene promoter, or driver gene, such as an endocardium-specific promoter or genetic element or promoter/enhancer combination or the like, while the UAS controls expression of a target gene. GAL4 is then only expressed in cells where the driver gene is usually active. In turn, GAL4 should only activate gene transcription where a UAS has been introduced. For example, by fusing a gene encoding a visible marker like GFP (Green Fluorescent Protein) the expression pattern of the driver genes can
- ³⁰ be determined. GAL4 and the UAS are very useful for studying gene expression in zebrafish as they are not normally present and their expression does not interfere with other processes in the cell.
 [0102] For technical reasons, variants of Gal4 and the Gal4-UAS system have been developed for application in zebrafish and other organisms. For example, the Gal4-VP16 fusion gene was used in zebrafish to overcome the weak gene expression activity of the full-length Gal4. An even improved version of Gal4-VP16 is represented by Gal4FF,
- ³⁵ which consists of the DNA binding domain from Gal4 and two transcription activation modules from VP16, which consists of 13 aa containing a critical phenylalanine.
 [0103] The upstream activating sequence or upstream activation sequence (UAS) is a cis-acting regulatory sequence.

It is distinct from the promoter and increases or activation sequence (UAS) is a cis-acting regulatory sequence. It is distinct from the promoter and increases or activates the expression of a neighboring gene. Due to its essential role in activating transcription, the upstream activating sequence is often considered to be analogous to the function of the enhancer in multicellular eukaryotes. Upstream activation sequences are a crucial part of induction, enhancing the

- enhancer in multicellular eukaryotes. Upstream activation sequences are a crucial part of induction, enhancing the expression of the protein of interest through increased transcriptional activity. The upstream activation sequence is found adjacently upstream to a minimal promoter (TATA box) and serves as a binding site for transactivators.
 [0104] In embodiments, the invention relates to a transgenic fish comprising a cardiovascular system with a heart that
- produces blood flow, and wherein said fish develops vascular lesions in cerebellar blood vessels, in particular in lowly
 perfused cerebellar blood vessels.
 [0105] As used herein the term "cardiovascular system" refers to the organ system that permits blood to circulate and transport nutrients (such as amino acids and electrolytes), oxygen, carbon dioxide, hormones, and blood cells to and from the cells in the body to provide nourishment and help in fighting diseases, stabilize temperature and pH, and maintain homeostasis. The terms circulatory system or vascular system may be used in the same sense.
- ⁵⁰ **[0106]** The cardiovascular system includes the lymphatic system, which circulates lymph. The passage of lymph for example takes much longer than that of blood. Blood is a fluid consisting of plasma, red blood cells, white blood cells, and platelets that is circulated by the heart through the vertebrate vascular system, carrying oxygen and nutrients to and waste materials away from all body tissues. Lymph is essentially recycled excess blood plasma after it has been filtered from the interstitial fluid (between cells) and returned to the lymphatic system. The cardiovascular system com-
- ⁵⁵ prises the blood, heart, and blood vessels. The lymph, lymph nodes, and lymph vessels form the lymphatic system, which returns filtered blood plasma from the interstitial fluid (between cells) as lymph.
 [0107] Zebrafish lacking a functional CCM complex have been shown to form massively dilated hearts that fail to produce blood flow and are marked by increased endocardial cell numbers as compared to wild-type. Furthermore, such

fish are characterized by collapsed intersegmental vessels, vascular anomalies of the lateral dorsal aorta, dilated and fused caudal venous plexus and oversprouting cerebrovasculature.

[0108] As used herein, the term vascular lesion can relate to vascular diseases and vascular malformation, which is a blood vessel abnormality. In general, the term "vascular lesion" describes any kind of unphysiological vascular formation or phenotype.

[0109] Vascular lesions include CCM lesions that consist of grossly dilated, capillary-like structures lined by endothelium and lacking mature vascular wall structure. Lesions can be found in -0.5% of the general population and affected individuals have a lifetime risk of focal neurological deficits and hemorrhagic stroke. Sporadic lesions are typically solitary, whereas familial CCM is characterized by multifocal cerebral lesions in the setting of mutations in one of three genes

5

- ¹⁰ encoding KRIT1 (CCM1), CCM2 and PDCD10 (CCM3) or other genes such as the gene encoding Heg1. [0110] Vascular disease is a class of diseases of the blood vessels - the arteries and veins of the circulatory system of the body. It is a subgroup of cardiovascular disease. Disorders in this vast network of blood vessels, can cause a range of health problems which can be severe or prove fatal. There are several types of vascular disease, which is a subgroup of cardiovascular disease, and the signs and symptoms depend on which type, among them are: Erythromela-
- ¹⁵ Igia is a rare peripheral vascular disease where syndromes includes burning pain, increased temperature, erythema and swelling, of mainly the hands and feet are affected. Peripheral artery disease happens when atheromatous plaques build up in the arteries that supply blood to the arms and legs, plaque causes the arteries to narrow or become blocked. Renal artery stenosis is the narrowing of renal arteries that carry blood to the kidneys from the aorta. Buerger's disease is due to small blood vessels that inflame and swell, vessels then narrow or are blocked by blood clots. Raynaud's
- ²⁰ disease is a rare peripheral vascular disorder of constriction of the peripheral blood vessels, in the fingers and toes when the person is cold. Disseminated intravascular coagulation is a widespread activation of clotting in the smaller blood vessels. Cerebrovascular disease is a group of vascular diseases that affect brain function. [0111] In the context of the invention, vascular diseases comprise also vascular diseases with a clonal nature of the
- disease such as in CCM, HHT, Tie2, RASA1, or Marfan syndrome.
 [0112] As used herein, the term vascular lesion comprises cerebrovascular disease, which includes a variety of medical conditions that affect the blood vessels of the brain and the cerebral circulation and in particular stroke. Arteries supplying
- oxygen and nutrients to the brain are often damaged or deformed in these disorders. The most common presentation of cerebrovascular disease is an ischemic stroke or mini-stroke and sometimes a hemorrhagic stroke. Hypertension (high blood pressure) is the most important contributing risk factor for stroke and cerebrovascular diseases as it can abarrate the structure of blood vessels and reput tin attended vessels and the brain are often damaged or deformed in these disorders. The most common presentation of cerebrovascular disease is an ischemic stroke or mini-stroke and sometimes a hemorrhagic stroke. Hypertension (high blood pressure) is the most important contributing risk factor for stroke and cerebrovascular diseases as it can
- 30 change the structure of blood vessels and result in atherosclerosis. Atherosclerosis narrows blood vessels in the brain, resulting in decreased cerebral perfusion. Other risk factors that contribute to stroke include smoking and diabetes. Narrowed cerebral arteries can lead to ischemic stroke, but continually elevated blood pressure can also cause tearing of vessels, leading to a hemorrhagic stroke. A stroke usually presents with an abrupt onset of a neurologic deficit such as hemiplegia (one-sided weakness), numbness, aphasia (language impairment), or ataxia (loss of coordination) -
- 35 attributable to a focal vascular lesion. The neurologic symptoms manifest within seconds because neurons need a continual supply of nutrients, including glucose and oxygen, that are provided by the blood. Therefore if blood supply to the brain is impeded, injury and energy failure is rapid. Besides hypertension, there are also many less common causes of cerebrovascular disease, including those that are congenital or idiopathic and include CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), aneurysms, amyloid angiopathy, arteriov-
- enous malformations, fistulas, and arterial dissections. Many of these diseases can be asymptomatic until an acute event, such as a stroke, occurs. Cerebrovascular diseases can also present less commonly with headache or seizures. Any of these diseases can result in vascular dementia due to ischemic damage to the brain.
 [0113] A stroke is a medical condition in which poor blood flow to the brain results in cell death. There are two main
- types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. Both result in parts of the brain not functioning properly. Signs and symptoms of a stroke may include an inability to move or feel on one side of the body, problems understanding or speaking, dizziness, or loss of vision to one side. Signs and symptoms often appear soon after the stroke has occurred. If symptoms last less than one or two hours it is known as a transient ischemic attack (TIA) or mini-stroke. A hemorrhagic stroke may also be associated with a severe headache. The symptoms of a stroke can be permanent. Long-term complications may include pneumonia or loss of bladder control. The main risk factor for
- 50 stroke is high blood pressure. Other risk factors include tobacco smoking, obesity, high blood cholesterol, diabetes mellitus, a previous TIA, and atrial fibrillation. An ischemic stroke is typically caused by blockage of a blood vessel, though there are also less common causes. A hemorrhagic stroke is caused by either bleeding directly into the brain or into the space between the brain's membranes. Bleeding may occur due to a ruptured brain aneurysm. Diagnosis is typically based on a physical exam and supported by medical imaging such as a CT scan or MRI scan. A CT scan can
- ⁵⁵ rule out bleeding, but may not necessarily rule out ischemia, which early on typically does not show up on a CT scan. Other tests such as an electrocardiogram (ECG) and blood tests are done to determine risk factors and rule out other possible causes. Low blood sugar may cause similar symptoms.

[0114] The most common blood vessel abnormality/vascular malformation is arteriovenous malformation. Arteriov-

enous malformation is an abnormal connection between arteries and veins, bypassing the capillary system. This vascular anomaly is widely known because of its occurrence in the central nervous system (usually cerebral AVM), but can appear in any location. Although many AVMs are asymptomatic, they can cause intense pain or bleeding or lead to other serious medical problems. AVMs are usually congenital and belong to the RASopathies.

⁵ [0115] The term "cerebellar blood vessels" relates to blood vessels of the cerebellum.

[0116] In the context of the invention, the term "lowly perfused blood vessel" refers to blood vessels, with a low blood flow, meaning that the rate of blood flowing through these vessels is low, in particular compared to strongly perfused main blood vessels, such as the aorta. In lowly perfused blood vessels, hemodynamic forces are less pronounced and can lead to endothelial-to-mesenchymal transition (endMT) within lowly-perfuse blood vessels, which is a process common to many vascular pathologies.

- [0117] Vascular lesions can be identified by visualizing the hollow or lumenized spaces of the cardiovascular system, which are the blood-filled spaces of the cardiovascular system. These can be visualized by various techniques known to a skilled person, for example by microangiography.
- [0118] In a transgenic fish, components of the blood such as blood cells or proteins present in the blood can be labeled, for example by using reporter proteins that are expressed in blood cells or are fused to proteins present in blood cells or in the extracellular space of the blood, for example serum proteins or plasma proteins. Reporter proteins include, without limitation, photoproteins, such as aequorin; obelin; Aequorea fluorescent proteins, such, e.g., green fluorescent proteins (GFP, EGFP, AcGFP1), cyan fluorescent proteins (CFP, ECFP), blue fluorescent proteins (BFP, EBFP), red fluorescent proteins (RFP), yellow fluorescent proteins (YFP, EYFP), ultraviolet fluorescent protein (GFPuv), their fluo-
- 20 rescence-enhancement variants, their peptide destabilization variants, and the like; coral reef fluorescent proteins, such, e.g., Discosoma red fluorescent proteins (DsRed, DsRed1, DsRed2, and DsRed-Express), Anemonia red fluorescent proteins (AsRed and AsRed2), Heteractis far-red fluorescent proteins (HcRed, HcRed1), Anemonia cyan fluorescent proteins (AmCyan, AmCyan1), Zoanthus green fluorescent proteins (ZsGreen, ZsGreen1), Zoanthus yellow fluorescent proteins (ZsYellow, ZsYellow1), their fluorescence-enhancement variants, their peptide destabilization variants, and the
- ²⁵ like; Renilla reniformis green fluorescent protein (Vitality hrGFP), its fluorescence-enhancement variants, its peptide destabilization variants, and the like; and Great Star Coral fluorescent proteins, such, e.g., Montastrea cavernosa fluorescent protein (Monster Green® Fluorescent Protein), its fluorescence-enhancement variants, its peptide destabilization variants, and the like. One skilled in the art understands that these and a variety of other fluorescent proteins can be useful as a fluorescent protein in aspects of the invention, see, e.g., Jennifer Lippincott-Schwartz & George H. Patterson,
- 30 Development and Use of Fluorescent Protein Markers in Living Cells, 300(5616) Science 87-91 (2003); and Jin Zhang et al., 3(12) Nat. Rev. Mol. Cell. Biol. 906-918 (2002). One skilled in the art understands that these and many other fluorescent proteins, including species orthologs and paralogs of the above described naturally occurring fluorescent proteins as well as engineered fluorescent proteins can be useful as a fluorescent protein disclosed in aspects of the present specification.
- 35 [0119] Furthermore, traceable reagent can be injected into the cardiovascular system or the blood stream of the fish. For example, fluorescently labeled dextran can be injected into the blood stream of the fish, for example into the common cardinal vein (CCV). Alternatively, labeled nanobeads/nanoparticals can be injected into the blood stream of the fish. Suitable fluorescent labels are known to the skilled person and include, without limitation, rhodamine and derivatives, such as Texas Red, fluorescein and derivatives, such as 5-bromomethyl fluorescein, Lucifer Yellow, IAEDANS, 7-Me2N-
- 40 coumarin-4-acetate, 7-OH-4-CH3-coumarin-3-acetate, 7-NH2-4CH3-coumarin-3-acetate (AMCA), monobromobimane, pyrene trisulfonates, such as Cascade Blue, and monobromotrimethyl-ammoniobimane, FAM, TET, CAL Fluor Gold 540, HEX, JOE, VIC, CAL Fluor Orange 560, Cy3, NED, Quasar 570, Oyster 556, TMR, CAL Fluor Red 590, ROX, LC red 610, CAL Fluor Red 610, Texas red, LC red 610, CAL Fluor Red 610, LC red 640, CAL Fluor Red 635, Cy5, LC red 670, Quasar 670, Oyster 645, LC red 705, Cy5.5, BODIPY FL, Oregon Green 488, Rhodamine Green, Oregon Green
- ⁴⁵ 514, Cal Gold, BODIPY R6Gj, Yakima Yellow, JOE, HEX, Cal Orange, BODIPY TMR-X, Quasar-570 /Cy3, TAMRA, Rhodamine Red-X, Rhodamine B, Rhodamine 6G, Redmond Red, BODIPY 581/591, Cy3.5, Cal Red/Texas Red, BOD-IPY TR-X, BODIPY 630/665-X, Pulsar-650, Quasar-670/Cy5.
 [0120] Further traceable dyes or reagents are known a person skilled in the art.
 [0121] Furthermore, the invention relates to a method for measuring or testing a pharmacological effect of a drug or for testing a pharmacological effect of a drug or compound, comprising
 - ⁰ for testing a pharmacological effect of a drug or compound, comprising
 - contacting a transgenic fish according to any one of claims 1 to 10 with a drug, and
 - measuring a pharmacological effect of the drug.

55

[0122] As used herein, the term "drug" relates to any compound, such as a biological or chemical molecule, such as a small molecule, a protein, a nucleic acid, chemicals, inorganic molecules, organic molecules, cDNA encoding a protein, a secreted protein, a large molecule, an antibody, a morpholino, a triple helix molecule, a peptide, siRNA, shRNA,

miRNA, antisense RNA, ribozyme or any other compound that can be envisioned to be used as a drug in the treatment of a patient.

[0123] In the context of the invention, "contacting" a transgenic fish with a drug or compound comprises incubation of the fish in a suitable medium comprising said compound, but also any other form of administration of said compound to

- the transgenic fish comprising feeding, oral administration and injection, such as injection into a body cavity or into the blood stream or into a tissue. Contacting also comprises implantation of pellets that release substances into the body or blood flow. Suitable routes of administration are known to a skilled person.
 [0124] In the context of the invention, the term "pharmacological effect" relates to a biochemical or physiological effect of a drug or compound on a cell, tissue or organ of the transgenic fish or on the whole organism, namely the transgenic
- fish. Such a pharmacological effect can be measured by determining the differences that occur in presence of the drug or compound as compared to its absence in a certain setup, such as an experimental setup.
 [0125] As the present invention is in particular directed to methods for measuring an effect of a drug on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke, the setup
- for measuring the pharmacological effect of the drug should be suitable for detecting vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke, for example by microscopic means, preferably involving microangiography. Such effects on can be quantified by various means, for example by measuring the number an the extend of the occurring lesions in the transgenic fish. Example of such measurements and quantifications can be found in the examples below.
- [0126] Microangiography is a type of angiography that consists of the imaging of small blood or lymphatic vessels of an organ. While most other types of angiography cannot produce images of vessels smaller than 200 μm in diameter, microangiography does just that. A microangiographic image is the result of injection of a contrast medium or traceable medium or dye into either the blood or the lymphatic system. Thus, an image is obtained in which there is contrast between vessel and surrounding tissue. It is often used in order to detect microvascular lesions in organs. Microangiography includes, without limitation, fluorescent, silicone rubber, and synchrotron radiation microangiography.
- ²⁵ **[0127]** The transgenic fish of the invention can be used as a model for the treatment and/or prevention of vascular lesions, cerebellar cavernous malformation and/or stroke. Since the fish is an easily accessible model organism that is transparent and can be easily applied to high throughput analysis, for example parallel analysis of a large number of drug candidates, the fish of the invention represent a great model system for the analysis of the effect of a compound or drug on the formation of vascular lesions. For example, screening of compounds of a compound library for their effect

on vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke using the transgenic fish as a experimental model system is possible.
 [0128] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant

- ³⁵ DNA, and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, e.g., J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons J. M. Polak
- 40 and James O'D. McGee, 1990, In Situ Hybridization: Principles and Practice; Oxford University Press; M. J. Gait (Editor), 1984, Oligonucleotide Synthesis: A Practical Approach, Irl Press; D. M. J. Lilley and J. E. Dahlberg, 1992, Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology, Academic Press; Using Antibodies: A Laboratory Manual: Portable Protocol NO. I by Edward Harlow, David Lane, Ed Harlow (1999, Cold Spring Harbor Laboratory Press, ISBN 0-87969-544-7); Antibodies: A Laboratory Manual by Ed Harlow (Editor), David
- ⁴⁵ Lane (Editor) (1988, Cold Spring Harbor Laboratory Press, ISBN 0-87969-3,4-2), 1855. Handbook of Drug Screening, edited by Ramakrishna Seethala, Prabhavathi B. Fernandes (2001, New York, N.Y., Marcel Dekker, ISBN 0-8247-0562-9); and Lab Ref: A Handbook of Recipes, Reagents, and Other Reference Tools for Use at the Bench, Edited Jane Roskams and Linda Rodgers, 2002, Cold Spring Harbor Laboratory, ISBN 0-87969-630-3. Also, all publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.

FIGURES

[0129] The invention is further described by the following figures. These are not intended to limit the scope of the invention, but represent preferred embodiments of aspects of the invention provided for greater illustration of the invention described herein.

Description of the figures:

[0130]

- ⁵ **Figure 1.** Rescue of vascular anomalies in Krit1-deficient zebrafish upon restoration of blood flow.
- a-g, Endothelial cells marked by the expression of Tg(kdrl:EGFP)^{s843} at 56 hpf (shown as black/white inverted maximum projections of several confocal z-stack images). a-c, Lateral overview of different vascular beds show that wild-type (a) morphologies of the heart, lateral dorsal aorta (LDA), intersegmental vessels (ISVs), and caudal vein plexus (CVP) are abnormal in krit1^{ty219c} mutants (b) and tnnt2a morphants (c). d-g, Phenotypes of LDA and 10 DA (labelled in green) in different genetic conditions. In krit1 ty219c mutants, the LDA and DA are massively dilated (e). tnnt2a morphants have a deformed LDA which is constricted in mid-section (f, red asterisks). g, krit1^{endocardium>mCherry-Krit1} embryo with restored morphology of the LDA and DA. h, Quantifications of EC numbers of LDA in wild-type (n=5 embryos), krit1ty219c mutants (n=6 embryos) and krit1endocardium>mCherry-Krit1 embryos (n=4 embryos). i, Quantification of the proximal DA diameter, in wild-type (n=5 embryos), krit1^{ty219c} mutants (n=6 embryos) and krit1^{endocardium>mCherry-Knt1} embryos (n=4 embryos). j-I, Maximum intensity projection of confocal z-stack of 15 endothelial cells of the lateral dorsal aorta are marked by immuno-labelling of VE-Cadherin (Cdh-5, black labelling). The red blood cell (RBC) velocities are indicated in the lower right corners. j, While wild-type endothelial cells are elongated in direction of blood flow (RBC velocity 1.53 µm/ms), k, krit1^{ty219c} mutant endothelial cells are strongly elongated (lack of blood flow, RBC velocity 0 mm/ms). In comparison, krit1endocardium>mCherry-Knt1 endothelial cells, 20 exposed to moderately normal RBC velocity (1.27 µm/ms), are less elongated and apparently have more of a wildtype morphology. j'-l', individual endothelial cell membranes have manually been redrawn with unique colors. m, n, Quantification of LDA endothelial cell shapes, circularity and surface area in wild-type, krit1ty219c mutants, and
- *krit 1^{endocardium>mCherry-Krit1* embryos, respectively (n=15 cells from 3 embryos for each condition). One-way ANOVA, Tukey's multiple comparison tests, **** $P \leq 0.0001$; ***P=0.005, **P=0.007; *P=0.027; ns, not significant. Scale bars: **a-c,** 200 µm; **d-g,** 50 µm; **j-l,** 10 µm.}

Figure 2. Loss of zebrafish CCM proteins results in klf2a expression within the lateral dorsal aorta even in the absence of blood.

a-c, Shown are reconstructions based on several confocal z-stack images of transgenic *Tg(klf2a:YFP)^{m107}* reporter expression in the LDA (outlined by dashed line) at 54 hpf. YFP expression is present in the LDA of wild-type (a) and *krit1^{ty219c}* mutant (b) which lacks blood flow. c, In contrast, the reporter *Tg(klf2a:YFP)¹¹⁰⁷* expression is completely absent in *tnnt2a* morphants (*tnnt2a* MO), which is another no-flow condition. d, Restoration of blood flow in *krit1<sup>endocardium>mCherry-Krit1* embryo does not alter high levels of *klf2a* expression. e, Quantification of Mf2a:YFP expression measured in the LDA (red rectangle in a-d). The fluorescent YFP intensity is significantly higher in *krit1^{ty219c}* mutant embryos (b) as compared to wild-type (a). Unlike in *tnnt2a* morphants, where *klf2a* reporter levels are significantly reduced (c), in *krit1<sup>endocardium>mCherry-Krit1* embryos, the *klf2a* reporter remains upregulated (d) Left panel, one-way ANOVA, Tukey's multiple comparison test; ***P*=0038, ns, not significant. Right panel, unpaired t-test ****P*=0.0003. a.u., arbitrary unit. Scale bars: 50 µm.
</sup></sup>

⁴⁰ **Figure 3.** *Microangiography reveals that low-flow vascular beds in the cerebrovasculature of Krit1-deficient zebrafish are dilated and leaky.*

a, Schematic representation of the microangiography experiment in 2 days post fertilization embryos. **b-e**, Immediately after injection, 70 kDa Texas-Red-conjugated dextran spreads rapidly throughout the entire vasculature, outlining all vessels. Lateral views of projection images are based on inverted black/white confocal z-stack images of the tracer dye in wild-type (**b**) and *krit1^{endocarilum>mCherry-Krit1* (**c**) embryos at 60 hpf. **b**, **c**, Red-dotted lines indicate area of the cerebrovasculature shown from dorsal views in **d** and **e**. **d**, In wild-type, the cerebellar central arteries (CCtA) are perfused and do not leak (n=31/31 embryos), whereas in *krit1^{endocardium>mCherry-Krit1* embryos (e), CCtAs are dilated (compare insets in **d** and **e**, diameters indicated by red lines) and tracer dye immediately leaks into the periphery within 10-15 minutes upon injection (n=5/33 embryos; arrowhead in **e**). **f**, Quantification of CCtA diameters after three independent experiments reveals increased diameter in *krit1^{endocardium>mCherry-Krit1* embryos as compared to wild-type. Unpaired, two-tailed t-test with Welch's correction; ***P<0.0001. Scale bars: 100 μm.}}}

Figure 4. Model figure.

45

50

Our work suggests that in the dorsal aorta blood flow is a physiological modifier with a vasoprotective effect on Krit1deficient endothelial cells (left panel). Upon loss of CCM proteins, pathological KLF2/4 signaling causes vascular anomalies (middle panel). These effects may be masked when high levels of fluid shear stress activate additional vasoprotective biomechanical signaling pathways or funnel KLF2/4 signal transduction towards vasoprotective target genes (right panel).

Figure 5. Endothelium- and endocardium-specific expression of mCherry-Krit1 restores cardiac morphology in krit1^{ty219c} mutants.

- a-o, Shown are different vascular beds visualised by endocardial and endothelial expression of the Tg(kdrl:EGFP)^{s843} reporter at 54 hpf. a-e, Endocardial phenotypes. a, Wild-type hearts form two distinct cardiac chambers in which ventricle (V) and atrium (A) are separated by the atrioventricular canal (AVC). b, krit1ty219c mutant hearts are 5 massively enlarged without a constriction at the AVC. c, The endocardium in tnnt2a morphants is smaller with two cardiac chambers separated by a constriction at the AVC. d, In krit1^{endothellium>mCherry-Krit1} embryos, the cardiac morphology of the two chambers, atrium and ventricle, is completely restored. e, Similarly, in krit1^{endocardium>mCherry-Krit1} embryos cardiac morphology is restored. f-j, Shown are morphologies of intersegmental 10 vessels (marked in magenta) and the caudal vein plexus (marked in blue) in the different genetic conditions tested, f, In wild-type embryos, the intersegmental vessels form patent tubes and the caudal vein plexus forms a network
- of vessels characterized by fenestra (outlined with red-dotted line). krit1ty219c mutants (g) and tnnt2a morphants (h) have similar vascular anomalies of collapsed intersegmental vessels (red arrowheads) and a fused caudal vein plexus. In krit1endothellium>mCherry-Krit1 embryos (i) and in krit1endocardium>mCherry-Krit1 embryos (i), the intersegmental vessel morphology and caudal vein plexus morphologies are restored. k-o, Shown are morphologies of the 15
- cerebrovasculature with the middle mesencephalic central artery (MMCtA), posterior mesencephalic central artery (PMCtA), and cerebellar central arteries (CCtA) in wild-type (k) and different genetic conditions tested (I-o). The cerebrovasculature is oversprouting between the MMCtA and PMCtA (labeled in magenta) in krit1ty219c mutant embryos (I) and to a lesser extend in *tnnt2a* morphants (h). In *krit1^{endothellium>mCherry-Krit1* embryos (n) and in}
- krt1^{endothellium>mCherry-Krit1} embryos (o) this oversprouting phenotype is reduced. p, Quantification of endocardial 20 cell numbers at 48 hpf show a significant increase in krit1ty219c mutant at compared to wild-type. Unpaired, twotailed t-test with Welch's correction; *** P=0.0005 q, Quantification of intersegmental vessel size. krit1^{ty219c} mutant and tnnt2a morphant intersegmental vessels are significantly smaller than wild-type vessels (left panel), whereas the intersegmental vessels of krit1^{endocardium>mCherry-Krit1} embryos are restored to wild-type dimensions (right panel). Left panel, one-way ANOVA, Tukey's multiple comparison test; **P=0.0077; ***P=0.0001; ns, not significant. Right 25
- panel, unpaired, two-tailed t-test with Welch's correction; P=0.4235; ns, not significant. a.u., arbitrary unit. Scale bars: 50 μm.
 - Figure 6. krit1^{ty219c} mutant embryos are rescued by endothelial transgenic expression of EGFP-Krit1.
- 30 a-c, Lateral views of embryos at 5 dpf. Compared with wild-type (a), krit1ty219c mutants (b) develop pericardial edema due to cardiovascular anomalies and have a shortened body length. c, krit1ty219c mutants expressing Tg(fli1a:GAL4FF)^{ubs3}; Tg(UAS:EGFP-Krit1)^{pbb21} (referred to as krit1^{endothelium>EGFP-Krit1}) develop normally until 5 dpf. d, Quantification of the occurrence of a wild-type phenotype among the progeny of different genetic crosses at 5 dpf. In a heterozygous incross of krit1^{ty219c/+}; Tg(fli1a:GAL4FF)^{ubs3/+}; Tg(UAS:EGFP-Krit1)^{pbb21/+} the percentage 35 of wild-type phenotypes is increased as compared to an incross of krit1ty219c/+fish. Student's t-test with s.d.; ****P*=0.0341. Scale bars: 100 μm.

Figure 7. Expression of EGFP-Krit1 and mCherry-Krit1 in wild-type embryos in different vascular beds.

40

a. b. Shown are projection images based on several confocal microscopy z-stack images of different vascular beds including intersegmental vessels (ISVs), dorsal aorta (DA), and caudal vein plexus (CVP) at 24 hpf. EGFP-Krit1 (a, Tg(fli1a:GAL4FF)^{ubs3}; Tg(UAS:EGFP-Krit1)^{pbb21}) and mCherry-Krit1 (b, Tg(fli1a:GAL4FF)^{ubs3}; Tg(UAS:mCherry-Krit1)md40) are expressed in endothelial cells where both fusion proteins also localize to cell junctions (red arrowheads). c-c", Single confocal z-planes of immunohistochemically stained transversal section in trunk region. c, Transgenically expressed mCherry-Krit1 protein localizes to endothelial cell junctions that are marked by junctional 45 proteins Cdh-5 (c') and ZO-1 (c") (yellow arrowheads). c"", Merge image of mCherry-Krit1 (red), Cdh-5 (green), ZO-1 (white), and endothelial cells. The endothelial cells are marked by reporter line Tg(kdrl:EGFP)^{s843} (blue). Scale bars: **a, b,** 50 μm; **c-c''',** 10 μm.

Figure 8. Endothelial expression of the TgBAC(nfatc1:GAL4FF)^{mu286} driver line is restricted to the endocardium. 50 Shown are projection images based on several confocal microscopy z-stack images. All endothelial cells are marked by expression of Tg(kdrl:EGFP)^{s843} (a'-f'', a"-f", false-colored in cyan). a-f, Shown is the Tg(UAS:Lifeact-RFP)^{mu262} expression, driven by TgBAC(nfatc1:GAL4FF)^{mu286} (a"-f", false-colored in magenta) in different embryonic tissues at 54 hpf (a-c) and 78 hpf (d-f). At 54 hpf (a, a") and 78 hpf (d, d") expression of TgBAC(nfatc1:GAL4FF)^{mu286}; $Tq(UAS:Lifeact-RFP)^{mu262}$ is restricted to endocardial cells of the AVC (arrowheads) in the heart, whereas expression is undetectable in other endothelial tissues (**b**, **c**, **e**, **f**,). Scale bars: 50 μ m. 55

Figure 9. TgBAC(nfatc1:GAL4FF)^{mu286}-driven endocardial expression of Tg(UAS:mCherry-Krit1)^{md40} restores endocardial morphology at the atrioventricular canal.

a-c, Embryonic hearts of different genotypes at 54 hpf; shown are projection images based of several confocal microscopy z-stack images. The myocardial cells are outlined by junctional marker Alcam (a-c, black; a'-c', white). The narrowing of the atrioventricular canal (AVC, arrowhead), which is separating the cardiac chambers ventricle (V) and atrium (A) as seen in wild-type (a) is lost in *krit1ty219c* mutants (b) and restored in *krit1endocardium>mCherry-Krit1* embryos (c). a'-c", Single confocal plane sections reveal that endocardial AVC cells (asterisks) express Alcam in wild-type (a', a"), whereas in *krit1ty219c* this Alcam expression is lost (b', b"). c', c", In *krit1endocardium>mCherry-Krit1* embryos, endocardial cell morphology and Alcam expression at the endocardial AVC cells are restored (asterisks). Scale bars: 50 μm.

¹⁰ **Figure 10.** Blood flow patterns in krit1^{endocardium>mCherry-Krit1} are restored.

a-d, Kymographs depicting the displacement (y-axis, μm) of red blood cells over time (x-axis, milli seconds, ms). **e-h**, Single confocal sections with differential interference contrast of blood vessels used for kymographs. The arrows indicate the length and position of the line-scan and the direction of blood flow. Insets show projections that are based on inverted black/white confocal z-stack images of 70 kDa Texas-Red-conjugated dextran tracer dye. **i**, Quantification of red blood cell velocities in the CCtA and DA in wild-type and *krit1^{endocardium>mCherry-Krit1* embryos at 56-60 hpf. Kruskal-Wallis test with s.d.; **P*=0.0468; ****P*=0.0057; ns, not significant. **j**, Quantitative relation of the red blood cell velocity in the CCtA compared with the DA within each embryo shows no significant difference between wild-type and *krit1^{endocardium>mCherry-Krit1* embryos. Unpaired t-test with s.d.; ns, not significant (*P*=0.9739). Scale bar: **e-h**, 50 μm.}}

20

25

30

35

15

5

Figure 11. krit1^{ty219c} endothelial cells contribute to the formation of patent blood vessels.

a-d, Projection images based on several confocal microscopy z-stack images of vessel beds with transplanted, *Krit1-deficient* (*krit1^{ty219c}*) endothelial cells expressing *Tg*(*kdrl:EGFP*)^{s843}, false-colored in magenta, which integrate normally within different vessel beds of the wild-type host. Endothelial cells are marked by immuno-labelling of VE-Cadherin (Cdh-5, white labelling). **g**, **h**, Live-imaging of Krit1-deficient endothelial cells. Intersegmental vessels that harbor Krit1-deficient cells do not collapse, but sustain normal ISV morphology in the presence of blood flow. ISVs, intersegmental vessels; DA, dorsal aorta; CV, caudal vein; CVP, caudal vein plexus. Scale bar: 50 μm.

Figure 12. *krit1^{endocardium>mCherry-Krit1* embryos show normal localization of adherens and tight junction markers, Cdh-5 and ZO-1, respectively.}

a-c, Single confocal z-planes transversal section in trunk region, immunohistochemically stained for cell-cell junctions, which are marked by Cdh-5 (magenta) and ZO-1 (yellow). Nuclei are stained with DAPI (white) and endothelial cells are marked by transgenic expression of *Tg(kdrl:EGFP)*^{s843} (false-colored in cyan). At the cell-cell junctions, Cdh-5 (**a'-c'**) and ZO-1 (**a"-c"**) labelling appears unchanged in *krit1*^{ty219c} (**b', b**") and *krit1*^{endocardium>mCherry-Krit1} embryos (**c', c"**) as compared to wildtype (**a'-a"**).

Figure 13. *Microangiography in krit1*^{ty219c} *mutants*.

a-d, Lateral views of projection images based on inverted black/white confocal z-stack images of the tracer dye in wild-type (a) and *krit1^{ty219c}* (b) embryos at 56 hpf. a, Immediately after injection, 70 kDa Texas-Red-conjugated dextran spreads rapidly throughout the entire vasculature, outlining all vessels, whereas in *krit1^{ty219c}* embryos (b) the tracer dye distributes only to the dilated heart where it remains. c, 3 hours after injection, most of the tracer dye in as diffused to surround tissues, also filling intercellular spaces such as brain ventricles. However tracer dye circulating is still visible in the vasculature such as the cerebral vessels (red arrowheads). d, In contrast, in *krit1^{ty219c}* embryos, the tracer remains located in the heart and diffusion occurs to a lesser degree due to the lack of active circulation.

EXAMPLES

[0131] The invention is further described by the following examples. These are not intended to limit the scope of the invention, but represent preferred embodiments of aspects of the invention provided for greater illustration of the invention described herein.

Introduction

⁵⁵ **[0132]** Hemodynamic forces play an important role in shaping the cardiovascular system¹⁻². The biomechanical forces induced by blood flow are dependent on factors such as vessel diameter and geometry, or blood viscosity and differ in regions closer to the heart than in more peripheral regions^{3,4}. These differences trigger gradations in levels of biomechanical signaling in endothelial cells of distinct vascular beds and have consequences on the cells' orientation, migration,

and proliferation¹. Pathological changes in biomechanical signaling pathways or abnormal patterns of blood flow have been implicated in the etiology of various vascular diseases² including cerebral cavernous malformations (CCMs)⁵⁻⁹. Familial forms of CCM occur with a prevalence of ~0.5 % within the general population¹⁰ and are mainly caused by a two-hit mechanism¹¹ whereby heterozygous carriers with a germline mutation in one allele of either CCM1/KRIT1(Kev

- 5 Interaction Trapped Protein 1)¹², CCM2/MGC4607, or CCM3/PDCD10 (Programmed Cell Death 10)¹³ acquire a second somatic mutation in the other allele¹⁴. The CCM defects occur mainly within the cerebrovasculature and patients have a continuous risk of neurological deficits and hemorrhagic stroke¹⁰. Several lines of evidence point at a role of blood flow in the etiology of CCM lesions: (1) CCM lesions are mostly restricted to venous blood vessels that are perfused at low levels in patients¹⁵; (2) a loss of CCM protein functions causes a strong upregulation of KLF2/4, which are blood-
- 10 flow sensitive mediators of biomechanical signaling within endothelial cell^{5,10,11,217,16-18}; (3) a knockdown of Klf2a/b suppresses cardiovascular malformations in zebrafish CCM mutants⁷; and (4) the formation of lesions in the cerebrovasculature in conditional endothelial-specific CCM1 or CCM2 mouse knock-outs is suppressed by knock-outs of KLF2/4¹⁶⁻¹⁸. Although all of these data suggest that blood flow plays an important role in the CCM pathology, how blood flow modulates the formation of vascular anomalies in CCM mutant tissues has remained unclear. Here we use the
- 15 zebrafish model of CCM1 to explore the role of blood flow within high shear stress vascular bed, the lateral dorsal aorta.

Methods of the Examples

Zebrafish genetics and maintenance.

20

25

[0133] Handling of zebrafish was performed in compliance with German and Brandenburg state law, carefully monitored by the local authority for animal protection (LUVG, Brandenburg, Germany; Animal protocol #2347-18-2015). The following strains of zebrafish were maintained under standard conditions as previously described¹⁹: krit1^{ty219c 20,21}, Tg(kdrl:EGFP)^{\$843 22}, Tg(flia:nEGFP)^{y7 23}, Tg(kdrl:Hsa.HRAS-mCherry)^{s89624}, Tg(YFP)^{mu107 25}. Tg(fli1a:GAL4FF)^{ubs326}, TgBAC(nfatc1:GAL4ff)^{mu28627}, Tg(UAS:EGFP-Krit1, cryaa:EGFP)^{pbb21} [referred to as Tg(UAS:EGFP-Krit1)^{pbb21}]²⁸, Tg(UAS:Lífeact-RFP)^{mu262} (gift from W. Herzog).

Molecular cloning and generation of transgenic zebrafish.

- 30 [0134] We used an existing Gateway pDONR221 vector containing the open reading frame of zebrafish krit1 (referred to as pME-Krit1)²⁹ to generate an N-terminal mCherry fusion construct pME-mCherry-Krit1. This middle-entry construct was used in combination with the Gateway plasmids pDestTol2 and p5E-UAS^{29,30} and p3E-cryaa:EGFPpA²⁸ to generate the final construct pDestTol2pA-UAS:mCherry-Krit1, cryaa:EGFP by standard Gateway cloning recombination reactions. pDestTol2pA-UAS:mCherry-Krit1,cryaa:EGFP (25 pg/embryo) was co-injected with mRNA encoding Tol2 transposase
- 35 (50 pg/embryo) into one-cell-stage zebrafish embryos and F0 fish were screened for germline transmission. The transgenic line Tg(UAS:mCherry-Krit1, cryaa:EGFP)^{md40} [referred to as Tg(UAS:mCherry-Krit1)^{md40}] was selected for further analyses.

Endothelial and endocardial rescue experiments.

40

[0135] For endothelial rescue experiments based on restoration of blood flow in *krit1*^{ty219c} mutants, expression from the stable Tg(UAS:EGFP-Krit1)pbb21 or Tg(UAS:mCherry-Krit1)md40 transgenes was driven using the pan-endothelial Gal4 driver line Tg(fli1a:GAL4FF)^{ubs3} in krit1^{ty219c} mutant embryos (referred to as krit1^{endothelium>EGFP-Krit1} and krit1^{endothelium>mCherry-Krit1}). The rescued embryos were genotyped for presence of the transgenic Gal4 driver, the UAS

- 45 responder constructs and the krit1^{ty219c} mutant allele. For endocardial rescue experiments, we used a comparable strategy using the TgBAC(nfatc1:GAL4ff)^{mu286} driver line to express the stable Tg(UAS:mCherry-Krit1)^{md40} transgene in krit1^{ty219c} mutant embryos (referred to as krit1^{endocardium>mCherry-Krit1}). Rescued krit1^{ty219c} embryos usually presented with mild blood pooling at the inflow tract. Those embryos were pre-selected at 48 hours post fertilization (hpf) and directly processed for further experiments. Subsequently, the presence of transgenic Gal4 driver, UAS responder con-50
- structs, and *krit1^{ty219c}* allele was tested by molecular genotyping.

Antisense oligonucleotide morpholino treatment.

[0136] All antisense oligonucleotide morpholinos were obtained from Gene Tools and injections were performed at 55 the one-cell-stage as previously described³¹. The following amounts were used: *tnnt2a* (5'-CATGTTTGCTCTGATCT-GACACGCA-3')³¹ 2 ng/embryo.

Microangiography and live imaging.

5

[0137] Embryos were treated with 1-phenyl-2-thiourea (PTU) (Sigma Aldrich) to inhibit the appearance of pigmentation. Embryos were manually dechorionated and embedded laterally or dorsally in 1% low melting agarose (Lonza 50081) containing 0.16 mg/ml Tricaine in glass-bottom dishes (MatTek). Microangiography was performed as previously described³². 5 µg/µl Dextran TexasRed (70 kDa, D1864, Invitrogen) was injected into the common cardinal vein (CCV) at 54-60 hpf and immediately processed for optical sectioning with a LSM 710 confocal microscope (Zeiss) using a 10x objective for lateral overviews and 20x objective for dorsal views.

¹⁰ Statistical analysis of genetic test crosses for krit1^{endothelium>EGFP-Krit1}.

[0138] The *krit1*^{ty219c/+} allele harbors a recessive mutation leading to embryonic lethality by 5 day post fertilization (dpf). For the statistical analysis, three independent single pair crosses using adult zebrafish of the genotype *krit1*^{ty219c/+}; $Tg(fli1a:GAL4FF)^{ubs3/+}$ and *krit1*^{ty219c/+}; $Tg(UAS.EGFP-Krit1)^{pbb21/+}$ were performed. The progeny of those crosses was screened for endothelial expression of EGFP-Krit1 at 24 hpf and raised separately from embryos without EGFP-Krit1

- ¹⁵ screened for endothelial expression of EGFP-Krit1 at 24 hpf and raised separately from embryos without EGFP-Krit1 expression. At 5 dpf, embryos were assessed by morphological inspection and considered wild-type when they presented normal blood flow, a defined atrioventricular canal, and two separated and non-ballooned cardiac chambers, all phenotypes characteristically lost in *krit1* mutants. Figure 6d shows the means of the percentages of the occurrence of phenotypically wild-type embryos at 5 dpf within each group among the progeny of three independent crosses with s.d..
- Prism 7 (GraphPad) was used to perform an unpaired, two-tailed t test (P=0.0341). Means are statistically significantly different when P < 0.05.</p>

Statistical analysis of lateral dorsal aorta cell numbers.

- [0139] For the statistical analysis of the endothelial cell numbers in Figure 1h, lateral dorsal aorta cell nuclei were visualized based on 3D reconstructions of confocal microscopy z-stack images using Imaris V7.7.2 software (Bitplane, UK). The *Tg(kdrl:GFP)*^{s843} expression was used to count endothelial cell numbers in an area defined between the branching point of the dorsal aorta and the branching point of the first aortic arch. Cell numbers are shown as means with s.d.. Prism 7 (GraphPad) was used to perform Shapiro-Wilk normality test and one-way ANOVA tests followed by Tukey's multiple comparisons tests. Means are statistically significantly different when P < 0.05.
 - Statistical analysis of the proximal dorsal aorta diameter.
- [0140] The statistical analysis of the diameter of the dorsal aorta in Figure 1i was assessed based on maximum projections of confocal microscopy z-stack images using Fiji software to quantify one measure point (diameter in μm) per proximal dorsal aorta and embryo. Figure 1i shows means with s.d.. Prism 7 (GraphPad) was used to perform Shapiro-Wilk normality test and one-way ANOVA tests followed by Tukey's multiple comparisons tests. Means are statistically significantly different when P < 0.05.</p>
- ⁴⁰ Statistical analysis of the cerebellar central arteries diameter.

[0141] The statistical analysis of the diameter of the cerebellar central arteries (CCtAs) in Figure 3f was assessed based on maximum projections of confocal microscopy z-stack images using Fiji software. Shown the average values of 8-10 measurements (diameter in μ m) of a single CCtA per embryo and means with s.d. from a total of three independent experiments (9-12 embryos per condition). Prism 7 (GraphPad) was used to perform D'Agostino and Pearson normality

test and unpaired, two-tailed t-test with Welch's correction. Means are statistically significantly different when P < 0.05.

Statistical analysis of endothelial cell shapes within the lateral dorsal aorta.

⁵⁰ **[0142]** The statistical analysis of endothelial cell morphologies within the lateral dorsal aorta in Figure 2m, n was assessed based on maximum projections of confocal microscopy z-stack images of immunohistochemically stained endothelial cells marked with an anti-VE-Cadherin (Cdh-5) antibody. Using Imaris and the Freehand tool of Fiji Software, the outlines of five endothelial cells of each lateral dorsal aorta were taken and measured for surface area and perimeter values. The circularity of endothelial cells was determined according to the following equation

55

45

Circularity = $4\pi(area/perimeter^2)$

(with a perfect circle equals 1). Prism 7 (GraphPad) was used to perform D'Agostino and Pearson normality test and one-way ANOVA test followed by Tukey's multiple comparisons test.. Means are statistically significantly different when P < 0.05.

⁵ Statistical analysis of the fluorescent intensity of klf2a:YFP expression in the lateral dorsal aorta.

[0143] For the statistical analysis of the fluorescence intensity of the transgenic expression of *Tg(klf2a:YFP)^{mu107}* in Figure 2e, a region within the lateral dorsal aorta was outlined using the transgenic expression of *Tg(kdrl:Hsa.HRAS-mCherry)^{s896}* based on maximum projections of 5 confocal microscopy z-stack images. Using Fiji Measure Tool, the mean *Tg(klf2a:YFP)^{mu107}* signal intensity was assessed. Figure 2e shows means with s.d. and Prism 7 (GraphPad) was used to perform statistical analyses and normal distribution was tested using Shapiro-Wilk normality test. For the analysis between wild-type, *krit1^{ty219c}* mutants and *krit1^{endocardium>mCherry-Krit1*, a one-way ANOVA tests followed by Tukey's multiple comparisons test was performed. For the analysis between wild-type and *tnnt2a* morphants, an unpaired, two-tailed t-test with Welch's correction was used. Means are statistically significantly different when *P*<0.05.}

15

10

Statistical analysis of endocardial cell numbers.

[0144] For the statistical analysis of the endocardial cell numbers in Figure 5p, endocardial cell nuclei were visualized based on 3D reconstructions of confocal microscopy z-stack images using Imaris V7.7.2 software (Bitplane, UK). Expression of *Tg(kdrl:GFP)*^{s843} was used to count endocardial cell numbers, shown as means with s.d.. Prism 7 (GraphPad) was used to perform D'Agostino and Pearson normality test and unpaired, two-tailed t-test with Welch's correction. Means are statistically significantly different when *P* < 0.05.

Statistical analysis of intersegmental vessel area.

25

[0145] For the statistical analysis of intersegmental vessel (ISV) areas as shown in Figure 5q, ISVs were visualized based on maximum projections of several confocal microscopy images using Fiji software. The $Tg(kdti:GFP)^{s843}$ expression was used to outline and measure the area of at least three ISVs per embryo (n=5-6 per condition) using Fiji software tools and are shown as means with s.d. in Figure 5q.

30 [0146] Prism 7 (GraphPad) was used to perform D'Agostino and Pearson normality test and one-way ANOVA test followed by Tukey's multiple comparisons (Figure 5q, left panel) and unpaired, two-tailed t-test with Welch's correction (Figure 5q, right panel). Means are statistically significantly different when P < 0.05.</p>

Kymographs and statistical analysis.

35

[0147] Embryos were mounted as described for microangiography. Kymographs were generated using differential interference contrast (DIC) and by selecting a line-scan of 106.26 μ m (0.415 μ m per pixel on the y-axis), positioned parallel to the direction of blood flow, and with 1000 cycles covering a time span of 945.45 ms (0.945 ms per pixel on the x-axis). The slope generated by the displacement of the DIC signal translates into the velocity of blood cells as in *m*

- 40 = [tan(α)](0.415 μm/0.945 ms). At least three kymographs per vessel (CCtA and DA, respectively) and embryo were generated (wild-type, n=5; *krit1<sup>endocardium>mCherry-Krit1*, n=3). Figure 10i shows blood flow velocity means with s.d.. Prism 7 (GraphPad) was used to perform D'Agostino and Pearson normality test, showing normal distribution for samples CCtA-WT and CCtA-*krit1<sup>endocadium>mCherry-Krit1*. Statistical analysis was performed using Kruskal-Wallis test and Dunn's multiple comparison test; means are statistically significantly different when *P* < 0.05. Figure 10j shows the ratio of the
 </sup></sup>
- ⁴⁵ blood flow velocity in the CCtA over the blood flow velocity in the DA within each embryo with s.d.. Prism 7 (GraphPad) was used to perform Shapiro-Wilk's normality test and an unpaired, two-tailed t test (*P*=0.9739).

Cell transplantations.

- 50 [0148] Cell transplantations were performed essentially as described³³. Approximately 10-20 cells from *krit1^{ty219c}* mutants marked by transgenic expression of *Tg(kdrl:EGFP)^{s843}* were removed at sphere stage (4-5 hpf) and transplanted into age-matched wild-type host embryos (Figure 11a-d) or *krit1^{ty219c}* mutants marked by transgenic expression of *Tg(kdtl:Hsa.HRAS-mCherry)^{s896}* were transplanted into wild-type embryos marked with *Tg(fli1a:nEGFP)^{y7}* (Figure 11e, f). Donor genotypes were determined based phenotypes at 48 hpf or by molecular genotyping. The visual inspection of
- ⁵⁵ cell shapes of transplanted cells was performed based on identifying the transgenic expression of *Tg(kdrl:EGFP)*^{s843} or *Tg(kdtl:Hsa.HRAS-mCherry)*^{s896} combined with immuno-labelling against the cell-junctional marker Cdh-5.

Sample preparation and mass spectrometry.

[0149] Pooled protein extracts (~25μg/sample) from 2 days post fertilization (dpf) zebrafish embryonic tails were mixed with SDS sample buffer and boiled at 95 °C for 10 min. Each sample was derived from approximately 30 embryos and experiments were performed in biological triplicates. Within each replicate, wild-type and *krit1^{ty219c}* mutant embryos were siblings derived from one clutch that were treated in parallel. Subsequently, the samples were separated side-by-side by SDS-PAGE (Tris-glycine gradient gel, 4-20%, Invitrogen). Whole gel lanes of corresponding samples were cut into 28 bands and in-gel digestion was performed using ¹⁶O/¹⁸O-labeling as previously described^{34,35}. In brief, samples were incubated over night at 37 °C with 50 ng trypsin (sequencing grade modified, Promega) in 25 μL of 50 mM ammonium

- ¹⁰ bicarbonate. Wild-type samples were digested in the presence of heavy water (Campro Scientific GmbH, 97% ¹⁸O), whereas *krit1ty219c* and *tnnt2a* morphant samples were digested in the presence of regular ¹⁶O-water. To prevent oxygen back-exchange by residual trypsin activity, samples were heated at 95 °C for 20 min. After cooling down, 50 µL of 0.5% TFA in acetonitrile was added to decrease the pH of the sample from ~8 to ~2. Afterwards, corresponding heavy- and light-isotope samples were combined and peptides were dried under vacuum. Peptides were reconstituted in 10 µL of
- 0.1% (v/v) TFA, 5% (v/v) acetonitrile and 6.5 μL were analyzed by a reversed-phase capillary nano liquid chromatography system (Ultimate 3000, Thermo Scientific) connected to an Orbitrap Velos mass spectrometer (Thermo Scientific). LC separations were performed on a capillary column (Acclaim PepMap100 C18, 2 μm, 100 Å, 75 μm i.d. × 25 cm, Thermo Scientific) at an eluent flow rate of 300 nL/min. The column was pre-equilibrated with 3% mobile phase B followed by a linear increase of 3-50% mobile phase B in 50 min. Mobile phase A contained 0.1% formic acid in water, and mobile
- ²⁰ phase B contained 0.1% formic acid in acetonitrile. Mass spectra were acquired in a data-dependent mode utilizing a single MS survey scan (m/z 350-1500) with a resolution of 60,000 in the Orbitrap and MS/MS scans of the 20 most intense precursor ions in the linear trap quadrupole.

Proteomic data analysis.

25

45

[0150] Identification and quantification of ¹⁶O/¹⁸O-labeled samples was performed using the Mascot Distiller Quantitation Toolbox (version 2.6.3.0) and Mascot Server (version 2.5.0, Matrix Science). Experimental data was searched against the SwissProt *Danio rerio* protein database (April 15, 2017, 43.539 sequences). A maximum of two missed cleavages was allowed and the mass tolerance of precursor and sequence ions was set to 10 ppm and 0.35 Da,

- ³⁰ respectively. Methionine oxidation, acetylation (protein N-terminus), propionamide (C), and C-terminal ¹⁸O₁ and ¹⁸O₂-isotope labelling were used as variable modifications. A significance threshold of 0.05 was used based on decoy database searches. For quantification at protein level, a minimum of two quantified peptides and a maximum standard deviation of 3 were set as thresholds. Relative protein ratios were calculated from the intensity-weighted average of all peptide ratios. Known contaminants (e.g. keratins) were removed from the protein output tables. Normalization of protein
- ³⁵ ratios was performed using the median ratio of all proteins. Only proteins that were identified and quantified in at least 2 out of 3 biological replicates are reported in table S2. Proteins with a consistent minimum fold change of >1.5 (in each replicate) were considered as affected. Proteins with conflicting ratios between biological replicates were considered as unchanged.

⁴⁰ Immunohistochemistry and imaging.

[0151] Zebrafish whole-mount immunohistochemistry was performed as previously described²⁸. The following antibodies were used: rabbit anti-VE-Cadherin (Cdh-5) (1:200, gift from M. Affolter³⁶); mouse anti-Alcam (1:200, DSHB AB_531904); mouse anti-ZO-1 (1:200, Life Technologies 33-9100). Secondary antibodies were Alexa Fluor 633-conjugated goat anti-rabbit (1:200, Invitrogen A21070); FITC-conjugated donkey anti-mouse (1:200, Jackson ImmunoResearch 715-095-150); goat anti-rabbit DyLight 405 (1:200, Jackson ImmunoResearch 123-475-021); goat anti-mouse Dylight 649 (1:200, Jackson ImmunoResearch 205-492-176). Embryos were fixed with 2% PFA overnight and permeabilized with PBST with 0.5% Triton X-100 for 1 hour and subsequently incubated with primary antibody diluted in PBST

with 0.2% Triton X-100, 1% BSA, and 5% NGS. All specimens were mounted in SlowFade Gold (Invitrogen S36936).
 Images were recorded on LSM 710 or LSM 780 confocal microscopes (Zeiss) and processed with Imaris V7.7.2 (Bitplane, UK) and Fiji software.

Results of the examples

⁵⁵ **[0152]** In animal models, a complete loss of CCM proteins disrupts cardiac function^{7,16,20,21,37} and vascular anomalies develop not only in small venous vascular beds, as in human patients, but also within the endocardium, aorta, and other major blood vessels^{,7,16,17,37,38}. The role of blood flow as an essential stimulus for correct cardiovascular development is poorly understood in the context of CCM vascular defects⁵⁻⁷. Hence we wondered whether the vascular anomalies

in high shear stress vascular beds such as the zebrafish aorta^{3,4} only developed because CCM mutant endothelial cells were lacking blood flow as a biomechanical stimulus.

[0153] Zebrafish mutants lacking blood flow, such as *troponin t2a (tnnt2a)* mutants that are defective in an essential regulatory sarcomeric protein required for cardiac contractility, can survive for several days; this has permitted longitudinal

- 5 studies into the developmental consequences of lacking blood flow³¹. To analyze the effects of a lack of hemodynamic forces on vascular patterning, we compared the vessels of *tnnt2a* morphants in which blood flow is absent with those in *krit1^{ty219c}* mutantS^{20,21} (Fig. 1a-c). The zebrafish *krit1^{ty219c}* mutants form massively dilated hearts that fail to produce blood flow and are marked by increased endocardial cell numbers as compared to wild-type (Fig. 5a, b, p). The *krit1^{ty219c}* mutant vasculature is also characterized by collapsed intersegmental vessels, dilated and fused caudal venous plexus
- (Fig. 1a, b; Fig. 5f, g, q), and oversprouting cerebrovasculature (Fig. 5k, I). The *tnnt2a* morphant animals had anomalies comparable to *krit1^{ty219c}* mutants in some smaller endothelial beds including intersegmental vessels, the caudal venous plexus, and the brain vasculature (Fig. 5f-h, k-m). However, in striking contrast to the massive hyperplasia of both endocardium and lateral dorsal aorta in *krit1^{ty219c}* mutants (Fig. 1d, e, h; Fig. 5a, b)⁷, *tnnt2a* morphants developed a smaller endocardium³⁹ (Fig. 5c) and lateral dorsal aorta (Fig. 1f). This indicates that the vascular anomaly of the lateral
- ¹⁵ dorsal aorta in *krit1^{ty219c}* mutants does not simply result from a loss of blood flow, but rather from a combined effect of loss of Krit1 and absence of blood flow. One way of testing this hypothesis would be to restore blood flow in *krit1^{ty219c}* mutants and to observe whether this suppressed the vascular malformation of the lateral dorsal aorta. [0154] To restore blood flow in *krit1^{ty219c}* mutants, we first generated transgenic lines of zebrafish for the tissue-specific rescue with functional EGFP-Krit1²⁸ or mCherry-Krit1 fusion proteins. Expression from the stable *Tq(UAS:EGFP*-
- Krit1)^{pbb21} or Tg(UAS:mCherry-Krit1)^{md40} transgenes was driven using the pan-endothelial Gal4 driver line Tg(fli1a:GAL4FF)^{ubs3} in krit1^{ty219c} mutant embryos (referred to as krit1^{endothelium>EGFP-Krit1} and krit1^{endothelium>mCherry-Krit1}) (see Materials and Methods for a more detailed explanation of the experimental procedure). This restored early cardiovascular development including the morphology of the endocardial chambers and atrioventricular canal (AVC), lumenization of intersegmental vessels, network formation of caudal venous plexus, and
- normal angiogenesis of cerebral vasculature (Fig. 5d, i, n). Accordingly, blood flow was re-established, and *krit1^{endothelium>EGFP-Krit1* or *krit1^{endothelium>mCherry-Krit1* embryos were phenotypically normal until 5 days post-fertilization (dpf) (Fig. 6). In line with previous observations from other cellular model systems, the EGFP-Krit1 and mCherry-Krit1 fusion proteins localized also to cell junctions within zebrafish endothelial cells (Fig. 7)⁴⁰⁻⁴². Hence, pan-endothelial expression of EGFP-Krit1 or mCherry-Krit1 in *krit1^{ty219c}* mutants rescues heart morphology and function and also permits a proper vascular development throughout embryogenesis.}}
- [0155] To address whether a restoration of blood flow would affect Krit1-deficient endothelial cells, we used a Gal4 driver line *TgBAC(nfatc1:GAL4FF)^{mu286}* which is not expressed within endothelial cells outside of the heart. Within the cardiovascular system, this transgenic driver line expresses Gal4 only within endocardial cells, an expression domain which is restricted mostly to the atrioventricular canal (AVC) between 54-78 hpf (Fig. 8a, d), but which is not present
- ³⁵ within any other endothelial tissue (Fig. 8b, c, e, f). This transgenic driver line was used to express mCherry-Krit1 within the *krit1^{ty219c}* mutant endocardium (referred to as *krit1^{endocardium>mCherry-Krit1*). This resulted in embryos whose hearts were functionally rescued including AVC morphology (Fig. 5e; Fig. 9) and that produced blood flow until 3-4 dpf within an endothelium that was otherwise depleted of Krit1. To further characterize blood flow conditions in *krit1^{endocardium>mCherry-Krit1* embryos, we quantified the pattern and the velocity of blood flow in cerebral arteries versus}}
- 40 the dorsal aorta. While the blood flow pattern in the dorsal aorta was generally more rapid and highly pulsatile, within smaller vessels of the cerebellar central arteries (CCtAs) in *krit1^{endocardium>mCherry-Krit1* and wild-type it was laminar and slower (Fig. 10a-i). Importantly, the quantitative differences in blood flow velocities between these two vascular beds within *krit1^{endocardium>mCherry-krit1* embryos were similar to those in wild-type embryos (Fig. 10j.).}}
- [0156] Strikingly, the morphology of the lateral dorsal aorta and its numbers of endothelial cells as well as the diameter of the adjacent dorsal aorta were completely restored in *krit1^{endocardium>mCherry-Krit1* embryos (Fig. 1g-i; n=4). We next set out to investigate whether the restoration of the lateral dorsal aorta morphology in *krit1^{endocardium>mCherry-Krit1* embryos was due to changes of endothelial cell morphologies compared to *krit1^{ty219c}* mutants at 54-60 hpf. To quantify endothelial cell morphologies, we counterstained embryos with an antibody against Cdh-5. This revealed that wild-type endothelial cells of the lateral dorsal aorta were aligned with the direction of blood flow and had moderate surface area sizes (Fig.}}
- 50 1j, m, n; n= 3) while *krit1^{ty219c}* mutant endothelial cells had enlarged surface area sizes and were highly elongated (less circularity) (Fig. 1k, m, n; n=3). Upon restoration of blood flow in *krit1^{endocardium>mCherry-Krit1* embryos, endothelial cell elongation was normalized whereas cell surface areas were not reduced (Fig. 11, m, n; n=3). We conclude that blood flow suppresses several aspects of vascular anomalies that are characteristic of the lateral dorsal aorta and the adjacent dorsal aorta in *krit1^{ty219c}* mutants. For instance, blood flow reverts the striking elongation phenotype of lateral dorsal 355 aorta endothelial cells in *krit1^{ty219c}* mutants.}
 - **[0157]** Previous studies showed that vascular defects due to the loss of CCM proteins involve pathological KLF2/4 signaling^{7,16-18}. This triggers an endothelial-to-mesenchymal transition (endMT) within lowly-perfused blood vessels^{18,43,44}, a process common to many vascular pathologies⁴⁵. To assess whether Klf2a expression was altered

also within the lateral dorsal aorta, we used a transgenic *klf2a* reporter line²⁵. Quantifications using this reporter line revealed that in comparison to wild-type, *krit1*^{ty219c} mutants strongly expressed *klf2a* within the lateral dorsal aorta, although these embryos lack blood flow (Fig. 2a, b, e). This was different from *tnnt2a* morphants which also lack blood and have a strongly reduced *klf2a* reporter expression⁴⁶ (Fig. 2c, e). Restoration of blood flow in

- *krit1<sup>endocardium>mCherry-Krit1* embryos did not alter the high levels of *klf2a* expression (Fig. 2d, e). We conclude that since *krit1<sup>endocardium>mCherry-Krit1* embryos lack a hyperplastic lateral dorsal aorta, high expression levels of Klf2a are apparently not sufficient to cause this vascular anomaly when blood flow is present.
 [0158] Other blood vessels that are normally affected in *krit1^{ty219c}* mutants were also rescued in
 </sup></sup>
- *krit1endocardium>mCherry-Krit1* embryos as assessed by morphological inspection; this included intersegmental vessels,
 which were lumenized and the caudal venous plexus that shaped into a network-like system (Fig. 5j, q). In a complementary approach, *krit1^{ty219c}* mutant endothelial cells that were transplanted into wild-type embryos contributed to intersegmental blood vessels which were also correctly lumenized (Fig. 11; n=6 host embryos with transplanted cells). Furthermore, the oversprouting brain vasculature phenotype in *krit1^{ty219c}* mutants was markedly reduced in *krit1<sup>endocardium>mCherry-Krit1* embryos (Fig. 5l, o).
 </sup>
- ¹⁵ **[0159]** Immunohistological stainings against adherens and tight junction markers Cdh-5 and ZO-1 in the dorsal aorta and the caudal vein plexus in *krit1endocardium>mCherry-Krit1* embryos were unchanged as compared to *krit1ty219c* or wildtype embryos (Fig. 12). These data indicated that the barrier function of the endothelial vasculature was intact within most blood vessels and preventing the tracer dye from leakage into the surrounding tissue. To further corroborate this finding, we performed mass spectrometric analyses of protein samples derived from tail regions of wild-type and *krit1ty219c*
- 20 mutant embryos at 2 dpf. In tune with the observation that most blood vessels were tight against leakiness, detectable cell junctional proteins in *krit1^{ty219c}* mutants did not significantly differ in their protein levels relative to wild-type (*Table* 3).

2	5
۷.	0

30

35

40

45

50

55

Table 3. List of known adherens and tight junctional proteins and their relative changes in krit1^{ty219c} mutant tissues compared to wild-type at 2 dpf determined using quantitative mass spectrometry.

5	Accession	Gene Name	Replicate	wild-type / mutant protein levels	SD (geo)	number quantified of peptides
10			A	1.088	1.087	20
	Q9PVF8_DANRE	ctnna1	В	1.026	1.045	25
			С	1.319	1.036	18
15			А	1.052supp	1.115	3
	CTNA2_DANRE	ctnna2	В	1.053	1.095	8
20			С	1.124	1.095	4
			А	0.668	1.153	12
25	A0A0N4SUA5_DANRE	ctnnb1	В	0.981	1.046	14
			с	1.175	1.205	8
	E7FC99_DANRE	ctnnb2	с	1.079	1.296	6
30			А	0.978	1.163	2
	E7F2W2_DANRE	tjp1a	В	1.166	1.176	3
35			с	0.750	1.086	4
		tin1b	В	1.171	1.239	3
40		урто	С	0.730	1.04	5
			А	0.727	1.088	4
45	F6PEN0_DANRE	tjp2a	В	1.160	1.089	10
40			С	1.023	1.083	8
	BOUXH8_DANRE	tjp2b	В	0.795	1.158	5
50	E9QGL7_DANRE	tjpЗ	В	0.899	1.378	3

55

|--|--|

[0160] The apparent phenotypic restoration of vascular morphology in *krit1^{endocardium>mCherry-Krit1* embryos prompted us to use microangiography to investigate whether blood vessels were also tight against leakage of a tracer dye anywhere}

within the vasculature. In particular, we wondered whether the loss of Krit1 would result in defects within lowly-perfused blood vessels^{3,4} since those were not protected by high levels of shear stress as seen in the dorsal aorta. We injected 70kDa Texas-Red-conjugated dextran into the lateral common cardinal vein, which spread rapidly throughout all vascular beds in *krit1endocardium>mCherry-Krit1* and wild-type embryos and investigated the distribution of the tracer dye immediately

- within 10-15 minutes upon injection (Fig. 3a-e). Of note, microangiography was not possible in *krit1^{ty219c}* embryos because the tracer dye remained at the site of injection close to and within the heart (Fig. 13). In tune with the finding by mass spectrometry and immunohistochemical sections of blood vessels that there were no obvious endothelial cell barrier dysfunctions, inspection through microangiography revealed that at 54-60 hpf nearly the entire vasculature was tightly sealed against a release of the dextran in wild-type and *krit1^{endocardium>mCherry-Krit1* embryos (Fig. 3c). The micro-}
- ¹⁰ angiography survey of the entire vasculature revealed an exception only in small anterior cerebellar central arteries, which were normally perfused with the tracer dye but were all dilated and showed a leakage of the tracer dye in some *krit1endocardium>mCherry-Krit1* embryos immediately upon injection (n=5/33 embryos injected; Fig. 3e, f). Taken together, the data suggest that in contrast to the restoration of the hyperplastic lateral dorsal aorta in *krit1endocardium>mCherry-Krit1* embryos, 1) lesions can occur within lowly-perfused blood vessels and 2) vessel dilation is not restored in all small Krit1-
- ¹⁵ deficient cerebral blood vessels.

Discussion of the examples

- [0161] Cerebral cavernous malformations are vascular pathologies that occur mainly within a subset of lowly-perfused blood vessels of the brain. Our study provides functional evidence for a modifying effect exerted by blood flow. Our results show that in *krit1^{endocardium>mCherry-Krit1* embryos, the lateral dorsal aorta is protected from vascular anomalies, while the embryonic cerebrovasculature recapitulates pathological phenotypes observed in mouse models that are based on conditional endothelial-specific knockouts of CCM genes^{17,38,45}. In mouse, the conditional pan-endothelial depletion of CCM proteins leads to lesion formation mainly within vascular beds of the cerebellar region of the brain which are}
- ²⁵ related to the cerebellar central arteries affected in zebrafish. Clearly, the presence of blood flow is not sufficiently protective in these small cerebral blood vessels. Apparently, other factors may modify the occurrence of vascular anomalies. For instance, the unique molecular identities of different cerebral vascular beds⁴⁷, unique cellular environments of the brain³⁸, autophagy⁹, the innate immune system⁴⁸, differences in redox signalling within particular vascular beds⁹, different developmental states of endothelial cells⁴⁹, or chromatin modifications/epigenetic states⁵⁰ may all contribute
- 30 to the etiology of the CCM pathology. [0162] Our current work implies that blood flow is a physiological modifier with a vasoprotective effect on Krit1-deficient endothelial cells. This suggests that the pathological effects of KLF2/4 signaling upon loss of CCM proteins may be masked when high levels of blood flow activate additional vasoprotective biomechanical signaling pathways or funnel KLF2/4 signal transduction towards vasoprotective target genes (Fig. 4). In support of this model, we found that upon
- 35 restoration of blood flow in *krit1^{endocardium>mCherry-Krit1* embryos, high expression levels of *klf2a* are not sufficient to trigger the pathological hyperplastic phenotype of the lateral dorsal aorta. This finding may provide an explanation why CCM patients never suffer from vascular anomalies within highly-perfused blood vessels, since these are protected by high levels of blood flow. Uncovering those fluid shear stress-dependent vasoprotective molecular pathways that shield large blood vessels from pathophysiological KLF2/4 signaling may be relevant not only for a better understanding of cerebral}
- 40 cavernous malformations but also of other vascular pathologies. It will be intriguing to revisit the possibility that KLF2/4 may be culprits in other vascular pathologies as well, when protective biomechanical signaling pathways become derailed.

REFERENCES

⁴⁵ [0163]

1. Baeyens N, Schwartz MA. Biomechanics of vascular mechanosensation and remodeling. Mol Biol Cell. 2016;27:7-11.

⁵⁰ 2. Baeyens N, Bandyopadhyay C, Coon BG, Yun S, Schwartz MA. Endothelial fluid shear stress sensing in vascular health and disease. J Clin Invest. 2016;126:821-828.

3. Anton H et al. Pulse propagation by a capacitive mechanism drives embryonic blood flow. Development. 2013;140:4426-4434.

55

4. Boselli F, Freund JB, Vermot J, Blood flow mechanics in cardiovascular development. Cell. Mol. Life Sci. 2015;72;2545-2559.

5. Macek Jilkova Z, Lisowska J, Manet S, Verdier C, Deplano V, Geindreau C, Faurobert E, Albigès-Rizo C, Duperray A. CCM proteins control endothelial β 1 integrin dependent response to shear stress. Biol Open. 2014;3:1228-1235.

 Mleynek TM, Chan AC, Redd M, Gibson CC, Davis CT, Shi DS, Chen T, Carter KL, Ling J, Blanco R, Gerhardt
 H, Whitehead K, Li DY. Lack of CCM1 induces hypersprouting and impairs response to flow. Hum Mol Genet. 2014;23:6223-6234.

7. Renz M, Otten C, Faurobert E, Rudolph F, Zhu Y, Boulday G, Duchene J, Mickoleit M, Dietrich A-C, Ramspacher C, Steed E, Manet-Dupé S, Benz A, Hassel D, Vermot J, Huisken J, Tournier-Lasserve E, Felbor U, Sure U, Albiges-Rizo C, Abdelilah-Seyfried S. Regulation of β1 integrin-Klf2-mediated angiogenesis by CCM proteins. Dev Cell. 2015;32:181-190.

8. Liu H, Rigamonti D, Badr A, Zhang J, Ccm1 Regulates Microvascular Morphogenesis during Angiogenesis. Journal of Vascular Research. 2011;48:130-140.

15

20

10

9. Retta SF, Glading AJ, Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin. The International Journal of Biochemistry & Cell Biology. 2016;81:254-270.

10. Spiegler S, Rath M, Paperlein C, Felbor U. Cerebral Cavernous Malformations: An Update on Prevalence, Molecular Genetic Analyses, and Genetic Counselling. Mol Syndromol. 2018;9:60-69.

11. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.

12. Dubovsky J, Zabramski JM, Kurth J, Spetzler RF, Rich SS, Orr HT, Weber JL. A gene responsible for cavernous
 malformations of the brain maps to chromosome 7q. Hum Mol Genet. 1995;4:453-458.

13. Craig HD, Günel M, Cepeda O, Johnson EW, Ptacek L, Steinberg GK, Ogilvy CS, Berg MJ, Crawford SC, Scott RM, Steichen-Gersdorf E, Sabroe R, Kennedy CT, Mettler G, Beis MJ, Fryer A, Awad IA, Lifton RP. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet. 1998;7:1851-1858.

14. Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet. 2009;18:919-930.

35

50

30

15. Chohan MO, Marchio S, Morrison LA, Sidman RL, Cavenee WK, Dejana E, Yonas H, Pasqualini R, Arap W. Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review. JAMA Neurol. 2018.

- 40 16. Zhou Z, Rawnsley DR, Goddard LM, Pan W, Cao X-J, Jakus Z, Zheng H, Yang J, Arthur JSC, Whitehead KJ, Li D, Zhou B, Garcia BA, Zheng X, Kahn ML. The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression. Dev Cell. 2015;32:168-180.
- 17. Zhou Z, Tang AT, Wong W-Y, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, Arthur
 JSC, Whitehead KJ, Awad IA, Li DY, Zheng X, Kahn ML. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016;532:122-126.

18. Cuttano R, Rudini N, Bravi L, Corada M, Giampietro C, Papa E, Morini MF, Maddaluno L, Baeyens N, Adams RH, Jain MK, Owens GK, Schwartz M, Lampugnani MG, Dejana E. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations. EMBO Mol Med. 2016;8:6-24.

19. Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). 2000. 4th ed., Univ. of Oregon Press, Eugene.

- ⁵⁵ 20. Chen JN et al, Mutations affecting the cardiovascular system and other internal organs in zebrafish. Development 1996; 123:293-302.
 - 21. Mably JD, Chuang LP, Serluca FC, Mohideen M-APK, Chen J-N, Fishman MC. santa and valentine pattern

concentric growth of cardiac myocardium in the zebrafish. Development. 2006;133:3139-3146.

5

15

25

35

40

50

22. Jin S-W, Beis D, Mitchell T, Chen J-N, Stainier DYR. Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. Development. 2005;132:5199-5209.

23. Roman BL, Phan VN, Lawson ND, Kulik M, Childs S, Lekven AC, Garrity DM, Moon RT, Fishman MC, Lechleider RJ, Weinstein BM. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development. 2002. 129;3009-3019.

10 24. Chi NC, Shaw RM, De Val S, Kang G, Jan LY, Black BL, Stainier DYR. Foxn4 directly regulates tbx2b expression and atrioventricular canal formation. Genes Dev. 2008;22:734-739.

Sugden WW, Meissner R, Aegerter-Wilmsen T, Tsaryk R, Leonard EV, Bussmann J, Hamm MJ, Herzog W, Jin Y, Jakobsson L, Denz C, Siekmann AF. Endoglin controls blood vessel diameter through endothelial cell shape changes in response to haemodynamic cues. Nat Cell Biol. 2017; 19:653-665.

26. Herwig L et al. Distinct Cellular Mechanisms of Blood Vessel Fusion in the Zebrafish Embryo. Current Biology. 2011 ;21:1942-1948.

20 27. Pestel J, Ramadass R, Gauvrit S, Helker C, Herzog W, Stainier DYR. Real-time 3D visualization of cellular rearrangements during cardiac valve formation. Development. 2016;143:2217-2227.

28. Donat S, Lourengo M, Paolini A, Otten C, Renz M, Abdelilah-Seyfried S. Heg1 and Ccm1/2 proteins control endocardial mechanosensitivity during zebrafish valvulogenesis. Elife. 2018;7.

29. Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS, Parant JM, Yost HJ, Kanki JP, Chien C-B. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev Dyn. 2007;236:3088-3099.

30 30. Villefranc JA, Amigo J, Lawson ND. Gateway compatible vectors for analysis of gene function in the zebrafish. Dev Dyn. 2007;236:3077-3087.

31. Sehnert AJ, Huq A, Weinstein BM, Walker C, Fishman M, Stainier DYR. Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. Nat Genet. 2002;31:106-110.

- 32. Weinstein BM, Stemple DL, Driever W, Fishman MC. Gridlock, a localized heritable vascular patterning defect in the zebrafish. Nat Med. 1995;1:1143-1147.
 - 33. Li P, White RM, Zon LI. Transplantation in zebrafish. Methods Cell Biol. 2011;105:403-417.

34. Lange S, Sylvester M, Schümann M, Freund C, Krause E. Identification of phosphorylation-dependent interaction partners of the adapter protein ADAP using quantitative mass spectrometry: SILAC vs (18)O-labeling. J Proteome Res. 2010;9:4113-4122.

⁴⁵ 35. Kristiansen TZ, Harsha HC, Grønborg M, Maitra A, Pandey A. Differential membrane proteomics using 180labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res. 2008;7:4670-4677.

36. Blum Y, Belting H-G, Ellertsdottir E, Herwig L, Lüders F, Affolter M. Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the zebrafish embryo. Dev Biol. 2008;316:312-322.

- 37. Kleaveland B, Zheng X, Liu JJ, Blum Y, Tung JJ, Zou Z, Sweeney SM, Chen M, Guo L, Lu M, Zhou D, Kitajewski J, Affolter M, Ginsberg MH, Kahn ML. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med. 2009;15:169-176.
- ⁵⁵ 38. Boulday G, Blécon A, Petit N, Chareyre F, Garcia LA, Niwa-Kawakita M, Giovannini M, Tournier-Lasserve E.
 Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis:
 implications for human cerebral cavernous malformations. Dis Model Mech. 2009;2:168-177.

39. Dietrich A-C, Lombardo VA, Veerkamp J, Priller F, Abdelilah-Seyfried S. Blood flow and Bmp signaling control endocardial chamber morphogenesis. Dev Cell. 2014;30:367-377.

40. Fisher OS, Boggon TJ. Signaling pathways and the cerebral cavernous malformations proteins: lessons from 5 structural biology. Cell Mol Life Sci. 2014;71:1881-1892.

41. Glading AJ, Ginsberg MH. Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. Dis Model Mech. 2010;3:73-83.

- ¹⁰ 42. Günel M, Laurans MSH, Shin D, DiLuna ML, Voorhees J, Choate K, Nelson-Williams C, Lifton RP. KRIT1, a gene mutated in cerebral cavernous malformation, encodes a microtubuleassociated protein. Proc Natl Acad Sci USA. 2002;99:10677-10682.
- 43. Bravi L, Malinverno M, Pisati F, Rudini N, Cuttano R, Pallini R, Martini M, Larocca LM, Locatelli M, Levi V, Bertani
 GA, Dejana E, Lampugnani MG. Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition. Stroke. 2016;47:886-890.

44. Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro C, Corada M, Ferrarini L, Orsenigo F, Papa E, Boulday G, Tournier-Lasserve E, Chapon F, Richichi C, Retta SF, Lampugnani MG, Dejana E. EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature. 2013;498:492-496.

45. Dejana E, Lampugnani MG. Endothelial cell transitions. Science. 2018;362:746-747.

46. Vermot J, Forouhar AS, Liebling M, Wu D, Plummer D, Gharib M, Fraser SE. Reversing blood flows act through
 klf2a to ensure normal valvulogenesis in the developing heart. PLoS Biol. 2009;7:e1000246.

47. Vanlandewijck M, He L, Mae MA, Andrae J, Ando K, Del Gaudio F, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554:475.

48. Tang AT, et al. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017;545:305-310.

49. Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity. Nature Communications. 2017;8:14361

35

20

50. Morini MF, Giampietro C, Corada M, Pisati F, Lavarone E, Cunha SI, et al. VE-Cadherin-Mediated Epigenetic Regulation of Endothelial Gene Expression. Circulation Research. 2018;122(2):231-45

- 51. Otten, C., Knox, J., Boulday, G., Eymery, M., Haniszewski, M., Neuenschwander, M., Radetzki, S., Vogt, I.,
 Hahn, K., De Luca, C., Cardoso, C., Hamad, S., Igual Gil, C., Roy, P., Albiges-Rizo, C., Faurobert, E., von Kries, J.P., Campillos, M., Tournier-Lasserve, E., Derry, W.B., Abdelilah-Seyfried, S., 2018. Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations. EMBO Mol Med 10.
- 52. Reinhard, M., Schuchardt, F., Meckel, S., Heinz, J., Felbor, U., Sure, U., Geisen, U., 2016. Propranolol stops
 progressive multiple cerebral cavernoma in an adult patient. J. Neurol. Sci. 367, 15-17.

53. Zabramski, J.M., Kalani, M.Y.S., Filippidis, A.S., Spetzler, R.F., 2016. Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. World Neurosurgery 88, 631-639.

50

SEQUENCE LISTING

	<11	0> U1	nive	rsitä	ät Po	otsda	am									
5	<12	0> TI	RANS	GENIC	C FIS	зн мо	ODEL	FOR	STR	OKE						
	<13	0> 22	224/:	19EP2	2											
	<16	0> 20	0													
10	<17	0> В:	issai	₽ 1.3	3.6											
	<21) <21	0> 1 1> 74	41													
	<21	2> PI	RT .		_											
15	<21.	3> Da	anio	rer	10											
	<22) <22:	0> 3> p:	rote	in se	eque	nce (of C	СМ1	(KRI	F1)						
20	<40	0> 1														
20	Met	Met	Gly	Asn	Gln 5	Glu	Leu	Glu	Glu	Val 10	Phe	Val	Ala	Val	Ile 15	Arg
	Pro	Lys	Asn	Thr 20	Thr	Ser	Leu	Asn	Ser 25	Lys	Glu	Tyr	Arg	Ala 30	Lys	Ser
25	Tyr	Glu	Ile 35	Leu	Leu	Ile	Glu	Val 40	Pro	Leu	Glu	Gly	Lys 45	Glu	Lys	Lys
	Arg	Lys 50	Lys	Val	Leu	Leu	Gly 55	Thr	Lys	Ile	His	Ala 60	Asp	Ser	Asp	Arg
	Thr 65	Lys	Ser	Ile	Leu	Glu 70	Phe	Val	Asp	Glu	Thr 75	Thr	Lys	Pro	Ile	Ser 80
30	Asn	Asn	Gln	Gly	Ile 85	Ile	Gly	Lys	Arg	Val 90	Val	His	Met	Arg	Lys 95	Phe
	Leu	Leu	Asp	Gly 100	Asp	Ser	Gly	Gly	Lys 105	Glu	Ala	Ser	Leu	Phe 110	Ile	Val
	Pro	Ile	Asn 115	Val	Lys	Asp	Asn	Ser 120	Lys	Ser	Val	His	His 125	Pro	Gly	Ser
35	Pro	Ser 130	Phe	Tyr	Cys	Leu	Gln 135	Asp	Ile	Met	Arg	Val 140	Cys	Ser	Glu	Thr
	Ser 145	Ala	His	Phe	Ser	Ser 150	Ser	Thr	Ser	Lys	Met 155	Leu	Leu	Ala	Leu	Asp 160
	Lys	Trp	Leu	Ala	Glu 165	Gln	His	Thr	Val	Pro 170	His	Ala	Ile	Pro	Ala 175	Leu
40	Phe	Arg	Pro	Ala 180	Pro	Val	Asp	Arg	Val 185	Lys	Thr	Asn	Val	Ser 190	Asn	Pro
	Ala	Tyr	Ala 195	Val	Glu	Lys	Gln	Thr 200	Asp	Gly	Thr	Leu	His 205	Met	Gly	Tyr
45	Thr	Ala 210	Leu	Glu	Ile	Lys	Ser 215	Lys	Leu	Met	Ser	Leu 220	Glu	Lys	Ala	Asp
	Leu 225	Cys	Ile	Gln	Asn	Pro 230	Leu	Tyr	Gly	Ser	Asp 235	Leu	Gln	Tyr	Thr	Asn 240
	Arg	Val	Asp	Lys	Val 245	Ile	Ile	Asn	Pro	Tyr 250	Phe	Gly	Leu	Gly	Ala 255	Pro
50	Asp	Tyr	Ser	Lys 260	Ile	Gln	Ile	Pro	Lys 265	Arg	Asp	Lys	Trp	Gln 270	His	Ser
	Met	Thr	Ser 275	Val	Thr	Glu	Asp	Lys 280	Glu	Arg	Gln	Trp	Val 285	Asp	Asp	Phe
	Pro	Leu 290	His	Arg	Ser	Ala	Cys 295	Glu	Gly	Asp	Thr	Glu 300	Leu	Leu	Ser	Lys
55	Leu 305	Leu	Asp	Gly	Gly	Phe 310	Ser	Val	Lys	Gln	Leu 315	Asp	Ser	Asp	His	Trp 320
	Ala	Pro	Ile	His	Tyr	Ala	Cys	Trp	His	Gly	Lys	Val	Glu	Ala	Thr	Lys

					325					330					335	
	Leu	Leu	Leu	Glu 340	Lys	Gly	Asn	Cys	As n 345	Pro	Asn	Leu	Leu	As n 350	Gly	Gln
5	Leu	Ser	Ser 355	Pro	Leu	His	Phe	Ala 360	Ala	Ile	Gly	Gly	His 365	Ala	Glu	Ile
	Val	Gln 370	Leu	Leu	Leu	Gln	His 375	Pro	Glu	Ile	Asp	Arg 380	His	Ile	Glu	Asp
	Gln 385	Gln	Lys	Arg	Ser	Pro 390	Leu	Gln	Val	Cys	Glu 395	Glu	Asn	Lys	Gln	Asn 400
10	Asn	Trp	Glu	Glu	Thr 405	Val	Asn	Leu	Leu	Gln 410	Gln	Ala	Ser	Asn	Lys 415	Pro
	Tyr	Glu	Lys	Val 420	Arg	Ile	Tyr	Arg	Met 425	Asp	Gly	Ser	Tyr	Arg 430	Ser	Val
	Glu	Leu	Lys 435	His	Gly	Asn	Asn	Thr 440	Thr	Val	Gln	Gln	Ile 445	Met	Glu	Gly
15	Met	Arg 450	Leu	Ser	Gln	Glu	Thr 455	Gln	Gln	Tyr	Phe	Thr 460	Ile	Trp	Ile	Cys
	Ser 465	Glu	Asn	Leu	Ser	Leu 470	Gln	Leu	Lys	Pro	Tyr 475	His	Lys	Pro	Leu	Gln 480
	His	Leu	Arg	Met	Trp 485	Ser	Glu	Ile	Val	Thr 490	Asp	Leu	Thr	Ala	Leu 495	Asp
20	Pro	Gln	Arg	Glu 500	Ser	Pro	Gln	Leu	Phe 505	Leu	Arg	Arg	Asp	Val 510	Arg	Leu
	Pro	Leu	Glu 515	Val	Glu	Lys	Lys	Val 520	Glu	Asp	Pro	Leu	Ser 525	Ile	Leu	Ile
25	Leu	Phe 530	Asp	Glu	Ala	Arg	His 535	Cys	Leu	Leu	Lys	Gly 540	Phe	Leu	Ser	Thr
	Ser 545	Asp	Asn	Lys _	Leu	Ile 550	Thr	Leu	Ala	Ser	Leu 555	Leu	Leu	Gln	Ile	Ile 560
	Tyr	GLY	Asn	Tyr -	Asp 565	Ser	Lys	Lys	His	Lys 570	Gln	GLY	Phe	Leu	Asn 575	Glu
30	GLu	Asn	Leu	Lys 580	Ser	Ile	Val	Pro	11e 585	Ser	Lys	Val	Lys	Ser 590	Lys	ALA
	HIS	HIS	Trp 595	Thr	Asn	Arg	11e	Leu 600	His	GLU	Tyr -	Lys	Ser 605	Leu -	Ser	Thr
	Ser	610	GLY	vai	Ser	Lys	615	Met	HIS	HIS	Leu	620	Arg	Leu	Pne	Leu
35	625 61n	ASI	Cys	Trp	Asp	630	Pro	Thr	Tyr	GTÀ	635	Ата	Pne	rne Tle	Inr	640
	GIN	val	Pne Class	Thr Vol	Lys 645	ALA	Ser	Ser	Ser	650	HIS	цуз	vai	TTE	655	vai
40	Tyr	val	Сту	660	Asn	for	цув	GLĀ	665	HIS	Leu	Met	Asn	Met 670	GIU	Thr
40	LYS	vai	675	Arr	Cla	Ser	vel	680 Clm	Tyr	GLY	Sor	Fne	Met 685	Trp	GIN	Leu
	GTA	690 Dbo	ALA Vol	Nol	GIU	Tyr	695	GIN	TT6		Jon	700	GIU Vol	Asii	түз	тол
45	705 Met	Tare	vai Leu	Vai		710 Gln	тір		ALA Pro	Aen	715	Arg	vai Ala	uys Val	Ser	720
	Lve	Туг	Ala	Tur	725	GTII	116	лта	FIU	730	лэр	лгу	лта	var	735	лэр
	цуз	1 y 1	nra	740	OTA											
50	<210)> 2 > 45	5													
	<212 <213	2> PH 3> Da	RT Anio	reri	lo											
55	<220 <223)> }> pi	otei	in se	equer	nce d	of CC	см2								

	<400)> 2														
	Met 1	Glu	Glu	Asp	Val 5	Lys	Lys	Val	Lys	Lys 10	Pro	Gly	Ile	Val	Ser 15	Pro
5	Phe	Lys	Arg	Val 20	Phe	Leu	Lys	Gly	Glu 25	Lys	Gly	Arg	Asp	Lys 30	Lys	Ala
5	Leu	Glu	Lys 35	Ser	Thr	Glu	Arg	Arg 40	Ala	Leu	His	Thr	Phe 45	Ser	Leu	Ser
	Leu	Pro 50	Asp	His	Arg	Ile	Asp 55	Pro	Asp	Ile	Leu	Leu 60	Asn	Asp	Tyr	Ile
10	Glu 65	Lys	Glu	Val	Lys	Tyr 70	Leu	Gly	Gln	Leu	Thr 75	Ser	Val	Pro	Gly	Tyr 80
	Leu	Asn	Pro	Ser	Ser 85	Arg	Thr	Glu	Val	Leu 90	Gln	Leu	Ile	Asp	Asn 95	Ala
	Arg	Lys	Ser	His 100	Gln	Leu	Ala	Gly	Gln 105	Leu	Thr	Ser	Glu	Gln 110	Asp	Ala
15	Val	Val	Ser 115	Leu	Ser	Ala	Tyr	Asn 120	Val	Lys	Leu	Val	Trp 125	Arg	Asp	Gly
	Glu	Asp 130	Ile	Ile	Leu	Arg	Val 135	Pro	Ile	His	Asp	Ile 140	Ala	Ala	Val	Ser
	Tyr 145	Ile	Arg	Asp	Asp	Ser 150	Leu	His	Leu	Val	Val 155	Leu	Lys	Thr	Ala	Gln 160
20	Glu	Pro	Gly	Gly	Ser 165	Pro	Cys	His	Ser	Thr 170	Glu	Met	Ser	Lys	Ser 175	Pro
	Thr	Leu	Ser	Ser 180	Leu	Ser	Glu	Ser	Gly 185	Ala	Val	Leu	Val	Glu 190	Val	Cys
25	Cys	Leu	Leu 195	Val	Leu	Ala	Val	Asp 200	Asn	Lys	Ala	Ala	Ala 205	Glu	Glu	Leu
25	Cys	Leu 210	Leu	Leu	Ser	Gln	Val 215	Phe	Gln	Ile	Val	Tyr 220	Thr	Glu	Ser	Thr
	11e 225	Asp	Phe	Leu	Asp	Arg 230	Ala	Ile	Phe	Asp	GLy 235	ALa	Thr	Thr	Pro	Thr 240
30	Arg	HIS	Leu	Ser	11e 245	Tyr	Ser	GLU	Asp	Ser 250	Ser	Ser	глг	vai	азр 255	Val
	Lys	Asp	Val	Phe 260	Glu	Ala	Glu	Ala	Ser 265	Thr	Phe	Ser	Phe	Gln 270	Ser	Ser
	Leu	Glu	Ala 275	Gly	His	Ser	Ser	Ser 280	Pro	Ser	Pro	Thr	Ser 285	Ala	Pro	Ala
35	Ser	Pro 290	Gln	Thr	Lys	Thr	Ala 295	Ser	Glu	Ser	Glu	Leu 300	Ser	Thr	Thr	Ala
	Ala 305	Glu	Leu	Leu	Gln	As p 310	Tyr	Met	Thr	Thr	Leu 315	Arg	Thr	Lys	Leu	Ser 320
	Ser	Lys	Glu	Ile	Gln 325	Gln	Phe	Ala	Thr	Leu 330	Leu	His	Glu	Tyr	Arg 335	Asn
40	Gly	Ala	Ser	Ile 340	His	Glu	Phe	Cys	Ile 345	Asn	Leu	Arg	Gln	Leu 350	Tyr	Gly
	Asp -	Ser	Arg 355	Lys	Phe	Leu	Leu	Leu 360	Gly	Leu -	Arg	Pro	Phe 365	Ile	Pro	Glu
	Lys -	Asp 370	Ser	GIn	His	Phe	GLu 375	Asn	Phe	Leu	GLu	Thr 380	IIe -	GTÀ	vai	Lys
45	Asp 385	GLY	Arg	GLÀ	11e	390	Thr	Asp	Ser	Pne	395	Arg	Tyr	Lys	Arg	400
	Thr	Ser	Ser	Ala	Ser 405	Asp	Ser	Thr	Thr	Asn 410	GLA	Asn	GLY	Ala	A1a 415	GLY
50	GIY	ser	Asp	420	GIY	THE	Ата	Thr	ser 425	GIU	σту	Asp	GIU	430	Asp	Arg
50	Met	Ile	Ser 435	Asp	Ile	Ser	Asn	Asp 440	Ile	Glu	Ala	Leu	Gly 445	Ser	Ser	Met
	Asp	GIN 450	Asp	θŢΆ	vai	Pro	ser 455									
55	<21(<21) <212)> 3 L> 21 2> PT	LO RT													

<213> Danio rerio

	<220)>														
5	<223	3> pi	rotei	in se	equer	nce d	of Po	dcd1()a ((Ccm3a	1)					
	<400)> 3														
	Met 1	Thr	Met	Glu	Glu 5	Met	Lys	Asn	Glu	Ala 10	Asp	Ala	Thr	Ser	Met 15	Val
10	Ser	Met	Thr	Leu 20	Tyr	Ala	Val	Met	Tyr 25	Pro	Val	Phe	Asn	Glu 30	Leu	Glu
	Ser	Val	As n 35	Leu	Ser	Ala	Ala	Gln 40	Thr	Leu	Arg	Ala	Ala 45	Phe	Lys	Lys
	Ala	Glu 50	Lys	Glu	Asn	Pro	Gly 55	Leu	Thr	Gln	Asp	Ile 60	Ile	Met	Lys	Ile
15	Leu 65	Glu	Lys	Lys	Asn	Val 70	Glu	Ile	Asn	Phe	Thr 75	Glu	Ser	Leu	Leu	Arg 80
	Met	Ala	Ala	Asp	Asp 85	Val	Glu	Glu	Tyr	Met 90	Ile	Asp	Arg	Pro	Glu 95	Arg
	Glu	Phe	Gln	Asp 100	Leu	Asn	Glu	Arg	Ala 105	Arg	Ala	Leu	Lys	Gln 110	Ile	Leu
20	Ser	Lys	Ile 115	Pro	Asp	Glu	Ile	Asn 120	Asp	Arg	Val	Arg	Phe 125	Leu	Gln	Thr
	Ile	Lys 130	Asp	Ile	Ala	Ser	Ala 135	Ile	Lys	Glu	Leu	Leu 140	Asp	Thr	Val	Asn
	As n 145	Val	Phe	Lys	Lys	Tyr 150	Gln	Tyr	Gln	Asn	A rg 155	Arg	Ala	Leu	Glu	His 160
25	Gln	Lys	Lys	Glu	Phe 165	Val	Lys	His	Ser	Lys 170	Ser	Phe	Ser	Asp	Thr 175	Leu
	Lys	Thr	Tyr	Phe 180	Lys	Asp	Gly	Lys	Ala 185	Ile	Asn	Val	Phe	Ala 190	Ser	Ala
30	Asn	Arg	Leu 195	Ile	His	Gln	Thr	Asn 200	Leu	Ile	Leu	Gln	Thr 205	Phe	Lys	Thr
	Val	Ala 210														
	<210)> 4														
35	<21.	ב> 2. בס אס	נ U סידי													
55	<213	3> Da	anio	reri	ίο											
	<221)>														
40	<223	3> pi	rotei	in se	equer	nce d	of Po	dcd1(ор (с	Ccm3b)					
40	<401) > 4														
	Met	Thr	Met	Glu	Glu 5	Met	Lys	Asn	Glu	Ala 10	Glu	Pro	Asn	Ser	Ile 15	Val
45	Ser	Met	Thr	Leu 20	Tyr	Ala	Val	Met	Tyr 25	Pro	Val	Phe	Asn	Glu 30	Leu	Gly
40	Arg	Ile	Asn 35	Pro	Ser	Ala	Ala	Gln 40	Thr	Leu	Arg	Ala	Ala 45	Phe	Val	Lys
	Ala	Glu 50	Lys	Glu	Asn	Pro	Gly 55	Leu	Thr	Gln	Asp	Ile 60	Ile	Met	Lys	Ile
50	Leu 65	Glu	Lys	Lys	Asn	Val 70	Glu	Ile	Asn	Phe	Thr 75	Glu	Ser	Leu	Leu	Arg 80
	Met	Ala	Ala	Asp	As p 85	Val	Glu	Glu	Tyr	Met 90	Ile	Lys	Arg	Pro	Glu 95	Gln
	Glu	Phe	Gln	Asp 100	Leu	Asn	Glu	Lys	Ala 105	Arg	Ala	Leu	Lys	His 110	Ile	Leu
55	Ser	Lys	Ile 115	Pro	Asp	Glu	Ile	Asn 120	Asp	Arg	Val	Arg	Phe 125	Leu	Gln	Thr
	Ile	Lys	Asp	Ile	Ala	Ser	Ala	Ile	Lys	Glu	Leu	Leu	Asp	Thr	Val	Asn

		130					135					140				
	As n 145	Val	Phe	Arg	Lys	Tyr 150	Gln	Tyr	Gln	Asn	Arg 155	Arg	Ala	Leu	Glu	His 160
5	Gln	Lys	Lys	Glu	Phe 165	Val	Lys	Tyr	Ser	Lys 170	Ser	Phe	Ser	Asp	Thr 175	Leu
0	Lys	Thr	Tyr	Phe 180	Lys	Asp	Gly	Lys	Ala 185	Ile	Asn	Val	Phe	Ile 190	Ser	Ala
	Asn	Arg	Leu 195	Ile	His	Gln	Thr	Asn 200	Leu	Ile	Leu	Gln	Thr 205	Phe	Lys	Thr
10	Val	Ala 210														
	<210 <211)> 5 L> 97	77													
15	<213	2> P1 3> Da	anio	reri	Lo											
		_														
	<220 <223)> 3> pi	rotei	in se	equer	nce d	of He	eg1								
20	<400)> 5														
	Met 1	Met	Glu	Thr	Cys 5	Ala	Arg	Arg	Val	Leu 10	Phe	Thr	Ala	Ala	Leu 15	Leu
	Val	Leu	Ser	Thr 20	Val	Ile	Ala	Glu	Thr 25	Phe	Ser	Thr	Asp	Ser 30	Asp	Thr
25	Asp	Asn	Pro 35	Leu	Ser	Thr	GLu	Thr 40	Phe	Tyr	Ser	Arg	Thr 45	Ser	GLY	Leu
	Lys	GIN 50	Thr	Ser	Ser	Trp	pro 55	GLÀ	Arg	GLU	Ala	finr 60	ALA	Thr	ALA	val
	65 65	Leu	Ser	ser	GLY	Teu 70	GIY	GIU	Met	Con	75	TTe	Pro	Ата	Ser	80 80
30	Ser	TTe	Thr	Ala	Ala 85	Arg	GIU	GLÀ	HIS	Ser 90 Sor	Pro	цуs	Pro	Leu	95 Clu	Thr
	Jer		Hie	100	Gln	sor	Aen	Thr	105 Glu	Leu	Thr	III Hie	Aen	Asp 110 Ala	Thr	
35	Gln	Tro	115 Glu	Ser	Pro	Ser	Ser	120 Ala	Ser	His	Ser		125 Thr	Ser	His	His
	Pro	130 Val	Thr	Glu	Thr	Arg	135 Thr	Val	Ara	Asp	Val	140 Thr	Asp	Leu	Ile	Asp
	145	_			_	150		_			155	_		_		160
40	Met	Asp	Thr	Thr	Asp 165	Ser	Val	Ser	His	Thr 170	Asp	Ser	Thr	Tyr	Ile 175	Ser
	Cor	Thr	ASI	180	va⊥	GLÀ	Glu	Arg	185 207	Leu	Leu	Ser	var	11e 190	ser	Asn
	Ser	TIIT	195	ніа	TÄT	THE	GTII	200	Ser	Ser	тте	Ser	205	мта	Gru	Ser
45	Gln	Thr 210	Ser	Pro	Trp	Glu	Glu 215	Lys	Thr	Ser	Gly	Ala 220	Thr	Gln	Val	Asn
	Glu 225	Glu	Thr	Glu	Glu	Thr 230	Val	Ser	Thr	Val	Ser 235	Glu	Gln	Thr	Asp	Pro 240
	Thr	Phe	GLu	Asp	Arg 245	Asn	Ile	Thr	Ser	ALa 250	Thr	Leu	GLu	Thr	GLy 255	Arg
50	ser	rnr	Leu	гле 260 ть~	GIN	стА	Thr	GTU	ser 265	GTU GTU	Thr	дал	GTU Dee	270 270	ber	vai
	Thr	Bro	275 Pro	Ten	nia Thr	лда Vəl	GIU Thr	280 Ser	Arg	Asp.	Val	Cl	285	Thr	ASI	Ala
	Thr	290 Ser	Val	Ser	Ser	Glu	295 Thr	Ser	TVT	Thr	Gln	300 Thr	Ser	Ser	Asn	Ser
55	305	~~1		~~1	~~+	310		~~1	-1-		315		~~1	~~-		320
	Ala	Ser	Ser	Ile	Leu	${\tt Pro}$	Phe	Thr	\mathtt{Ser}	Ser	Glu	Arg	Asn	Val	Thr	Ser

					325					330					335	
	Thr	Ser	Gln	Glu 340	Ser	His	Asn	Ser	Thr 345	Leu	Ile	Tyr	Ser	Thr 350	Asn	Thr
5	Gly	Gly	Ser 355	Thr	Glu	Phe	Ser	Thr 360	Gly	Ser	Val	Ser	Ser 365	Thr	Ala	His
•	Glu	Glu 370	Thr	Glu	Arg	Ser	Ser 375	Thr	Gln	Ile	Val	Asp 380	Glu	Thr	Thr	Leu
	His 385	Asp	Val	Thr	Ser	Ala 390	Pro	Pro	Val	Leu	Glu 395	Asp	Val	Ala	Thr	Thr 400
10	Ile	Asp	Asp	Ser	Leu 405	Ser	Lys	Phe	Pro	Ser 410	Gly	Gln	Ser	Pro	Thr 415	Ile
	Pro	Lys	Thr	A sp 420	Asp	Gln	Thr	Asn	Thr 425	Gln	Val	Val	Pro	Thr 430	Ser	Thr
	His	Arg	Pro 435	Gln	Val	Thr	Asp	Glu 440	Ala	Thr	Asp	Glu	Val 445	Ser	Thr	Val
15	Tyr	Ser 450	Ser	Thr	Thr	Thr	Leu 455	Thr	Thr	Thr	Thr	Pro 460	Ser	Val	Thr	Thr
	Arg 465	Gln	Leu	Gln	Pro	His 470	His	Thr	Thr	Val	Glu 475	Thr	Gln	Thr	Gln	His 480
	Thr	Thr	Ile	Val	Thr 485	Thr	Asp	Ile	Ile	Gln 490	Val	Leu	Arg	Thr	Thr 495	Pro
20	Ser	Thr	Ala	His 500	His	Val	Pro	Thr	Ser 505	Thr	Thr	Ser	Gly	Pro 510	Gln	Ala
	Pro	Ser	Thr 515	Ala	Asp	Ser	Ser	Asp 520	Val	Thr	Thr	Leu	His 525	Leu	Glu	Thr
A 5	Ser	Thr 530	Ala	Thr	Pro	Gly	Asn 535	Thr	Thr	Ala	His	Gly 540	Gly	Arg	Ala	Thr
25	Thr 545	Pro	Phe	Ser	Lys	Ser 550	Ser	Pro	Ser	Arg	$\frac{\text{Thr}}{555}$	Thr	Val	Val	Val	Thr 560
	Thr	Gly	His	Leu	Thr 565	Asp	Lys	Ser	Thr	Thr 570	Glu	Thr	Gly	Ser	Ala 575	Thr
30	Thr	Gln	Met	Pro 580	Leu	Arg	Thr	Ser	Ala 585	Ser	Pro	Gly	His	Val 590	Cys	Gly
	Pro	Lys	Thr 595	Cys	Ala	Asn	Gly	Gly 600	His	Cys	Val	Arg	Ser 605	Ala	Glu	Gly
	Ser	Tyr 610	Tyr	Cys	Gln	Cys	Leu 615	Ser	Ala	Trp	Thr	Gly 620	Pro	Phe	Cys	Thr
35	Glu 625	Asp	Val	Asp	Glu	Cys 630	Val	Asn	Ser	Pro	Cys 635	Pro	Gln	Gly	Ser	Val 640
	Cys	Val	Asn	Thr	Gly 645	Gly	Ser	Phe	Ser	Cys 650	Glu	Cys	Asp	Leu	Gly 655	Phe
	Asp	Leu	Glu	Asp 660	Gly	Arg	Ser	Cys -	Thr 665	Gln	Val	Lys	Thr	Phe 670	Leu -	Gly
40	Thr	Phe	Thr 675	Val	Asn	Asn	Ser	Leu 680	His	Leu -	Arg	Asn	Leu 685	GLÀ	Leu	His
	Glu	Leu 690	HIS	Arg	GLU	IIe	695	GIN	Leu -	Leu	Asn	ALA 700	Ser	Leu	Ser	11e
	705 705	HIS	GLY	Tyr	Arg	Arg 710	Pne	Thr	Leu	GLÀ	Lys 715	Arg	Asp	GIY	GIN	GLY 720
45	vai	GIN	TTe	Pro	vai 725	vai	Ser	Met	Pne	5er 730	Leu	Ser	Ser	Asn	vai 735	Thr
	Ser	Ala	Asp	vai 740	Pne	Asn	Ser	IIe	G1n 745	Met	Ser	Leu	Asn	Asn 750	Cys	Ser
50	Arg	Thr Wel	755	Ser	HIS	Cys	Pro	760	Lуs	Leu	GIN	HIS	765	Leu	Ser	Tyr
	пта	770	Gru Ban	Ser	Leu	Cys	775	Ata	GIN	Lys	Dme	1ys 780	Cys	Asp	Var	GIII
	19r 785	ser	лэр	Cys	ser	нэр 790	тте	ber	CI	тте	795	ASI	Cys	GTU GTU	Cys	цец 800 Сис
55	PT0	σтλ	т Ат.	File	цув 805	Arg	ASII	PT0	GLU	азр 810	met	TUT.	cys	Arg	нэр 815	cys
	Gly	Asp	Gly	Leu 820	Lys	Leu	Val	Asn	Gly 825	Lys	Cys	Val	Glu	Cys 830	Met	Phe

	Gly	Phe	Gly 835	Gly	Phe	Asn	Cys	Asn 840	Asn	Phe	Tyr	Lys	Leu 845	Ile	Ala	Val	
	Val	Val 850	Ser	Pro	Ala	Gly	Gly 855	Ala	Leu	Leu	Leu	Ile 860	Val	Val	Ile	Ala	
5	Leu 865	Ile	Val	Thr	Cys	C ys 870	Lys	Lys	Asp	Lys	As n 875	Asp	Ile	Asn	Lys	Ile 880	
	Ile	Phe	Lys	Ser	Gly 885	Glu	Leu	Gln	Met	Ser 890	Pro	Tyr	Ala	Glu	Phe 895	Pro	
10	Lys	Ser	Asn	Arg 900	Val	Ser	Met	Glu	Trp 905	Gly	Arg	Glu	Thr	Ile 910	Glu	Met	
10	Gln	Glu	Asn 915	Gly	Ser	Thr	Lys	Asn 920	Leu	Leu	Gln	Met	Thr 925	Asp	Ile	Tyr	
	Tyr	Ser 930	Pro	Ala	Leu	Arg	As n 935	Ser	Asp	Leu	Glu	Arg 940	Asn	Gly	Leu	Tyr	
15	Pro 945	Phe	Ser	Gly	Leu	Pro 950	Gly	Ser	Arg	His	Ser 955	Cys	Ile	Tyr	Pro	Ala 960	
	Gln	Trp	Asn	Pro	Ser 965	Phe	Leu	Ser	Asp	Asp 970	Ser	Arg	Arg	Arg	Asp 975	Tyr	
	Phe																
20	<210	> 6															
	<211 <212	> 22 > DN	226 NA		_												
	<213	> Da	inio	rer	10												
25	<220 <223	> > Co	odinç	g nuc	cleot	ide	sequ	ience	e of	ccml	l (kı	rit1))				
	<400	> 6				-						++ ~+					60
30	atga	.tggg	jaa a	accaa	agago	st aq	Jagga	iggto		-gttç	JCCG	ttat	.ccga		1222	acaca	100
	acca	.gcct		acteo	aaaq	ja ai	acco	JEGCI		ateet	Latg	agat			Late	Jaagtt	120
	~~~~	at ar	igg q	Jaaa	agaga	id do	ageg	igaaq	,	agtge		LLGG	gaci	aa a		totaq	240
35	gaca	.gtga		Jgaca	aagt	c a	ittei	-ggaq		lgrgç	Jacg	aaad	caco	aa q	JCCCs	itatee	240
	аата	acca	igg ç	gcata	ataç	là da	ageç	JEGEC	c gtq	gcaca	itga	ggaa	igtto	CT Q	gttaç	Jatgga	300
10	gaca	.gtgg	jag ç	gaaaa	agago	je ci	cgti	Latti		-gtgc	caa	ttaa	itgto	aa a	agaca	acage	360
40	aagt	ccgt	igc a	atcad	CCCT	ad da	igeco	cag	2 220	CTACT	gcc	TTC	iggad		catgo	cgtgtg	420
	tgta	.gtga	iaa (	ccagi	Egeta			CCTCC	c ago	cacct	caa	agat	getç	JCT (	egeta	ctegae	480
45	aagt	ggtt	ag d	cggao	gcago		ictgi	geet	c cao	CGCLA	ITTC	etge	tete	JEE (	ccgga	CCGGCT	540
	ccgg	rgga		grgrq	Jaaaa	ic ta	acgt	gagi		ceege	JCGT	acgo	agto	iga q	jaago	agaca	600
	gacg	ggad	ege t	-gcad	catgo	jg ci	acad	ggei	t Ctq	Jgaga	itca	agag	JLAAA	ict q	gatgi	Letetg	700
50	gaga	aago	ay a		JEGGS	10 CC	agaa	10000	,	JEACO	iget	cage		jca (	JEACS	accaac	700
	ayag	-yga	ta a	ayto	JauCe	at Ca		acad	, LTI	.9900		yago		iya 1	act		040
	atco	ayat	LC (		Jagaç	ya Ca	adt(	ygcaq		agea	ilya	ccaç			Jyaaq	Jacada	040
55	yayo	+ ~	iyi ç	JUGCO	yyato	ya 11				ocyaa	ugeg	CCTC	ugaq	yyy a	ayada	notter	900
	CUUL	LyLC	ud d	aauu	Jurge	ja iç	Jacad	jail		ayuud	aac	ayet	Jygac	ay (	Jyace	Jacuyy	500

	gcacccattc	attatgcatg	ctggcatggg	aaggtggagg	ccactaaact	gctgctggag	1020
	aaaggcaact	gtaaccccaa	cctgctgaac	ggccagctga	gctctccttt	acacttcgca	1080
5	gctatcggcg	gtcatgcaga	aatcgtgcag	ctcctcctgc	agcacccaga	gatcgacaga	1140
	cacatcgagg	accagcagaa	acgatcgccg	cttcaagtat	gtgaagaaaa	caagcagaac	1200
	aactgggagg	aaaccgtgaa	tctccttcaa	caagccagca	ataaaccata	cgagaaggtg	1260
10	aggatttacc	gtatggatgg	atcgtaccgc	tctgtggagc	tgaagcatgg	gaacaacacc	1320
	accgtgcagc	agatcatgga	gggcatgaga	ttatcacagg	agacccagca	gtattttacc	1380
45	atctggatct	gctccgaaaa	ccttagtctg	cagctgaagc	cgtaccacaa	gcccttgcag	1440
15	cacttacgga	tgtggagcga	gatcgtgacg	gatctcactg	ctctggatcc	acagagagaa	1500
	agtccacagc	tcttcctgcg	cagagacgtt	cggctgcctt	tagaggtcga	gaaaaaggtt	1560
20	gaagatccgc	tgtccatcct	catcctattt	gatgaagctc	gtcactgcct	ccttaaaggt	1620
	ttcctctcga	cgtcagataa	caagctaatc	acgctcgcaa	gcctcctcct	gcagatcatc	1680
	tacggaaact	acgacagcaa	gaagcacaaa	cagggctttc	taaatgagga	aaacctgaaa	1740
25	tccatagttc	ccatttcaaa	ggtcaagagc	aaagcacatc	actggactaa	caggatactt	1800
	cacgagtaca	agagtctgag	cactagtgag	ggtgtgagta	aagaaatgca	tcacctccag	1860
	aggctcttcc	tgcagaactg	ctgggatatt	cctacttatg	gtgcagcgtt	tttcacagga	1920
30	caggtcttca	ctaaagccag	ctccagcaca	cacaaggtga	tccgcgtgta	tgtgggcgtc	1980
	aacaccaaag	gcctgcatct	gatgaacatg	gagacaaaag	tgcttcacct	cagtctggag	2040
	tatgggacat	ttatgtggca	gctgggtcag	gctgatcaat	acgtgcaaat	ccacagtctg	2100
35	gagaacaaga	agaactttgt	cgttcacacc	aaacaggctg	gtcttatcgt	gaagctgctg	2160
	atgaagctga	gtggacaaat	tgcaccaaac	gacagagctg	tgtctgataa	atatgcgtat	2220
40	gggtaa						2226
45	<210> 7 <211> 1368 <212> DNA <213> Danic	o rerio					
	<220> <223> Codir	ng nucleotic	le sequence	of ccm2			
50	<400> 7 atggaggagg	atgtaaagaa	agtcaaaaag	ccaggtatcg	tatctccatt	caagcgggtg	60
	tttctgaaag	gggagaaaggg	tagggataag	aaggetetge	agaagteeac	tgaacgcagg	120
	accatacaca	cettetetet	ctctctccca	gaccaccota	togaccaga	tattetete	180
55	aatgagtaga	traagaagga	anttaantat	ctagaacaac	taaceteaat	toctocatac	240
	ulyaccaca	uuyayaayya	uyulaaylal	cuyyyacayc	Lyaccicayi	lectyyatae	230

	ctgaatccct	ccagccgcac	tgaagttctg	cagctcattg	acaatgccag	gaagtctcat	300
	cagttggctg	ggcagctgac	ctcagagcag	gatgctgttg	tcagtttatc	agcgtacaat	360
5	gtgaagcttg	tgtggcgtga	tggagaggac	atcattctgc	gcgtacccat	ccacgacatt	420
	gcagctgtgt	cctacatcag	agacgactcg	cttcatctag	tggtgctaaa	aacagctcag	480
	gagcccggag	gttccccatg	tcatagtaca	gagatgtcga	aatctcccac	tctgagctct	540
10	ctatctgaga	gtggggctgt	gctggtggag	gtctgctgtc	tgcttgtgct	ggctgttgac	600
	aacaaggctg	cagcagagga	gctctgtctt	ctactcagtc	aagtcttcca	gatcgtctat	660
45	accgagtcca	ccatcgactt	cctagacagg	gccatctttg	atggagccac	aacacccacc	720
15	aggcatctct	caatctatag	tgaagactcc	tcaagtaaag	ttgatgtcaa	agatgtgttt	780
	gaggccgagg	caagcacatt	ctcgttccag	agttctctag	aggcgggaca	ttcctctagc	840
20	ccctccccca	cctcggcccc	ggcctcgcca	caaaccaaaa	cagccagtga	gagcgaactg	900
	agcacaacag	ctgctgaact	gctgcaagac	tacatgacca	cattgaggac	aaagctttcg	960
	tccaaagaga	tccagcagtt	tgccacactg	ttacatgaat	acagaaacgg	cgcctccatc	1020
25	catgagttct	gtatcaacct	gcggcagctt	tatggagaca	gcaggaagtt	ccttctcctc	1080
	ggactgcggc	cgttcatccc	cgagaaggac	agccagcatt	ttgagaactt	tctggagacc	1140
	atcggcgtga	aggatggccg	cggaatcatc	acagacagtt	tcggccgtta	taagcgcacg	1200
30	acgagctctg	cgtctgactc	caccacgaac	ggaaacggtg	ctgcgggcgg	atcagatgag	1260
	ggaacagcca	cctctgaggg	cgacgaatgg	gaccgcatga	tttcagacat	aagcaatgac	1320
	attgaagcct	taggaagcag	catggatcaa	gacggcgtgc	catcttga		1368
<i>35</i> <i>40</i>	<210> 8 <211> 633 <212> DNA <213> Danic	o rerio					
	<220> <223> Codir	ng nucleotio	le sequence	of pdcd10a	(ccm3a)		
45	<400> 8 atgacaatgg	aagagatgaa	gaatgaagcg	gacgcgacct	ccatggtatc	catgaccctc	60
	tacgccgtga	tgtacccggt	gttcaatgag	ctggagagtg	taaatctgtc	tgcggcacag	120
50	actctgcgag	ctgctttcaa	aaaggcagag	aaggaaaacc	caggactgac	tcaggacatt	180
	atcatgaaaa	tactggagaa	gaagaacgtg	gagatcaact	tcaccgagtc	tttattacgc	240
	atggctgctg	atgatgttga	ggagtacatg	attgacaggc	ccgagcggga	gttccaggac	300
55	ctgaatgaaa	gagctcgcgc	gctgaaacag	atcctcagca	aaatcccaga	cgaaattaat	360
	gaccgagtcc	gattcctgca	gacaatcaaa	gatatagcca	gtgccataaa	agagctgctg	420

	gacacagtga	acaacgtctt	caagaaatat	cagtaccaga	acagaagggc	acttgagcat	480
	cagaagaaag	agtttgtgaa	acattcgaaa	agcttcagcg	acactctgaa	aacatacttc	540
5	aaagacggaa	aggcaataaa	cgtgtttgcc	agtgccaacc	ggctcatcca	ccaaaccaac	600
	ttgatactgc	agaccttcaa	aactgtcgca	tag			633
10	<210> 9 <211> 633 <212> DNA <213> Danic	o rerio					
15	<220> <223> Codir	ng nucleotic	le sequence	of pdcd10b	(ccm3b)		
	<400> 9 atgacaatgg	aagagatgaa	gaatgaagct	gagccaaatt	caatagtctc	tatgacattg	60
20	tacgcagtca	tgtatccagt	cttcaatgag	ttggggagga	taaacccgtc	agcagcacag	120
	acattgcggg	cagcatttgt	caaagcagag	aaggagaacc	cagggctcac	tcaagatatc	180
	attatgaaga	tactggagaa	gaagaatgtg	gagatcaact	tcacagagtc	actactgcgc	240
25	atggctgcag	atgatgtgga	ggagtacatg	attaagagac	ctgaacagga	gttccaggac	300
	ctgaatgaga	aagcacgagc	tctaaaacat	atcctgagta	aaatcccaga	tgagatcaac	360
	gacagagtgc	gcttcctaca	gactatcaaa	gacatcgcca	gtgctataaa	ggagctgctg	420
30	gacacagtca	acaatgtttt	taggaagtat	cagtaccaga	atcgcagggc	acttgaacac	480
	caaaagaagg	agtttgtgaa	gtactccaaa	agcttcagtg	atacgctgaa	aacatacttc	540
35	aaagacggaa	aggcaataaa	cgtctttatc	agtgccaaca	ggcttatcca	ccaaactaac	600
00	ttgatactgc	agaccttcaa	aaccgtcgcc	tag			633
40	<210> 10 <211> 2934 <212> DNA <213> Danio	o rerio					
45	<220> <223> Codir	ng nucleotio	le sequence	of hegl			
	<400> 10 atgatggaaa	cgtgcgctcg	ccgtgtgctt	ttcacggccg	ctctgctcgt	cctcagtact	60
50	gtgatagcgg	aaactttctc	cacagactcg	gacaccgata	atccactgag	tacagaaact	120
	ttttatagcc	gaacaagtgg	cttgaaacaa	acctcctcct	ggccagggag	agaggccact	180
	gccacagccg	tggatctatc	gagcggactg	ggagagatga	cggagattcc	cgccagtgta	240
55	tccatcactg	cagcccgaga	gggacattca	ccaaaacctt	tacaaacctc	tacaaatgca	300
	gcggattgga	agaccagtat	gacctcagat	gagacaacag	aacatcttca	atctgacact	360

	gagettacce	ataatgcgac	cgcccaatgg	gagagtccat	catcagcatc	tcacagcatt	420
	accagccacc	atccagtaac	agagacacga	accgtgcgag	atgtaacaga	tctgatagac	480
5	atggacacca	cagactcagt	ctcccacact	gatagcacct	acatttccac	aaccaaccga	540
	gttggagaac	gcacactgct	ctcagtgatc	tccaacagca	cctttgcgta	cacccagaac	600
	tcaagcatct	ctgatgcaga	gtctcaaacg	tccccatggg	aggagaagac	atcaggagcc	660
10	acccaagtca	atgaggaaac	tgaagaaact	gtgtcaacag	tgtccgaaca	gactgatccc	720
	acttttgaag	accgcaatat	caccagtgca	actctggaga	ctgggcggtc	aacattattc	780
15	caaggcactg	agtcacagac	aggacaacct	agtgtcacag	gacagaccgc	taaggaggtg	840
10	actgatatcg	<pre>igcttacc atatgoga cgcccatgg gagagtcat cateageat tacagaat isgacacca atccagtaa agagacacga accgtgcgag atgtaacaga totgataga iggacacca cagactoagt otoccacact gatagcacct acatttocac aaccaccga itggagaac gcacactget otoagtgato toccacaga cotttgogta caccacagaa iaagcatot otgatgoaga gtotcaaacg tocccatggg aggagaagac atcaggage iccaagta atgaggaac tgaagaact gtgtcaacag tgtocgaaca gactgatoo itttgaag accgcaatat caccagtga actotgaga ctgggcggt aacattat iaagcactg agtoacaga aggacaacet agtgtcacag gacagacog taaggaggt itggatatog acaatocaa ttoacacgo cototcacag taaccagtag ggatgttga iaacagatg ocacatoagt gagoagtgag acatottat cacaaaccag cagtgacto iotoctcaa tottgoott taottotag gaacgcaagt tocactaga gttocacag igacaacco ttoatgatg taottotag occcagtgo ttaagagag igacaacco ttoatgatg taottotag coccagtgo ttaagaggt igacaacco ttoatgatg taottotag coccagtgo ttaagaggt aggacaaca igacaacco ttoatgatg taottotag coccagtgo ttaagaggt aggacacac igacagac ggtgtotac agttacag tocacacag tggacacac acacaca igacaacca acacacagt ggtgccaaca tocaccata ggccacaggt tacagatga icacaaca acacacaagt ggtgccaaca tocaccaca ttaactac cacaacca iggacacca tagacacac cocaccaca cacaccacag tggaaacca acacacaca itgtoacca ctagacaac cocaccaca cacaccacag tggaaacca acacacaca itgtoacca ctagacaac cagtggaca aggccgagg ggacacaca ggccgcagg igacgtcaa cacacacag ggtgccaaca cacaccacag tggaaacca aggccgagg igacgtcaa cacacacag aggcacaca cacaccacag tggaaacca aggcacagg iaccacact tgcacttga aaccagcaa gcacagccg ggaacacac ggcgcacgg igacgtcaa cacacacat tagcagaa aggacagag aggcagaga gcgaacacac gagatgco itggacat cacacacac aggcagaga aggacaga gcgaaccac gagatgco itggacat cacacacac aggcagaga aggacaga ggaacacac ggagacgag itggacacaca cagacaga ggagatac aggacacaca diacacaca itgtgocta categacac caggagaca gccacacac aggacagce ggacacac ggagagag itggacacac tigacacac caggagaca gagacagag ggaacacac ggagagag itggacacac caggaggg ggagagta tactacaca aaaccagag ggagagaga itggacacac caggaggg ggagagta tactagaga ggacacac gagaggg itggacacac caggaggg ggagaggg gagagagg gccacacac caggaggg itggacacac caggaggg gagaggg gagagagg ggacagac caggacacc ggagagg</pre>	ggatgttgag	900			
	gaaacagatg	ccacatcagt	gagcagtgag	acatcttata	cacaaaccag	cagtgactct	960
20	gcctcctcaa	tcttgccttt	tacttctagt	gaacgcaatg	tcactagcac	gtcccaagag	1020
25	agccataatt	ccacactcat	ttattccaca	aatactggtg	gttccactga	gttttcgact	1080
	ggatcagtga	gctctaccgc	ccatgaagaa	actgaacggt	cttcaactca	aatagtagat	1140
25	gagacaaccc	ttcatgatgt	tacttctgca	cccccagtgc	ttgaagatgt	agccacaact	1200
	atcgatgact	cgctttccaa	gttcccttcc	ggccaatcgc	ctaccatccc	taaaaccgat	1260
	gaccaaacca	acacacaagt	ggtgccaaca	tcaactcata	ggccacaggt	tacagatgaa	1320
30	gccaccgatg	aggtgtctac	agtttacagt	tctaccacta	ctttaactac	cacaactcct	1380
	tctgtcacca	ctagacaact	ccaaccacac	cacaccacag	tggaaaccca	aacacaacac	1440
35	actaccattg	ttaccaccga	tatcattcag	gtactgcgaa	cgacaccttc	tacagcccat	1500
5 4 10 4 15 4 20 4 2	catgtgccta	catcgactac	cagtggacca	caggctccaa	gtacagctga	ttcttctgac	1560
	gtcaccacat	tgcacttgga	aaccagcaca	gccacgccgg	ggaacactac	ggcgcacggt	1620
40	ggacgtgcaa	caacgccttt	tagcaagagc	agcccgagta	gaacaactgt	ggtagtgacc	1680
	actggacatc	tcactgacaa	aagcactaca	gagacaggaa	gcgcaaccac	gcagatgcct	1740
	cttagaacat	cagcatcacc	aggtcatgta	tgtggaccta	aaacctgtgc	aaatggaggt	1800
45	cattgtgtta	gatcagctga	aggaagttac	tactgtcagt	gtctctccgc	atggaccgga	1860
	cccttctgca	ctgaagatgt	ggacgagtgt	gtgaacagtc	catgtcctca	gggttcagtg	1920
50	tgtgtcaaca	caggtggttc	tttcagctgt	gaatgtgacc	tgggctttga	cctggaggat	1980
50	ggccgcagtt	gtacacaagt	caagacattt	ttgggcactt	tcacagtcaa	caactctctt	2040
	catctcagaa	atttaggtct	gcacgagcta	cacagagaga	tccaacagct	gctcaatgct	2100
55	tctctctcca	tcttccatgg	ttatagacgc	tttaccctgg	gtaaaagaga	tggacaaggt	2160
	gtgcaaatcc	cagtggtgag	catgttttca	ctctcctcca	atgtgaccag	cgcggatgtt	2220

	ttcaacagca	tccagatgtc	ccttaacaac	tgcagccgga	catactcgca	ctgtcccatt	2280
	aaacttcagc	accagctctc	ctatcacgtg	gagagcctgt	gcatggccca	gaagaccaag	2340
5	tgtgatgtgc	agtactcaga	ttgctcggat	attagcggga	ttcccaactg	tcagtgcctt	2400
	cctgggtact	ttaaaaggaa	cccagaagac	atgacctgca	gagactgtgg	agatggactc	2460
	aagcttgtta	atggcaaatg	tgtcgaatgc	atgtttggat	ttggaggttt	caactgcaat	2520
10	aatttctata	agctgatagc	cgtggtggtc	tcgcctgctg	gaggagctct	tctgttgatt	2580
	gtggtcattg	ctcttattgt	cacctgctgc	aaaaaagaca	aaaacgacat	caacaagatc	2640
	atcttcaaaa	gtggagagct	tcagatgtcg	ccatacgcag	agtttcctaa	gagcaatcgc	2700
15	gtgtccatgg	agtggggtag	agagactatc	gagatgcagg	agaacggcag	tacaaaaaac	2760
	ctcctgcaaa	tgactgacat	ttattactcg	cctgcactga	gaaactccga	cctggagcgt	2820
20	aatggtctgt	atccattctc	gggccttcct	ggttcaaggc	attcctgcat	ctatccggct	2880
	cagtggaacc	cttccttctt	aagcgacgat	tcacgccgaa	gagactactt	ttga	2934
25	<210> 11 <211> 11311 <212> DNA <213> Artif	l Ficial Seque	ence				
30	<220> <223> Plasm	nid Sequenz	of pDestTo:	L2_UAS:mChei	ry-Krit1,a	Lpha-cry:EGFP	
	<400> 11 taccacctaa	attgtaagcg	ttaatatttt	gttaaaattc	gcgttaaatt	tttgttaaat	60
35	cagctcattt	tttaaccaat	aggccgaaat	cggcaaaatc	ccttataaat	caaaagaata	120
	gaccgagata	gggttgagtg	ttgttccagt	ttggaacaag	agtccactat	taaagaacgt	180
	ggactccaac	gtcaaagggc	gaaaaaccgt	ctatcagggc	gatggcccac	tacgtgaacc	240
40	atcaccctaa	tcaagttttt	tggggtcgag	gtgccgtaaa	gcactaaatc	ggaaccctaa	300
	agggagcccc	cgatttagag	cttgacgggg	aaagccggcg	aacgtggcga	gaaaggaagg	360
	gaagaaagcg	aaaggagcgg	gcgctagggc	gctggcaagt	gtagcggtca	cgctgcgcgt	420
45	aaccaccaca	cccgccgcgc	ttaatgcgcc	gctacagggc	gcgtcccatt	cgccattcag	480
	gctgcgcaac	tgttgggaag	ggcgatcggt	gcgggcctct	tcgctattac	gccagctggc	540
50	gaaaggggga	tgtgctgcaa	ggcgattaag	ttgggtaacg	ccagggtttt	cccagtcacg	600
50	acgttgtaaa	acgacggcca	gtgagcgcgc	gtaatacgac	tcactatagg	gcgaattggg	660
	taccaaatag	taggaattac	ccacctgtac	aagtgctgaa	aacttggatg	aataagcccg	720
55	tttgccattt	tctactgcta	ttttaaatct	tttctgtatt	tgtctgcatt	tgtctttacc	780

	caataatatg	taatagtagt	acacactatt	attatgtaat	agtacttgtt	gactgtattt	900
	gagaactgga	ccgagtgagt	gttacgtcac	ccattcaaaa	tgacttactt	ctggctccaa	960
5	caaaatgaag	ttaattcagt	tgccattttt	cactgtatgg	acatcgccgt	gttggagcta	1020
	gacgtcgcca	ataagcaaga	aagagccgag	atgcgtcgag	tctgagtcac	cgttcctatg	1080
	gcaacccctc	taaccaatca	gaagtaagct	tgttggaagt	ccacagccta	ccacttgaaa	1140
10	gcgggctgca	caaaatctgt	caaacgtttt	gaacgttgga	tgtgagagca	catactttta	1200
	ttaaggcatc	tggttggtca	gtttataata	tcaacaactt	gggctacaga	aaagaaaagt	1260
	tattacagaa	attatgatta	acaagtacat	gttaaataaa	gattttaata	tgaatgccac	1320
15	cactggagca	ttcatgccat	ttggagcttc	ttcctgtttg	gatcactaga	aggaggaggt	1380
	cactcattac	agttctcata	tacagtcgtt	ggttggttgg	ttggttggtt	tacttctggctccaagccgtgttggagctagtcaccgttcctatgggctacaacttgaaagagcacatactttaacagaaaagaaaagttaatatgaatgccacctagaggttggtagatggttgdttggtagaaaaactgggggggggggagtaaagaaaatcaatggttgccagcccagtggttgccagcccagtggttgccagcccagtggttgccagcccagtgcatgccagcccagtgcatgccagcccagtgcatgccagcccagtgcatgccagcccagtgcatgccagcccagtgcatgccagcccaggttttgacaaagtaaatgaacacacaaaacatctggcaaagaacaatgacttggatgaaatagaacacacaaaacatctggatacgagtactacatggtgccatcctctgatctgcaaacadagaatgtaacgagtcaggtcagaggtttgcataaaatcttactaatgaaatcttactactacatggtgcaataatagaatcttactcatctgataaagtacatcaatggagttgcaatcaaaaaatcttactaatggaatcttactaatggaatcttactaatggaatcttactaatggaatcttact	1440
20	ttgattgatt	gattgattga	ttgattgatt	gattgattga	ttgattgatt	gattgattga	1500
20	ttgattgatt	gattgattga	ttgattgatt	gattgattga	ttggtagtca	aaataagaaa	1560
	taatttccac	agattcatta	cagaaatgat	taaatgcata	cataaaaaac	tggggggggg	1620
25	gggatacaac	aacacactta	agtcacattt	gcctacgtaa	agaaaagtaa	agaaaatcaa	1680
	tagctatatt	ttacatctcc	ttttttgct	gtcttttaat	tagccttgtt	ttgctgttat	1740
	cttgattgaa	actgtaactt	cttcacctgc	ttcttttctt	tgtaggtttt	gccagcccag	1800
30	aaacaggcat	ggctgtgcaa	ggccagagca	ccatgcacaa	tgcgctgcat	gtcttcatga	1860
	acggctcaat	gtcctcagtc	cagggctcag	ccaacgaccc	catcttcctc	cttcaccatg	1920
	ctttcattga	caggtaacaa	acacgtcatg	acattagact	gcacagtttt	tgacaaagtt	1980
35	catacaatct	gttgtttata	gctgctacaa	ttagtgaagt	ttgtgaatgt	acttggatga	2040
5 6 5 6 6 70 6 75 7 75 7	gcagcgaaag	atcaattgag	atcaattgtt	agagtttggt	tgccctgcag	agcaaagaac	2100
	aaaaataat	ctggtggctt	tactgcgtga	ggttattatt	ggtggaatag	aaacacaaaa	2160
40	cataattgca	tttatttgtt	taatttttta	tcttatctta	actttcatct	tgcatatttg	2220
	tttcttacat	catttctagc	atctttgagc	gctggctaag	aactcatcag	cctccccggt	2280
45	ccatctaccc	acgtaccaat	gcaccaattg	gccacaatga	cggctactac	atggtgccat	2340
45	tccttcctct	ttataggaat	ggagactacc	tcctgtccaa	caaggctctt	ggatacgagt	2400
	acgcctacct	gttggaccca	ggtcattgca	caacaccaga	aatgccctct	gatctgcaaa	2460
50	agacgtgaat	atctgttcag	acacccatat	ccactctgtt	ccacacaggt	cagaggtttg	2520
	tccaggagtt	cttgacagag	gtgtaaaaag	tactcaaaaa	ttttactcaa	gtgaaagtac	2580
	aagtacttag	ggaaaatttt	actcaattaa	aagtaaaagt	atctggctag	aatcttactt	2640
55	gagtaaaagt	aaaaagtac	tccattaaaa	ttgtacttga	gtattaagga	agtaaaagta	2700
	aaagcaagaa	agaaaactag	agattcttgt	ttaagctttt	aatctcaaaa	aacattaaat	2760
	gaaatgcata	caaggtttta	tcctgcttta	gaactgtttg	tatttaatta	tcaaactata	2820
------------	------------	------------	------------	------------	------------	------------	------
	agacagacaa	tctaatgcca	gtacacgcta	ctcaaagttg	taaaacctca	gatttaactt	2880
5	cagtagaagc	tgattctcaa	aattgttagt	gtcaagccta	gctcttttgg	ggctgaaaag	2940
	caatcctgca	gtgctgaaaa	gcctctcaca	ggcagccgat	gcgggaagag	gtgtattagt	3000
	cttgatagag	aggctgcaaa	tagcaggaaa	cgtgagcaga	gactccctgg	tgtctgaaac	3060
10	acaggccaga	tgggccctcg	agcaggaaac	agctatgacc	atgattacgc	caagctatca	3120
	actttgtata	gaaaagttgg	taatacgact	cactataggg	cgaattgggt	accgggcccc	3180
15	ccctcgaggt	cgacggtatc	gataagctta	ggcctccaag	gcggagtact	gtcctccggg	3240
	ctggcggagt	actgtcctcc	ggcaaggtcg	gagtactgtc	ctccgacact	agaggtcgga	3300
	gtactgtcct	ccgacgcaag	gcggagtact	gtcctccggg	ctggcggagt	actgtcctcc	3360
20	ggcaaggtcg	gagtactgtc	ctccgacact	agaggtcgga	gtactgtcct	ccgacgcaag	3420
	gcggagtact	gtcctccggg	ctggcggagt	actgtcctcc	ggcaagggtc	gactctagag	3480
	ggtatataat	ggatcccatc	gcgtctcagc	ctcactttga	gctcctccac	acgaattcct	3540
25	gcagcccggg	ggatccacta	gttctagagc	ggccgccacc	gcggtggagc	tccagctttt	3600
	gttcccttta	gtgagggtta	attcaagttt	gtacaaaaaa	gcaggctcat	ggcatggtga	3660
<b>2</b> 2	gcaagggcga	ggacgacaac	atggccatca	tcaaggagtt	catgcgcttc	aaggtgcaca	3720
30	tggagggctc	cgtgaacggc	cacgagttcg	agatcgaggg	cgagggcgag	ggccgcccct	3780
	acgagggcac	ccagaccgcc	aagctgaagg	tgaccaaggg	cggccccctg	cccttcgcct	3840
35	gggacatcct	gtcccctcag	ttcatgtacg	gctccaaggc	ctacgtgaag	caccccgccg	3900
	acatccccga	ctacttgaag	ctgtccttcc	ccgagggctt	caagtgggag	cgcgtgatga	3960
	acttcgagga	cggcggcgtg	gtgaccgtga	cccaggactc	ctccctgcag	gacggcgagt	4020
40	tcatctacaa	ggtgaagctg	cgcggcacca	acttcccctc	cgacggcccc	gtaatgcaga	4080
	agaagaccat	gggctgggag	gcctcctccg	agcggatgta	ccccgaggac	ggcgccctga	4140
	agggcgagat	caagcagagg	ctgaagctga	aggacggcgg	ccactacgac	gccgaggtca	4200
45	agaccaccta	caaggccaag	aagcccgtgc	agctgcccgg	cgcctacaac	gtcaacatca	4260
	agctggacat	cacctcccac	aacgaggact	acaccatcgt	ggaacagtac	gagcgcgccg	4320
50	agggccgcca	ctccaccggc	ggcatggacg	agctgtacaa	gggaggcgct	gcaggaggct	4380
50	ctagaatggg	aaaccaagag	ctagaggagg	tgtttgttgc	tgttatccga	ccaaaaaaca	4440
	caaccagcct	caactccaaa	gaataccgtg	ctaaatccta	tgagatttta	cttatcgaag	4500
55	ttcccctgga	gggaaaagag	aaaaagcgga	agaaagtgct	gcttgggact	aaaattcacg	4560
	ccgacagtga	ccggacaaag	tcaattctgg	agtttgtgga	tgaaaccacc	aagcccatat	4620

	ccaataacca	gggcataata	gggaagcgtg	ttgtgcacat	gaggaagttc	ctgttagatg	4680
	gagacagtgg	aggaaaagag	gcctcgttat	ttattgtgcc	aattaatgtc	aaagacaaca	4740
5	gcaagtccgt	gcatcaccct	gggagcccca	gtttctactg	ccttcaggac	atcatgcgtg	4800
	tgtgtagtga	aaccagtgct	catttctcct	ccagcacctc	aaagatgctg	ctcgctctcg	4860
	acaagtggtt	agcggagcag	cacactgtgc	ctcacgctat	tcctgctctg	ttccggccgg	4920
10	ctccggtgga	ccgtgtgaaa	actaacgtga	gtaacccggc	gtacgcagtg	gagaagcaga	4980
	cagacgggac	gctgcacatg	ggctacacgg	ctctggagat	caagagtaaa	ctgatgtctc	5040
	tggagaaagc	agatctgtgc	atccagaacc	cgctgtacgg	ctcagatctg	cagtacacca	5100
15	acagagtgga	caaagtcatc	atcaaccctt	actttggctt	gggagctcca	gattactcca	5160
	aaatccagat	tccaaagaga	gacaaatggc	agcacagcat	gaccagcgtc	accgaagaca	5220
20	aagagcgcca	gtgggtggat	gatttccctc	tgcaccgaag	cgcctgtgag	ggagacactg	5280
20	agcttttgtc	taaattgctg	gatggcggat	tctcagtcaa	acagctggac	agcgaccatt	5340
	gggcacccat	tcattatgca	tgctggcatg	ggaaggtgga	ggccactaaa	ctgctgctgg	5400
25	agaaaggcaa	ctgtaacccc	aacctgctga	acggccagct	gagctctcct	ttacacttcg	5460
	cagctatcgg	cggtcatgca	gaaatcgtgc	agctcctcct	gcagcaccca	gagatcgaca	5520
	gacacatcga	ggaccagcag	aaacgatcgc	cgcttcaagt	atgtgaagaa	aacaagcaga	5580
30	acaactggga	ggaaaccgtg	aatctccttc	aacaagccag	caataaacca	tacgagaagg	5640
	tgaggattta	ccgtatggat	ggatcgtacc	gctctgtgga	gctgaagcat	gggaacaaca	5700
	ccaccgtgca	gcagatcatg	gagggcatga	gattatcaca	ggagacccag	cagtatttta	5760
35	ccatctggat	ctgctccgaa	aaccttagtc	tgcagctgaa	gccgtaccac	aagcccttgc	5820
	agcacttacg	gatgtggagc	gagatcgtga	cggatctcac	tgctctggat	ccacagagag	5880
	aaagtccaca	gctcttcctg	cgcagagacg	ttcggctgcc	tttagaggtc	gagaaaaagg	5940
40	ttgaagatcc	gctgtccatc	ctcatcctat	ttgatgaagc	tcgtcactgc	ctccttaaag	6000
	gtttcctctc	gacgtcagat	aacaagctaa	tcacgctcgc	aagcctcctc	ctgcagatca	6060
45	tctacggaaa	ctacgacagc	aagaagcaca	aacagggctt	tctaaatgag	gaaaacctga	6120
45	aatccatagt	tcccatttca	aaggtcaaga	gcaaagcaca	tcactggact	aacaggatac	6180
	ttcacgagta	caagagtctg	agcactagtg	agggtgtgag	taaagaaatg	catcacctcc	6240
50	agaggctctt	cctgcagaac	tgctgggata	ttcctactta	tggtgcagcg	ttttcacag	6300
	gacaggtctt	cactaaagcc	agctccagca	cacacaaggt	gatccgcgtg	tatgtgggcg	6360
	tcaacaccaa	aggcctgcat	ctgatgaaca	tggagacaaa	agtgcttcac	ctcagtctgg	6420
55	agtatgggac	atttatgtgg	cagctgggtc	aggctgatca	atacgtgcaa	atccacagtc	6480
	tggagaacaa	gaagaacttt	gtcgttcaca	ccaaacaggc	tggtcttatc	gtgaagctgc	6540

	tgatgaagct	gagtggacaa	attgcaccaa	acgacagagc	tgtgtctgat	aaatatgcgt	6600
	atgggtaaac	ccagctttct	tgtacaaagt	ggaattcact	agtgatttaa	tagtgtgcat	6660
5	tcagtgcagg	atgttatgta	tttattttct	gtagtgcaaa	ctttttcaaa	gaattttcca	6720
	gtctaagctt	ttcagtcaag	aaaaaaaag	gcgtctgatt	atctgtgata	ttttaaataa	6780
	ttagctctta	aatctggtga	accaagtggc	cacaacacat	taaatactga	cgttctacag	6840
10	ccatgtagct	tcatctggtc	tggtttgttt	tggcaggcac	ttattttccg	gtgatagttg	6900
	gccacaagag	tattgtctga	gccattcagt	gctagactgt	cattctcagg	tcagaatcca	6960
15	ccccactgat	tctgctgaca	acactgttcc	caccatgaga	taatgccatt	ccagagagat	7020
	ccatttgtaa	gcccctcttt	ctgcagcaca	ggtatataac	cagggctctg	cctccactaa	7080
	ggccggcaca	catcatttgg	ggatctttgt	actgtactag	cctctattag	cctcctactt	7140
20	gcgttcagtt	cacatctttt	gttcatcagg	tgcaataagt	tacagtaagg	agttaccagg	7200
	tctgacatta	atcgaattcc	accatggtga	gcaagggcga	ggagctgttc	accggggtgg	7260
	tgcccatcct	ggtcgagctg	gacggcgacg	taaacggcca	caagttcagc	gtgtccggcg	7320
25	agggcgaggg	cgatgccacc	tacggcaagc	tgaccctgaa	gttcatctgc	accaccggca	7380
	agctgcccgt	gccctggccc	accctcgtga	ccaccctgac	ctacggcgtg	cagtgcttca	7440
	gccgctaccc	cgaccacatg	aagcagcacg	acttcttcaa	gtccgccatg	cccgaaggct	7500
30	acgtccagga	gcgcaccatc	ttcttcaagg	acgacggcaa	ctacaagacc	cgcgccgagg	7560
	tgaagttcga	gggcgacacc	ctggtgaacc	gcatcgagct	gaagggcatc	gacttcaagg	7620
35	aggacggcaa	catcctgggg	cacaagctgg	agtacaacta	caacagccac	aacgtctata	7680
	tcatggccga	caagcagaag	aacggcatca	aggtgaactt	caagatccgc	cacaacatcg	7740
	aggacggcag	cgtgcagctc	gccgaccact	accagcagaa	cacccccatc	ggcgacggcc	7800
40	ccgtgctgct	gcccgacaac	cactacctga	gcacccagtc	cgccctgagc	aaagacccca	7860
	acgagaagcg	cgatcacatg	gtcctgctgg	agttcgtgac	cgccgccggg	atcactctcg	7920
	gcatggacga	gctgtacaag	ggcggtggaa	gatctgggaa	ttcaaggcct	ctcgagcctc	7980
45	tagattctgc	agccctatag	tgagtcgtat	tacgtagatc	cagacatgat	aagatacatt	8040
	gatgagtttg	gacaaaccac	aactagaatg	cagtgaaaaa	aatgctttat	ttgtgaaatt	8100
50	tgtgatgcta	ttgctttatt	tgtaaccatt	ataagctgca	ataaacaagt	taacaacaac	8160
50	aattgcattc	attttatgtt	tcaggttcag	ggggaggtgt	gggaggtttt	ttccaacttt	8220
	attatacata	gttgataatt	cactggccgt	cgttttacat	cgatgatgat	ccagacatga	8280
55	taagatacat	tgatgagttt	ggacaaacca	caactagaat	gcagtgaaaa	aaatgcttta	8340
	tttgtgaaat	ttgtgatgct	attgctttat	ttgtaaccat	tataagctgc	aataaacaag	8400

	ttaacaacaa	caattgcatt	cattttatgt	ttcaggttca	ggggggaggtg	tgggaggttt	8460
	tttaaagcaa	gtaaaacctc	tacaaatgtg	gtatggctga	ttatgatcct	ctagatcaga	8520
5	tctgcgaaga	tacggccacg	ggtgctcttg	atcctgtggc	tgattttgga	ctgtgctgct	8580
	cgcagctgct	gatgaatcac	atacttcctc	cattttcttc	cactgattga	ctgttataat	8640
	ttccctaatt	tccaggtcaa	ggtgctgtgc	attgtggtaa	tagatgtgac	atgacgtcac	8700
10	ttccaaagga	ccaatgaaca	tgtctgacca	atttcatata	atgtgaaaac	gattttcata	8760
	ggcagaataa	ataacattta	aattaaactg	ggcatcagcg	caattcaatt	ggtttggtaa	8820
	tagcaaggga	aaatagaatg	aagtgatctc	caaaaataa	gtactttttg	actgtaaata	8880
15	aaattgtaag	gagtaaaaag	tactttttt	tctaaaaaaa	tgtaattaag	taaaagtaaa	8940
	agtattgatt	tttaattgta	ctcaagtaaa	gtaaaatcc	ccaaaaataa	tacttaagta	9000
20	cagtaatcaa	gtaaaattac	tcaagtactt	tacacctctg	gttcttgacc	ccctaccttc	9060
20	agcaagccca	gcagatccac	tagttctaga	gcggccgcca	ccgcggtgga	gctccagctt	9120
	ttgttccctt	tagtgagggt	taattgcgcg	cttggcgtaa	tcatggtcat	agctgtttcc	9180
25	tgtgtgaaat	tgttatccgc	tcacaattcc	acacaacata	cgagccggaa	gcataaagtg	9240
	taaagcctgg	ggtgcctaat	gagtgagcta	actcacatta	attgcgttgc	gctcactgcc	9300
	cgctttccag	tcgggaaacc	tgtcgtgcca	gctgcattaa	tgaatcggcc	aacgcgcggg	9360
30	gagaggcggt	ttgcgtattg	ggcgctcttc	cgcttcctcg	ctcactgact	cgctgcgctc	9420
	ggtcgttcgg	ctgcggcgag	cggtatcagc	tcactcaaag	gcggtaatac	ggttatccac	9480
	agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	9540
35	ccgtaaaaag	gccgcgttgc	tggcgttttt	ccataggete	cgcccccctg	acgagcatca	9600
	caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	9660
	gtttccccct	ggaageteee	tcgtgcgctc	tcctgttccg	accctgccgc	ttaccggata	9720
40	cctgtccgcc	tttctccctt	cgggaagcgt	ggcgctttct	catageteae	gctgtaggta	<b>9</b> 780
	tctcagttcg	gtgtaggtcg	ttcgctccaa	gctgggctgt	gtgcacgaac	cccccgttca	9840
45	gcccgaccgc	tgcgccttat	ccggtaacta	tcgtcttgag	tccaacccgg	taagacacga	9900
45	cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	9960
	tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagga	cagtatttgg	10020
50	tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	10080
	caaacaaacc	accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	ttacgcgcag	10140
	aaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	10200
55	cgaaaactca	cgttaaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	10260
	ccttttaaat	taaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	10320

	tgacagttac	caatgcttaa	tcagtgaggc	acctatctca	gcgatctgtc	tatttcgttc	10380
	atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	10440
5	tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	atttatcagc	10500
	aataaaccag	ccagccggaa	gggccgagcg	cagaagtggt	cctgcaactt	tatccgcctc	10560
	catccagtct	attaattgtt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	10620
10	gcgcaacgtt	gttgccattg	ctacaggcat	cgtggtgtca	cgctcgtcgt	ttggtatggc	10680
	ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	tgatccccca	tgttgtgcaa	10740
	aaaagcggtt	agctccttcg	gtcctccgat	cgttgtcaga	agtaagttgg	ccgcagtgtt	10800
15	atcactcatg	gttatggcag	cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	10860
	cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	gaatagtgta	tgcggcgacc	10920
20	gagttgctct	tgcccggcgt	caatacggga	taataccgcg	ccacatagca	gaactttaaa	10980
	agtgctcatc	attggaaaac	gttcttcggg	gcgaaaactc	tcaaggatct	taccgctgtt	11040
	gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	tcttcagcat	cttttacttt	11100
25	caccagcgtt	tctgggtgag	caaaaacagg	aaggcaaaat	gccgcaaaaa	agggaataag	11160
	ggcgacacgg	aaatgttgaa	tactcatact	cttccttttt	caatattatt	gaagcattta	11220
	tcagggttat	tgtctcatga	gcggatacat	atttgaatgt	atttagaaaa	ataaacaaat	11280
30	aggggttccg	cgcacatttc	cccgaaaagt	g			11311
35	<210> 12 <211> 11314 <212> DNA <213> Artif	4 ficial Seque	ence				
40	<220> <223> Plasm	nid Sequenz	of pDestTo	L2_UAS:EGFP-	-Kritl,alpha	a-cry:EGFP	
	<400> 12 taccacctaa	attgtaagcg	ttaatatttt	gttaaaattc	gcgttaaatt	tttgttaaat	60
	cagctcattt	tttaaccaat	aggccgaaat	cggcaaaatc	ccttataaat	caaaagaata	120
45	gaccgagata	gggttgagtg	ttgttccagt	ttggaacaag	agtccactat	taaagaacgt	180
	ggactccaac	gtcaaagggc	gaaaaaccgt	ctatcagggc	gatggcccac	tacgtgaacc	240
50	atcaccctaa	tcaagttttt	tggggtcgag	gtgccgtaaa	gcactaaatc	ggaaccctaa	300
	agggagcccc	cgatttagag	cttgacgggg	aaagccggcg	aacgtggcga	gaaaggaagg	360
	gaagaaagcg	aaaggagcgg	gcgctagggc	gctggcaagt	gtagcggtca	cgctgcgcgt	420
55	aaccaccaca	cccgccgcgc	ttaatgcgcc	gctacagggc	gcgtcccatt	cgccattcag	480
	gctgcgcaac	tgttgggaag	ggcgatcggt	gcgggcctct	tcgctattac	gccagctggc	540

	gaaaggggga	tgtgctgcaa	ggcgattaag	ttgggtaacg	ccagggtttt	cccagtcacg	600
	acgttgtaaa	acgacggcca	gtgagcgcgc	gtaatacgac	tcactatagg	gcgaattggg	660
5	taccaaatag	taggaattac	ccacctgtac	aagtgctgaa	aacttggatg	aataagcccg	720
	tttgccattt	tctactgcta	ttttaaatct	tttctgtatt	tgtctgcatt	tgtctttacc	780
	cttgaataaa	tgttttagtt	gtttttttc	aattatgact	gtgtttaaca	gacattatta	840
10	caataatatg	taatagtagt	acacactatt	attatgtaat	agtacttgtt	gactgtattt	900
	gagaactgga	ccgagtgagt	gttacgtcac	ccattcaaaa	tgacttactt	ctggctccaa	960
15	caaaatgaag	ttaattcagt	tgccattttt	cactgtatgg	acatcgccgt	gttggagcta	1020
	gacgtcgcca	ataagcaaga	aagagccgag	atgcgtcgag	tctgagtcac	cgttcctatg	1080
	gcaacccctc	taaccaatca	gaagtaagct	tgttggaagt	ccacagccta	ccacttgaaa	1140
20	gcgggctgca	caaaatctgt	caaacgtttt	gaacgttgga	tgtgagagca	catactttta	1200
	ttaaggcatc	tggttggtca	gtttataata	tcaacaactt	gggctacaga	aaagaaaagt	1260
	tattacagaa	attatgatta	acaagtacat	gttaaataaa	gattttaata	tgaatgccac	1320
25	cactggagca	ttcatgccat	ttggagcttc	ttcctgtttg	gatcactaga	aggaggaggt	1380
	cactcattac	agttctcata	tacagtcgtt	ggttggttgg	ttggttggtt	ggttggtaga	1440
	ttgattgatt	gattgattga	ttgattgatt	gattgattga	ttgattgatt	gattgattga	1500
30	ttgattgatt	gattgattga	ttgattgatt	gattgattga	ttggtagtca	aaataagaaa	1560
	taatttccac	agattcatta	cagaaatgat	taaatgcata	cataaaaaac	tggggggggg	1620
35	gggatacaac	aacacactta	agtcacattt	gcctacgtaa	agaaaagtaa	agaaaatcaa	1680
	tagctatatt	ttacatctcc	ttttttgct	gtcttttaat	tagccttgtt	ttgctgttat	1740
	cttgattgaa	actgtaactt	cttcacctgc	ttcttttctt	tgtaggtttt	gccagcccag	1800
40	aaacaggcat	ggctgtgcaa	ggccagagca	ccatgcacaa	tgcgctgcat	gtcttcatga	1860
	acggctcaat	gtcctcagtc	cagggctcag	ccaacgaccc	catcttcctc	cttcaccatg	1920
	ctttcattga	caggtaacaa	acacgtcatg	acattagact	gcacagtttt	tgacaaagtt	1980
45	catacaatct	gttgtttata	gctgctacaa	ttagtgaagt	ttgtgaatgt	acttggatga	2040
	gcagcgaaag	atcaattgag	atcaattgtt	agagtttggt	tgccctgcag	agcaaagaac	2100
50	aaaaataat	ctggtggctt	tactgcgtga	ggttattatt	ggtggaatag	aaacacaaaa	2160
50	cataattgca	tttatttgtt	taattttta	tcttatctta	actttcatct	tgcatatttg	2220
	tttcttacat	catttctagc	atctttgagc	gctggctaag	aactcatcag	cctccccggt	2280
55	ccatctaccc	acgtaccaat	gcaccaattg	gccacaatga	cggctactac	atggtgccat	2340
	tccttcctct	ttataggaat	ggagactacc	tcctgtccaa	caaggctctt	ggatacgagt	2400

	acgcctacct	gttggaccca	ggtcattgca	caacaccaga	aatgccctct	gatctgcaaa	2460
	agacgtgaat	atctgttcag	acacccatat	ccactctgtt	ccacacaggt	cagaggtttg	2520
5	tccaggagtt	cttgacagag	gtgtaaaaag	tactcaaaaa	ttttactcaa	gtgaaagtac	2580
	aagtacttag	ggaaaatttt	actcaattaa	aagtaaaagt	atctggctag	aatcttactt	2640
	gagtaaaagt	aaaaagtac	tccattaaaa	ttgtacttga	gtattaagga	agtaaaagta	2700
10	aaagcaagaa	agaaaactag	agattcttgt	ttaagctttt	aatctcaaaa	aacattaaat	2760
	gaaatgcata	caaggtttta	tcctgcttta	gaactgtttg	tatttaatta	tcaaactata	2820
	agacagacaa	tctaatgcca	gtacacgcta	ctcaaagttg	taaaacctca	gatttaactt	2880
15	cagtagaagc	tgattctcaa	aattgttagt	gtcaagccta	gctcttttgg	ggctgaaaag	2940
	caatcctgca	gtgctgaaaa	gcctctcaca	ggcagccgat	gcgggaagag	gtgtattagt	3000
20	cttgatagag	aggctgcaaa	tagcaggaaa	cgtgagcaga	gactccctgg	tgtctgaaac	3060
20	acaggccaga	tgggccctcg	agcaggaaac	agctatgacc	atgattacgc	caagctatca	3120
	actttgtata	gaaaagttgg	taatacgact	cactataggg	cgaattgggt	accgggcccc	3180
25	ccctcgaggt	cgacggtatc	gataagctta	ggcctccaag	gcggagtact	gtcctccggg	3240
	ctggcggagt	actgtcctcc	ggcaaggtcg	gagtactgtc	ctccgacact	agaggtcgga	3300
	gtactgtcct	ccgacgcaag	gcggagtact	gtcctccggg	ctggcggagt	actgtcctcc	3360
30	ggcaaggtcg	gagtactgtc	ctccgacact	agaggtcgga	gtactgtcct	ccgacgcaag	3420
	gcggagtact	gtcctccggg	ctggcggagt	actgtcctcc	ggcaagggtc	gactctagag	3480
	ggtatataat	ggatcccatc	gcgtctcagc	ctcactttga	gctcctccac	acgaattcct	3540
35	gcagcccggg	ggatccacta	gttctagagc	ggccgccacc	gcggtggagc	tccagctttt	3600
	gttcccttta	gtgagggtta	attcaagttt	gtacaaaaaa	gcaggctatg	gtgagcaagg	3660
	gcgaggagct	gttcaccggg	gtggtgccca	tcctggtcga	gctggacggc	gacgtaaacg	3720
40	gccacaagtt	cagcgtgtcc	ggcgagggcg	agggcgatgc	cacctacggc	aagctgaccc	3780
	tgaagttcat	ctgcaccacc	ggcaagctgc	ccgtgccctg	gcccaccctc	gtgaccaccc	3840
45	tgacctacgg	cgtgcagtgc	ttcagccgct	accccgacca	catgaagcag	cacgacttct	3900
40	tcaagtccgc	catgcccgaa	ggctacgtcc	aggagcgcac	catcttcttc	aaggacgacg	3960
	gcaactacaa	gacccgcgcc	gaggtgaagt	tcgagggcga	caccctggtg	aaccgcatcg	4020
50	agctgaaggg	catcgacttc	aaggaggacg	gcaacatcct	ggggcacaag	ctggagtaca	4080
	actacaacag	ccacaacgtc	tatatcatgg	ccgacaagca	gaagaacggc	atcaaggtga	4140
	acttcaagat	ccgccacaac	atcgaggacg	gcagcgtgca	gctcgccgac	cactaccagc	4200
55	agaacacccc	catcggcgac	ggccccgtgc	tgctgcccga	caaccactac	ctgagcaccc	4260
	agtccgccct	gagcaaagac	cccaacgaga	agcgcgatca	catggtcctg	ctggagttcg	4320

	tgaccgccgc	cgggatcact	ctcggcatgg	acgagctgta	caagggaggc	gctgcaggag	4380
	gctctagaat	gggaaaccaa	gagctagagg	aggtgtttgt	tgctgttatc	cgaccaaaaa	4440
5	acacaaccag	cctcaactcc	aaagaatacc	gtgctaaatc	ctatgagatt	ttacttatcg	4500
	aagttcccct	ggagggaaaa	gagaaaaagc	ggaagaaagt	gctgcttggg	actaaaattc	4560
	acgccgacag	tgaccggaca	aagtcaattc	tggagtttgt	ggatgaaacc	accaagccca	4620
10	tatccaataa	ccagggcata	atagggaagc	gtgttgtgca	catgaggaag	ttcctgttag	4680
	atggagacag	tggaggaaaa	gaggcctcgt	tatttattgt	gccaattaat	gtcaaagaca	4740
15	acagcaagtc	cgtgcatcac	cctgggagcc	ccagtttcta	ctgccttcag	gacatcatgc	4800
	gtgtgtgtag	tgaaaccagt	gctcatttct	cctccagcac	ctcaaagatg	ctgctcgctc	4860
	tcgacaagtg	gttagcggag	cagcacactg	tgcctcacgc	tattcctgct	ctgttccggc	4920
20	cggctccggt	ggaccgtgtg	aaaactaacg	tgagtaaccc	ggcgtacgca	gtggagaagc	4980
	agacagacgg	gacgctgcac	atgggctaca	cggctctgga	gatcaagagt	aaactgatgt	5040
	ctctggagaa	agcagatctg	tgcatccaga	acccgctgta	cggctcagat	ctgcagtaca	5100
25	ccaacagagt	ggacaaagtc	atcatcaacc	cttactttgg	cttgggagct	ccagattact	5160
	ccaaaatcca	gattccaaag	agagacaaat	ggcagcacag	catgaccagc	gtcaccgaag	5220
	acaaagagcg	ccagtgggtg	gatgatttcc	ctctgcaccg	aagcgcctgt	gagggagaca	5280
30	ctgagctttt	gtctaaattg	ctggatggcg	gattctcagt	caaacagctg	gacagcgacc	5340
	attgggcacc	cattcattat	gcatgctggc	atgggaaggt	ggaggccact	aaactgctgc	5400
35	tggagaaagg	caactgtaac	cccaacctgc	tgaacggcca	gctgagctct	cctttacact	5460
	tcgcagctat	cggcggtcat	gcagaaatcg	tgcagctcct	cctgcagcac	ccagagatcg	5520
	acagacacat	cgaggaccag	cagaaacgat	cgccgcttca	agtatgtgaa	gaaaacaagc	5580
40	agaacaactg	ggaggaaacc	gtgaatctcc	ttcaacaagc	cagcaataaa	ccatacgaga	5640
	aggtgaggat	ttaccgtatg	gatggatcgt	accgctctgt	ggagctgaag	catgggaaca	5700
	acaccaccgt	gcagcagatc	atggagggca	tgagattatc	acaggagacc	cagcagtatt	5760
45	ttaccatctg	gatctgctcc	gaaaacctta	gtctgcagct	gaagccgtac	cacaagccct	5820
	tgcagcactt	acggatgtgg	agcgagatcg	tgacggatct	cactgctctg	gatccacaga	5880
50	gagaaagtcc	acagctcttc	ctgcgcagag	acgttcggct	gcctttagag	gtcgagaaaa	5940
50	aggttgaaga	tccgctgtcc	atcctcatcc	tatttgatga	agctcgtcac	tgcctcctta	6000
	aaggtttcct	ctcgacgtca	gataacaagc	taatcacgct	cgcaagcctc	ctcctgcaga	6060
55	tcatctacgg	aaactacgac	agcaagaagc	acaaacaggg	ctttctaaat	gaggaaaacc	6120
	tgaaatccat	agttcccatt	tcaaaggtca	agagcaaagc	acatcactgg	actaacagga	6180

	tacttcacga	gtacaagagt	ctgagcacta	gtgagggtgt	gagtaaagaa	atgcatcacc	6240
	tccagaggct	cttcctgcag	aactgctggg	atattcctac	ttatggtgca	gcgtttttca	6300
5	caggacaggt	cttcactaaa	gccagctcca	gcacacacaa	ggtgatccgc	gtgtatgtgg	6360
	gcgtcaacac	caaaggcctg	catctgatga	acatggagac	aaaagtgctt	cacctcagtc	6420
	tggagtatgg	gacatttatg	tggcagctgg	gtcaggctga	tcaatacgtg	caaatccaca	6480
10	gtctggagaa	caagaagaac	tttgtcgttc	acaccaaaca	ggctggtctt	atcgtgaagc	6540
	tgctgatgaa	gctgagtgga	caaattgcac	caaacgacag	agctgtgtct	gataaatatg	6600
	cgtatgggta	aacccagctt	tcttgtacaa	agtggaattc	actagtgatt	taatagtgtg	6660
15	cattcagtgc	aggatgttat	gtatttattt	tctgtagtgc	aaactttttc	aaagaatttt	6720
	ccagtctaag	cttttcagtc	aagaaaaaaa	aaggcgtctg	attatctgtg	atattttaaa	6780
20	taattagctc	ttaaatctgg	tgaaccaagt	ggccacaaca	cattaaatac	tgacgttcta	6840
20	cagccatgta	gcttcatctg	gtctggtttg	ttttggcagg	cacttatttt	ccggtgatag	6900
	ttggccacaa	gagtattgtc	tgagccattc	agtgctagac	tgtcattctc	aggtcagaat	6960
25	ccaccccact	gattctgctg	acaacactgt	tcccaccatg	agataatgcc	attccagaga	7020
	gatccatttg	taagcccctc	tttctgcagc	acaggtatat	aaccagggct	ctgcctccac	7080
	taaggccggc	acacatcatt	tggggatctt	tgtactgtac	tagcctctat	tagcctccta	7140
30	cttgcgttca	gttcacatct	tttgttcatc	aggtgcaata	agttacagta	aggagttacc	7200
	aggtctgaca	ttaatcgaat	tccaccatgg	tgagcaaggg	cgaggagctg	ttcaccgggg	7260
	tggtgcccat	cctggtcgag	ctggacggcg	acgtaaacgg	ccacaagttc	agcgtgtccg	7320
35	gcgagggcga	gggcgatgcc	acctacggca	agctgaccct	gaagttcatc	tgcaccaccg	7380
	gcaagctgcc	cgtgccctgg	cccaccctcg	tgaccaccct	gacctacggc	gtgcagtgct	7440
	tcagccgcta	ccccgaccac	atgaagcagc	acgacttctt	caagtccgcc	atgcccgaag	7500
40	gctacgtcca	ggagcgcacc	atcttcttca	aggacgacgg	caactacaag	acccgcgccg	7560
	aggtgaagtt	cgagggcgac	accctggtga	accgcatcga	gctgaagggc	atcgacttca	7620
45	aggaggacgg	caacatcctg	gggcacaagc	tggagtacaa	ctacaacagc	cacaacgtct	7680
45	atatcatggc	cgacaagcag	aagaacggca	tcaaggtgaa	cttcaagatc	cgccacaaca	7740
	tcgaggacgg	cagcgtgcag	ctcgccgacc	actaccagca	gaacaccccc	atcggcgacg	7800
50	gccccgtgct	gctgcccgac	aaccactacc	tgagcaccca	gtccgccctg	agcaaagacc	7860
	ccaacgagaa	gcgcgatcac	atggtcctgc	tggagttcgt	gaccgccgcc	gggatcactc	7920
	tcggcatgga	cgagctgtac	aagggcggtg	gaagatctgg	gaattcaagg	cctctcgagc	7 <b>9</b> 80
55	ctctagattc	tgcagcccta	tagtgagtcg	tattacgtag	atccagacat	gataagatac	8040
	attgatgagt	ttggacaaac	cacaactaga	atgcagtgaa	aaaaatgctt	tatttgtgaa	8100

	atttgtgatg	ctattgcttt	atttgtaacc	attataagct	gcaataaaca	agttaacaac	8160
	aacaattgca	ttcattttat	gtttcaggtt	cagggggagg	tgtgggaggt	tttttccaac	8220
5	tttattatac	atagttgata	attcactggc	cgtcgtttta	catcgatgat	gatccagaca	8280
	tgataagata	cattgatgag	tttggacaaa	ccacaactag	aatgcagtga	aaaaatgct	8340
	ttatttgtga	aatttgtgat	gctattgctt	tatttgtaac	cattataagc	tgcaataaac	8400
10	aagttaacaa	caacaattgc	attcatttta	tgtttcaggt	tcaggggggag	gtgtgggagg	8460
	tttttaaag	caagtaaaac	ctctacaaat	gtggtatggc	tgattatgat	cctctagatc	8520
15	agatctgcga	agatacggcc	acgggtgctc	ttgatcctgt	ggctgatttt	ggactgtgct	8580
	gctcgcagct	gctgatgaat	cacatacttc	ctccattttc	ttccactgat	tgactgttat	8640
	aatttcccta	atttccaggt	caaggtgctg	tgcattgtgg	taatagatgt	gacatgacgt	8700
20	cacttccaaa	ggaccaatga	acatgtctga	ccaatttcat	ataatgtgaa	aacgattttc	8760
	ataggcagaa	taaataacat	ttaaattaaa	ctgggcatca	gcgcaattca	attggtttgg	8820
	taatagcaag	ggaaaataga	atgaagtgat	ctccaaaaaa	taagtacttt	ttgactgtaa	8880
25	ataaaattgt	aaggagtaaa	aagtactttt	ttttctaaaa	aaatgtaatt	aagtaaaagt	8940
	aaaagtattg	atttttaatt	gtactcaagt	aaagtaaaaa	tccccaaaaa	taatacttaa	9000
	gtacagtaat	caagtaaaat	tactcaagta	ctttacacct	ctggttcttg	accccctacc	9060
30	ttcagcaagc	ccagcagatc	cactagttct	agagcggccg	ccaccgcggt	ggagctccag	9120
	cttttgttcc	ctttagtgag	ggttaattgc	gcgcttggcg	taatcatggt	catagctgtt	9180
35	tcctgtgtga	aattgttatc	cgctcacaat	tccacacaac	atacgagccg	gaagcataaa	9240
	gtgtaaagcc	tggggtgcct	aatgagtgag	ctaactcaca	ttaattgcgt	tgcgctcact	9300
	gcccgctttc	cagtcgggaa	acctgtcgtg	ccagctgcat	taatgaatcg	gccaacgcgc	9360
40	ggggagaggc	ggtttgcgta	ttgggcgctc	ttccgcttcc	tcgctcactg	actcgctgcg	9420
	ctcggtcgtt	cggctgcggc	gagcggtatc	agctcactca	aaggcggtaa	tacggttatc	9480
	cacagaatca	ggggataacg	caggaaagaa	catgtgagca	aaaggccagc	aaaaggccag	9540
45	gaaccgtaaa	aaggccgcgt	tgctggcgtt	tttccatagg	ctccgccccc	ctgacgagca	9600
	tcacaaaaat	cgacgctcaa	gtcagaggtg	gcgaaacccg	acaggactat	aaagatacca	9660
50	ggcgtttccc	cctggaagct	ccctcgtgcg	ctctcctgtt	ccgaccctgc	cgcttaccgg	9720
50	atacctgtcc	gcctttctcc	cttcgggaag	cgtggcgctt	tctcatagct	cacgctgtag	9780
	gtatctcagt	tcggtgtagg	tcgttcgctc	caagctgggc	tgtgtgcacg	aaccccccgt	9840
55	tcagcccgac	cgctgcgcct	tatccggtaa	ctatcgtctt	gagtccaacc	cggtaagaca	9900
	cgacttatcg	ccactggcag	cagccactgg	taacaggatt	agcagagcga	ggtatgtagg	9960

	cggtgctaca	gagttcttga	agtggtggcc	taactacggc	tacactagaa	ggacagtatt	10020
	tggtatctgc	gctctgctga	agccagttac	cttcggaaaa	agagttggta	gctcttgatc	10080
5	cggcaaacaa	accaccgctg	gtagcggtgg	ttttttgtt	tgcaagcagc	agattacgcg	10140
	cagaaaaaaa	ggatctcaag	aagatccttt	gatcttttct	acggggtctg	acgctcagtg	10200
	gaacgaaaac	tcacgttaag	ggattttggt	catgagatta	tcaaaaagga	tcttcaccta	10260
10	gatcctttta	aattaaaaat	gaagttttaa	atcaatctaa	agtatatatg	agtaaacttg	10320
	gtctgacagt	taccaatgct	taatcagtga	ggcacctatc	tcagcgatct	gtctatttcg	10380
15	ttcatccata	gttgcctgac	tccccgtcgt	gtagataact	acgatacggg	agggcttacc	10440
15	atctggcccc	agtgctgcaa	tgataccgcg	agacccacgc	tcaccggctc	cagatttatc	10500
	agcaataaac	cagccagccg	gaagggccga	gcgcagaagt	ggtcctgcaa	ctttatccgc	10560
20	ctccatccag	tctattaatt	gttgccggga	agctagagta	agtagttcgc	cagttaatag	10620
	tttgcgcaac	gttgttgcca	ttgctacagg	catcgtggtg	tcacgctcgt	cgtttggtat	10680
	ggcttcattc	agctccggtt	cccaacgatc	aaggcgagtt	acatgatccc	ccatgttgtg	10740
25	caaaaaagcg	gttagctcct	tcggtcctcc	gatcgttgtc	agaagtaagt	tggccgcagt	10800
	gttatcactc	atggttatgg	cagcactgca	taattctctt	actgtcatgc	catccgtaag	10860
	atgettttet	gtgactggtg	agtactcaac	caagtcattc	tgagaatagt	gtatgcggcg	10920
30	accgagttgc	tcttgcccgg	cgtcaatacg	ggataatacc	gcgccacata	gcagaacttt	10980
	aaaagtgctc	atcattggaa	aacgttcttc	ggggcgaaaa	ctctcaagga	tcttaccgct	11040
25	gttgagatcc	agttcgatgt	aacccactcg	tgcacccaac	tgatcttcag	catctttac	11100
35	tttcaccagc	gtttctgggt	gagcaaaaac	aggaaggcaa	aatgccgcaa	aaaagggaat	11160
	aagggcgaca	cggaaatgtt	gaatactcat	actcttcctt	tttcaatatt	attgaagcat	11220
40	ttatcagggt	tattgtctca	tgagcggata	catatttgaa	tgtatttaga	aaaataaaca	11280
	aatagggggtt	ccgcgcacat	ttccccgaaa	agtg			11314

<210> 13
<211> 484
<212> DNA
<213> Artificial Sequence

50 <220> <223> UAS promoter sequence <400> 13 gtaatacgac tcactatagg gcgaattggg taccgggccc cccctcgagg tcgacggtat cgataagctt aggcctccaa ggcggagtac tgtcctccgg gctggcggag tactgtcctc cggcaaggtc ggagtactgt cctccgacac tagaggtcgg agtactgtcc tccgacgcaa

83

60

120

15	<210> 14 <211> 2955 <212> DNA <213> Artificial Sequence <220> <223> Coding nucleotide sequence of an mCherry-KRIT1 fusion protein	
20	including a linker sequence	
	<400> 14 atggtgagca agggcgagga cgacaacatg gccatcatca aggagttcat gcgcttcaag	60
25	gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc	120
	cgcccctacg agggcaccca gaccgccaag ctgaaggtga ccaagggcgg ccccctgccc	180
	ttegeetggg acateetgte eeeteagtte atgtaegget eeaaggeeta egtgaageae	240
30	cccgccgaca tccccgacta cttgaagctg tccttccccg agggcttcaa gtgggagcgc	300
	gtgatgaact tegaggaegg eggegtggtg acegtgaeee aggaeteete eetgeaggae	360
	ggcgagttca tetacaaggt gaagetgege ggeaceaaet teeeeteega eggeeeegta	420
35	atgcagaaga agaccatggg ctgggaggcc teeteegage ggatgtaeee egaggaegge	480
	gccctgaagg gcgagatcaa gcagaggctg aagctgaagg acggcggcca ctacgacgcc	540
	gaggtcaaga ccacctacaa ggccaagaag cccgtgcagc tgcccggcgc ctacaacgtc	600
40	aacatcaagc tggacatcac ctcccacaac gaggactaca ccatcgtgga acagtacgag	660
	cgcgccgagg gccgccactc caccggcggc atggacgagc tgtacaaggg aggcgctgca	720
45	ggaggctcta gaatgggaaa ccaagagcta gaggaggtgt ttgttgctgt tatccgacca	780
45	aaaaacacaa ccagcctcaa ctccaaagaa taccgtgcta aatcctatga gattttactt	840
	atcgaagttc ccctggaggg aaaagagaaa aagcggaaga aagtgctgct tgggactaaa	900
50	attcacgccg acagtgaccg gacaaagtca attctggagt ttgtggatga aaccaccaag	960
	cccatatcca ataaccaggg cataataggg aagcgtgttg tgcacatgag gaagttcctg 1	.020
	ttagatggag acagtggagg aaaagaggcc tcgttattta ttgtgccaat taatgtcaaa 1	.080
55	gacaacagca agteegtgea teaceetggg ageeceagtt tetactgeet teaggaeate 1	.140
	atgcgtgtgt gtagtgaaac cagtgeteat tteteeteea geaceteaaa gatgetgete 1	.200

- ggcggagtac tgtcctccgg gctggcggag tactgtcctc cggcaaggtc ggagtactgt
   240

   cctccgacac tagaggtcgg agtactgtcc tccgacgcaa ggcggagtac tgtcctccgg
   300

   5
   gctggcggag tactgtcctc cggcaagggt cgactctaga gggtatataa tggatcccat
   360

   cgcgtctcag cctcactttg agctcctca cacgaattcc tgcagcccgg gggatccact
   420

   agttctagag cggccgccac cgcggtggag ctccagcttt tgttcccttt agtgagggt
   484
- EP 3 782 465 A1

	gctctcgaca	agtggttagc	ggagcagcac	actgtgcctc	acgctattcc	tgctctgttc	1260
	cggccggctc	cggtggaccg	tgtgaaaact	aacgtgagta	acccggcgta	cgcagtggag	1320
5	aagcagacag	acgggacgct	gcacatgggc	tacacggctc	tggagatcaa	gagtaaactg	1380
	atgtctctgg	agaaagcaga	tctgtgcatc	cagaacccgc	tgtacggctc	agatctgcag	1440
	tacaccaaca	gagtggacaa	agtcatcatc	aacccttact	ttggcttggg	agctccagat	1500
10	tactccaaaa	tccagattcc	aaagagagac	aaatggcagc	acagcatgac	cagcgtcacc	1560
	gaagacaaag	agcgccagtg	ggtggatgat	ttccctctgc	accgaagcgc	ctgtgaggga	1620
	gacactgagc	ttttgtctaa	attgctggat	ggcggattct	cagtcaaaca	gctggacagc	1680
15	gaccattggg	cacccattca	ttatgcatgc	tggcatggga	aggtggaggc	cactaaactg	1740
	ctgctggaga	aaggcaactg	taaccccaac	ctgctgaacg	gccagctgag	ctctccttta	1800
20	cacttcgcag	ctatcggcgg	tcatgcagaa	atcgtgcagc	tcctcctgca	gcacccagag	1860
	atcgacagac	acatcgagga	ccagcagaaa	cgatcgccgc	ttcaagtatg	tgaagaaaac	1920
	aagcagaaca	actgggagga	aaccgtgaat	ctccttcaac	aagccagcaa	taaaccatac	1980
25	gagaaggtga	ggatttaccg	tatggatgga	tcgtaccgct	ctgtggagct	gaagcatggg	2040
	aacaacacca	ccgtgcagca	gatcatggag	ggcatgagat	tatcacagga	gacccagcag	2100
	tattttacca	tctggatctg	ctccgaaaac	cttagtctgc	agctgaagcc	gtaccacaag	2160
30	cccttgcagc	acttacggat	gtggagcgag	atcgtgacgg	atctcactgc	tctggatcca	2220
	cagagagaaa	gtccacagct	cttcctgcgc	agagacgttc	ggctgccttt	agaggtcgag	2280
	aaaaaggttg	aagatccgct	gtccatcctc	atcctatttg	atgaagctcg	tcactgcctc	2340
35	cttaaaggtt	tcctctcgac	gtcagataac	aagctaatca	cgctcgcaag	cctcctcctg	2400
	cagatcatct	acggaaacta	cgacagcaag	aagcacaaac	agggctttct	aaatgaggaa	2460
40	aacctgaaat	ccatagttcc	catttcaaag	gtcaagagca	aagcacatca	ctggactaac	2520
	aggatacttc	acgagtacaa	gagtctgagc	actagtgagg	gtgtgagtaa	agaaatgcat	2580
	cacctccaga	ggctcttcct	gcagaactgc	tgggatattc	ctacttatgg	tgcagcgttt	2640
45	ttcacaggac	aggtcttcac	taaagccagc	tccagcacac	acaaggtgat	ccgcgtgtat	2700
	gtgggcgtca	acaccaaagg	cctgcatctg	atgaacatgg	agacaaaagt	gcttcacctc	2760
	agtctggagt	atgggacatt	tatgtggcag	ctgggtcagg	ctgatcaata	cgtgcaaatc	2820
50	cacagtctgg	agaacaagaa	gaactttgtc	gttcacacca	aacaggctgg	tcttatcgtg	2880
	aagctgctga	tgaagctgag	tggacaaatt	gcaccaaacg	acagagctgt	gtctgataaa	2940
	tatgcgtatg	ggtaa					2955

55

<210> 15

	<211> 708 <212> DNA <213> Artificial Sequence	
5	<220> <223> Coding nucleotide sequence of an mCherry	
10	<400> 15 atggtgagca agggcgagga cgacaacatg gccatcatca aggagttcat gcgcttcaag	60
10	gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc	120
	cgcccctacg agggcaccca gaccgccaag ctgaaggtga ccaagggcgg ccccctgccc	180
15	ttcgcctggg acatectgte eceteagtte atgtaegget ecaaggeeta egtgaageae	240
	cccgccgaca tccccgacta cttgaagetg tccttccccg agggettcaa gtgggagege	300
	gtgatgaact tegaggaegg eggegtggtg acegtgaeee aggaeteete eetgeaggae	360
20	ggcgagttca tetacaaggt gaagetgege ggeaceaaet teeeeteega eggeeeegta	420
	atgcagaaga agaccatggg ctgggaggcc tcctccgagc ggatgtaccc cgaggacggc	480
	gccctgaagg gcgagatcaa gcagaggctg aagctgaagg acggcggcca ctacgacgcc	540
25	gaggtcaaga ccacctacaa ggccaagaag cccgtgcagc tgcccggcgc ctacaacgtc	600
	aacatcaagc tggacatcac ctcccacaac gaggactaca ccatcgtgga acagtacgag	660
	cgcgccgagg gccgccactc caccggcggc atggacgagc tgtacaag	708
30		
	<210> 16 <211> 24 <212> DNA	
35	<213> Artificial Sequence	
	<220> <223> Coding nucleotide sequence of a linker that can be used for encoding a linker of a fusion protein of the invention.	
40	<400> 16	
	ggaggcgctg caggaggctc taga	24
45	<210> 17 <211> 586	
	<212> DNA <213> Artificial Sequence	
50	<220> <223> Nucleotide sequence of an alpha-crystallin promoter	
	<400> 17	60
	aarreacced tettacces attiticate areastitt attiticity	100
55	ayuycaaacu uuucaaaya auutteeagt etaagetttt eagteaagaa aaaaaaagge	100
	yreryarrat etytyatatt ttaaataatt agetettaaa tetggtgaae caagtggeea	T80

	caacacatta a	atactgacg	ttctacagcc	atgtagcttc	atctggtctg	gtttgttttg	240
	gcaggcactt a	ttttccggt	gatagttggc	cacaagagta	ttgtctgagc	cattcagtgc	300
5	tagactgtca t	tctcaggtc	agaatccacc	ccactgattc	tgctgacaac	actgttccca	360
	ccatgagata a	tgccattcc	agagagatcc	atttgtaagc	ccctctttct	gcagcacagg	420
	tatataacca g	ggctctgcc	tccactaagg	ccggcacaca	tcatttgggg	atctttgtac	480
10	tgtactagcc t	ctattagcc	tcctacttgc	gttcagttca	catcttttgt	tcatcaggtg	540
	caataagtta c	agtaaggag	ttaccaggtc	tgacattaat	cgaatt		586
15	<210> 18 <211> 717 <212> DNA <213> Artifi	cial Seque	ence				
20	<220> <223> Coding	g nucleotic	le sequence	of an EGFP			
25	<400> 18 atggtgagca a	lgggcgagga	gctgttcacc	ggggtggtgc	ccatcctggt	cgagctggac	60
25	ggcgacgtaa a	lcggccacaa	gttcagcgtg	tccggcgagg	gcgagggcga	tgccacctac	120
	ggcaagctga c	cctgaagtt	catctgcacc	accggcaagc	tgcccgtgcc	ctggcccacc	180
30	ctcgtgacca c	cctgaccta	cggcgtgcag	tgcttcagcc	gctaccccga	ccacatgaag	240
	cagcacgact t	cttcaagtc	cgccatgccc	gaaggctacg	tccaggagcg	caccatcttc	300
	ttcaaggacg a	lcggcaacta	caagacccgc	gccgaggtga	agttcgaggg	cgacaccctg	360
35	gtgaaccgca t	cgagctgaa	gggcatcgac	ttcaaggagg	acggcaacat	cctggggcac	420
	aagctggagt a	acaactacaa	cagccacaac	gtctatatca	tggccgacaa	gcagaagaac	480
	ggcatcaagg t	gaacttcaa	gatccgccac	aacatcgagg	acggcagcgt	gcagctcgcc	540
40	gaccactacc a	igcagaacac	ccccatcggc	gacggccccg	tgctgctgcc	cgacaaccac	600
	tacctgagca c	ccagtccgc	cctgagcaaa	gaccccaacg	agaagcgcga	tcacatggtc	660
45	ctgctggagt t	cgtgaccgc	cgccgggatc	actctcggca	tggacgagct	gtacaag	717
50	<210> 19 <211> 2964 <212> DNA <213> Artifi	cial Seque	ence				
	<220> <223> Coding includ	g nucleotic ling a link	le sequence er sequence	of an EGFP-	-KRIT1 fusio	on protein	
55	<400> 19 atggtgagca a	ıgggcgagga	gctgttcacc	ggggtggtgc	ccatcctggt	cgagctggac	60

	ggcgacgtaa	acggccacaa	gttcagcgtg	tccggcgagg	gcgagggcga	tgccacctac	120
	ggcaagctga	ccctgaagtt	catctgcacc	accggcaagc	tgcccgtgcc	ctggcccacc	180
5	ctcgtgacca	ccctgaccta	cggcgtgcag	tgcttcagcc	gctaccccga	ccacatgaag	240
	cagcacgact	tcttcaagtc	cgccatgccc	gaaggctacg	tccaggagcg	caccatcttc	300
	ttcaaggacg	acggcaacta	caagacccgc	gccgaggtga	agttcgaggg	cgacaccctg	360
10	gtgaaccgca	tcgagctgaa	gggcatcgac	ttcaaggagg	acggcaacat	cctggggcac	420
	aagctggagt	acaactacaa	cagccacaac	gtctatatca	tggccgacaa	gcagaagaac	480
15	ggcatcaagg	tgaacttcaa	gatccgccac	aacatcgagg	acggcagcgt	gcagctcgcc	540
10	gaccactacc	agcagaacac	ccccatcggc	gacggccccg	tgctgctgcc	cgacaaccac	600
	tacctgagca	cccagtccgc	cctgagcaaa	gaccccaacg	agaagcgcga	tcacatggtc	660
20	ctgctggagt	tcgtgaccgc	cgccgggatc	actctcggca	tggacgagct	gtacaaggga	720
	ggcgctgcag	gaggctctag	aatgggaaac	caagagctag	aggaggtgtt	tgttgctgtt	780
	atccgaccaa	aaaacacaac	cagcctcaac	tccaaagaat	accgtgctaa	atcctatgag	840
25	attttactta	tcgaagttcc	cctggaggga	aaagagaaaa	agcggaagaa	agtgctgctt	900
	gggactaaaa	ttcacgccga	cagtgaccgg	acaaagtcaa	ttctggagtt	tgtggatgaa	960
	accaccaagc	ccatatccaa	taaccagggc	ataataggga	agcgtgttgt	gcacatgagg	1020
30	aagttcctgt	tagatggaga	cagtggagga	aaagaggcct	cgttatttat	tgtgccaatt	1080
	aatgtcaaag	acaacagcaa	gtccgtgcat	caccctggga	gccccagttt	ctactgcctt	1140
35	caggacatca	tgcgtgtgtg	tagtgaaacc	agtgctcatt	tctcctccag	cacctcaaag	1200
	atgctgctcg	ctctcgacaa	gtggttagcg	gagcagcaca	ctgtgcctca	cgctattcct	1260
	gctctgttcc	ggccggctcc	ggtggaccgt	gtgaaaacta	acgtgagtaa	cccggcgtac	1320
40	gcagtggaga	agcagacaga	cgggacgctg	cacatgggct	acacggctct	ggagatcaag	1380
	agtaaactga	tgtctctgga	gaaagcagat	ctgtgcatcc	agaacccgct	gtacggctca	1440
	gatctgcagt	acaccaacag	agtggacaaa	gtcatcatca	acccttactt	tggcttggga	1500
45	gctccagatt	actccaaaat	ccagattcca	aagagagaca	aatggcagca	cagcatgacc	1560
	agcgtcaccg	aagacaaaga	gcgccagtgg	gtggatgatt	tccctctgca	ccgaagcgcc	1620
50	tgtgagggag	acactgagct	tttgtctaaa	ttgctggatg	gcggattctc	agtcaaacag	1680
	ctggacagcg	accattgggc	acccattcat	tatgcatgct	ggcatgggaa	ggtggaggcc	1740
	actaaactgc	tgctggagaa	aggcaactgt	aaccccaacc	tgctgaacgg	ccagctgagc	1800
55	tctcctttac	acttcgcagc	tatcggcggt	catgcagaaa	tcgtgcagct	cctcctgcag	1860
	cacccagaga	tcgacagaca	catcgaggac	cagcagaaac	gatcgccgct	tcaagtatgt	1920

	gaagaaaaca	agcagaacaa	ctgggaggaa	accgtgaatc	tccttcaaca	agccagcaat	1980
	aaaccatacg	agaaggtgag	gatttaccgt	atggatggat	cgtaccgctc	tgtggagctg	2040
5	aagcatggga	acaacaccac	cgtgcagcag	atcatggagg	gcatgagatt	atcacaggag	2100
	acccagcagt	attttaccat	ctggatctgc	tccgaaaacc	ttagtctgca	gctgaagccg	2160
10	taccacaagc	ccttgcagca	cttacggatg	tggagcgaga	tcgtgacgga	tctcactgct	2220
	ctggatccac	agagagaaag	tccacagctc	ttcctgcgca	gagacgttcg	gctgccttta	2280
	gaggtcgaga	aaaaggttga	agatccgctg	tccatcctca	tcctatttga	tgaagctcgt	2340
15	cactgcctcc	ttaaaggttt	cctctcgacg	tcagataaca	agctaatcac	gctcgcaagc	2400
	ctcctcctgc	agatcatcta	cggaaactac	gacagcaaga	agcacaaaca	gggctttcta	2460
	aatgaggaaa	acctgaaatc	catagttccc	atttcaaagg	tcaagagcaa	agcacatcac	2520
20	tggactaaca	ggatacttca	cgagtacaag	agtctgagca	ctagtgaggg	tgtgagtaaa	2580
	gaaatgcatc	acctccagag	gctcttcctg	cagaactgct	gggatattcc	tacttatggt	2640
25	gcagcgtttt	tcacaggaca	ggtcttcact	aaagccagct	ccagcacaca	caaggtgatc	2700
	cgcgtgtatg	tgggcgtcaa	caccaaaggc	ctgcatctga	tgaacatgga	gacaaaagtg	2760
	cttcacctca	gtctggagta	tgggacattt	atgtggcagc	tgggtcaggc	tgatcaatac	2820
30	gtgcaaatcc	acagtctgga	gaacaagaag	aactttgtcg	ttcacaccaa	acaggctggt	2880
	cttatcgtga	agctgctgat	gaagctgagt	ggacaaattg	caccaaacga	cagagctgtg	2940
	tctgataaat	atgcgtatgg	gtaa				2964
35							
	<210> 20						
	<211> 25 <212> DNA						
	<213> Arti	ficial Seque	ence				
40							
	<220>	_					
	<223> tnnt2	2a antisense	e sequence				

45 <400> 20
catgtttgct ctgatctgac acgca

25

#### Claims

- 50
- 1. A transgenic fish lacking at least one endogenous functional protein required for a functional CCM complex, comprising an exogenous nucleic acid encoding a functional version of said at least one protein under the transcriptional control of an endocardium-specific genetic system.
- ⁵⁵ **2.** Transgenic fish according to claim 1, wherein the fish is a zebrafish.
  - **3.** Transgenic fish according to any one of the preceding claims, wherein the at least one protein required for a functional CCM complex is selected from the group comprising CCM1 (KRIT1), CCM2, CCM3, and Heg1.

- 4. Transgenic fish according to any one of the preceding claims, wherein the at least one protein is CCM1 and the fish lacking at least one endogenous functional protein required for a functional CCM complex is a zebrafish homozygously carrying a loss-of-function allele of krit1, such as a krit1-ty219c allele.
- 5 5. Transgenic fish according to any one of the preceding claims, wherein the endocardium-specific genetic system comprises a Gal4-UAS system, wherein the Gal4-UAS system comprises a Gal4 gene, preferably Gal4ff, under the control of an endocardium-specific transcriptional regulator, such as an endocardium-specific promoter, and a nucleic acid sequence encoding said functional protein required for a functional CCM complex under the control of a UAS region.

10

- 6. Transgenic fish according to the preceding claim, wherein the endocardium-specific expression of the Gal4 gene is driven by an nfatc1 promoter.
- Transgenic fish according to any one of the preceding claims, wherein the functional version of said at least one protein is a fusion protein of the at least one functional protein and a reporter protein, such as a fluorescent reporter protein.
  - 8. Transgenic fish according to any one of the preceding claims, wherein said transgenic fish comprises a cardiovascular system with a heart that produces blood flow, and wherein said fish develops vascular lesions in cerebellar blood vessels, in particular in lowly perfused cerebellar blood vessels.
  - 9. Transgenic fish according to the preceding claim, wherein the vascular lesions can be visualized by
- 25

20

- a traceable reagent injected into the cardiovascular system of said transgenic fish, such as a traceable dye or labeled nanobeads, or

- by using a transgenic fish additionally expressing fluorescently-labelled blood proteins or blood cells.
- **10.** Transgenic fish according to any one of the preceding claims, wherein the fish is at a stage of development selected from the group consisting of an embryo stage, a larva stage, and an adult stage.
- 30
- **11.** Method for measuring a pharmacological effect of a drug, comprising
  - contacting a transgenic fish according to any one of claims 1 to 10 with a drug, and
  - measuring a pharmacological effect of the drug.
- 35
- **12.** Method for measuring a pharmacological effect of a drug according to the previous claim, wherein the pharmacological effect of the drug is an effect on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke.
- 40 13. Method for measuring a pharmacological effect of a drug according to claim 12, wherein the pharmacological effect of the drug is measured by comparing the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke in the transgenic fish contacted with the drug to the formation of vascular lesions, the development of stroke in a transgenic fish according to any one of claims 1 to 10 not contacted with said drug.
- 45

- **14.** Use of a transgenic fish according to any one of claims 1 to 10 as a model for the treatment and/or prevention of vascular lesions, cerebellar cavernous malformation and/or stroke.
- 15. Use of a transgenic fish according to any one of claims 1 to 10 in a method of screening a compound for an effect
   on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development
   of stroke, the method comprising
  - contacting said transgenic fish to a compound and
  - measuring the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke.





Tg(kdrl:EGFP)^{s843}

# Figure 1 (Continued)



# Figure 1 (Continued)









# Figure 3 (continued)







# Figure 5 (continued)







# Figure 7 (continued)







# Figure 8 (continued)



# Figure 9 (continued)






# Figure 12



Tg(kdrl:EGFP)^{s843}; Tg(nfatc1:GAL4FF)^{mu286}; Tg(UAS:mCherny-Krit1)^{md40}

# Figure 13





5

# **EUROPEAN SEARCH REPORT**

Application Number EP 19 19 3235

		DOCUMENTS CONSID			
	Category	Citation of document with in of relevant passa	idication, where appropriate, ages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
10 15	A,D	STEFAN DONAT ET AL: proteins control en mechanosensitivity valvulogenesis", ELIFE, vol. 7, 24 January XP055658204, DOI: 10.7554/eLife. * page 7 - page 11;	"Heg1 and Ccm1/2 docardial during zebrafish 2018 (2018-01-24), 28939 figure 5 *	1-15	INV. A01K67/027 C07K14/46
20	A	AUBREY C. CHAN ET A into cerebral caver animal models of CC phenotype : CCM ani FEBS JOURNAL, vol. 277, no. 5, Ma	L: "Recent insights nous malformations: M and the human mal models", rch 2010 (2010-03),	1-15	
25		GB ISSN: 1742-464X, DO 10.1111/j.1742-4658 * page 1077 - page	I: .2009.07536.x 1080 *		TECHNICAL FIELDS SEARCHED (IPC)
30	A	D. A. MCDONALD ET A model of cerebral c based on the two-hi recapitulates the h HUMAN MOLECULAR GEN vol. 20, no. 2,	L: "A novel mouse avernous malformations t mutation hypothesis uman disease", ETICS,	1-15	A01K C07K
35		15 January 2011 (20 211-222, XP05565809 ISSN: 0964-6906, D0 * page 217 - page 2	11-01-15), pages 3, I: 10.1093/hmg/ddq433 20 *		
40			7		
45					
1		I he present search report has been drawn up for all claims Place of search Date of completion of the search Date of completion of the search			Examiner
04C01)	Munich 16 January 2020		Deleu, Laurent		
EPO FORM 1503 03.82 (Pd	CATEGORY OF CITED DOCUMENTS       T : theory or principle underlying the invention         X : particularly relevant if taken alone       T : theory or principle underlying the invention         Y : particularly relevant if combined with another document of the same category       D : document of the application         A : technological background       C : non-written disclosure         P : intermediate document       & : member of the same patent family, corresponding document				

55

page 1 of 2



# **EUROPEAN SEARCH REPORT**

Application Number EP 19 19 3235

	DOCUMENTS CONSID				
Category	Citation of document with i of relevant pass	ndication, where appropriate, ages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)	
A,D	G. BOULDAY ET AL: conditional CCM2 kr the essential role angiogenesis: impl ² cerebral cavernous DISEASE MODELS & ME vol. 2, no. 3-4, Ma pages 168-177, XP55 GB ISSN: 1754-8403, DC * page 173 - page 1	"Tissue-specific nockout mice establish of endothelial CCM2 in ications for human malformations", ECHANISMS, arch 2009 (2009-03), 5466448, DI: 10.1242/dmm.001263 L74 *	1-15		
Ą	CN 106 226 531 A (0 MEDICINE TECH CO L 14 December 2016 (2 * the whole documer	GUANGZHOU DAORUI FD) 2016-12-14) ht *	1-15		
				SEARCHED (IFC)	
	The present search report has	been drawn up for all claims		Fyaminer	
	Munich	16 January 2020	Date of completion of the search     Examiner       16 January 2020     Deleu, Laurent       T : theory or principle underlying the invention       E : earlier patent document, but published on, or		
C	ATEGORY OF CITED DOCUMENTS	T : theory or principle E : earlier patent doo			
X : par Y : par	ticularly relevant if taken alone ticularly relevant if combined with anot ument of the same category	her D : document cited fo	the application	he application	
A : tec O : no P : inte	hnological background n-written disclosure rrmediate document	& : member of the same patent family document		, corresponding	

page 2 of 2

# EP 3 782 465 A1

### ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 19 19 3235

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

16-01-2020

10	Patent document cited in search report	Publication date	Patent family member(s)	Publication date
	CN 106226531 A	14-12-2016	NONE	
15				
20				
25				
30				
35				
40				
45				
50				
55 6540 MRO 1 Od=	For more details about this annex : see	Official Journal of the Euro	ppean Patent Office, No. 12/82	

### **REFERENCES CITED IN THE DESCRIPTION**

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

#### Patent documents cited in the description

- US 7034141 B [0083]
- US 7037645 B [0083]
- US 6087476 A **[0083]**
- US 6730822 B [0086]
- US 6380458 B [0086]
- US 5932780 A [0086]
- US 6949242 B [0086]
- US 6897045 B [0086]

#### Non-patent literature cited in the description

- KLEAVELAND et al. Nat Med., February 2009, vol. 15 (2), 169-76 [0017]
- KIMMEL. Trends Genet, 1989, vol. 5, 283-8 [0046]
   [0047]
- DRIEVER et al. Development, 1996, vol. 123, 37-46
   [0046]
- HAFFTER et al. Development, 1996, vol. 123, 1-36 [0046]
- STREISINGER. Natl. Cancer Inst. Monogr., 1984, vol. 65, 53-58 [0046]
- CULP et al. Proc Natl Acad Sci USA, 1991, vol. 88, 7953-7957 [0050]
- INOUE et al. Cell. Differ. Develop., 1990, vol. 29, 123-128 [0050]
- MULLER et al. FEBS Lett., 1993, vol. 324, 27-32 [0050]
- MURAKAMI et al. J. Biotechnol., 1994, vol. 34, 35-42 [0050]
- MULLER et al. Mol. Mar. Biol. Biotechnol., 1992, vol. 1, 276-281 [0050]
- SYMONDS et al. Aquaculture, 1994, vol. 119, 313-327 [0050]
- ZELENIN et al. FEBS Lett., 1991, vol. 287, 118-120
   [0050]
- LU et al. Mol Mar Biol Biotechnol, 1997, vol. 6, 289-95 [0050]
- SZELEI et al. Transgenic Res., 1994, vol. 3, 116-119 [0050]
- KAWAKAMI, K. Genome Biol., 2007, vol. 8 (1), S7 [0053]
- KLEAVELAND et al. Nature Medicine, February 2009, vol. 15 (2), 169-176 [0062]
- SPIEGELER et al. Mol Syndromol, 2018, vol. 9, 60-69 [0062]

- US 6784289 B [0086]
- US 6395549 B [0087]
- US 6229070 B [0087]
- US 6100448 A [0087]
- US 5610053 A [0087]
- US 6239328 B [0087]
- US 5773695 A [0087]
- US 5773689 A [0087]
- JENNIFER LIPPINCOTT-SCHWARTZ; GEORGE H. PATTERSON. Development and Use of Fluorescent Protein Markers in Living Cells. *Science*, 2003, vol. 300 (5616), 87-91 [0118]
- JIN ZHANG et al. Nat. Rev. Mol. Cell. Biol., 2002, vol. 3 (12), 906-918 [0118]
- J. SAMBROOK ; E. F. FRITSCH ; T. MANIATIS. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0128]
- AUSUBEL, F. M. et al. Current Protocols in Molecular Biology. John Wiley & Sons, 1995 [0128]
- DNA Isolation and Sequencing: Essential Techniques. B. ROE; J. CRABTREE; A. KAHN. Situ Hybridization: Principles and Practice. Oxford University Press, 1996 [0128]
- Oligonucleotide Synthesis: A Practical Approach. Irl Press, 1984 [0128]
- D. M. J. LILLEY; J. E. DAHLBERG. Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology. Academic Press, 1992 [0128]
- Using Antibodies: A Laboratory Manual: Portable Protocol NO. I. Cold Spring Harbor Laboratory Press, 1999 [0128]
- Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1988 [0128]
- Handbook of Drug Screening. Marcel Dekker, 2001 [0128]
- A Handbook of Recipes, Reagents, and Other Reference Tools for Use at the Bench. Cold Spring Harbor Laboratory, 2002 [0128]
- BAEYENS N; SCHWARTZ MA. Biomechanics of vascular mechanosensation and remodeling. *Mol Bi*ol Cell, 2016, vol. 27, 7-11 [0163]

- BAEYENS N; BANDYOPADHYAY C; COON BG; YUN S; SCHWARTZ MA. Endothelial fluid shear stress sensing in vascular health and disease. J Clin Invest, 2016, vol. 126, 821-828 [0163]
- ANTON H et al. Pulse propagation by a capacitive mechanism drives embryonic blood flow. *Development*, 2013, vol. 140, 4426-4434 [0163]
- BOSELLI F; FREUND JB; VERMOT J. Blood flow mechanics in cardiovascular development. *Cell. Mol. Life Sci.*, 2015, vol. 72, 2545-2559 [0163]
- MACEK JILKOVA Z; LISOWSKA J; MANET S; VERDIER C; DEPLANO V; GEINDREAU C; FAU-ROBERT E; ALBIGÈS-RIZO C; DUPERRAY A. CCM proteins control endothelial β1 integrin dependent response to shear stress. *Biol Open.*, 2014, vol. 3, 1228-1235 [0163]
- MLEYNEK TM; CHAN AC; REDD M; GIBSON CC; DAVIS CT; SHI DS; CHEN T; CARTER KL; LING J; BLANCO R. Lack of CCM1 induces hypersprouting and impairs response to flow. *Hum Mol Genet.*, 2014, vol. 23, 6223-6234 [0163]
- RENZ M; OTTEN C; FAUROBERT E; RUDOLPH F; ZHU Y; BOULDAY G; DUCHENE J; MICKO-LEIT M; DIETRICH A-C; RAMSPACHER C. Regulation of β1 integrin-Klf2-mediated angiogenesis by CCM proteins. *Dev Cell.*, 2015, vol. 32, 181-190 [0163]
- LIU H; RIGAMONTI D; BADR A; ZHANG J. Ccm1 Regulates Microvascular Morphogenesis during Angiogenesis. *Journal of Vascular Research*, 2011, vol. 48, 130-140 [0163]
- RETTA SF; GLADING AJ. Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin. The International Journal of Biochemistry & Cell Biology, 2016, vol. 81, 254-270 [0163]
- SPIEGLER S; RATH M; PAPERLEIN C; FELBOR
   U. Cerebral Cavernous Malformations: An Update on Prevalence, Molecular Genetic Analyses, and Genetic Counselling. *Mol Syndromol.*, 2018, vol. 9, 60-69
   [0163]
- KNUDSON AG. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci USA.*, 1971, vol. 68, 820-823 [0163]
- DUBOVSKY J; ZABRAMSKI JM; KURTH J; SPETZLER RF; RICH SS; ORR HT; WEBER JL. A gene responsible for cavernous malformations of the brain maps to chromosome 7q. *Hum Mol Genet.*, 1995, vol. 4, 453-458 [0163]
- CRAIG HD; GÜNEL M; CEPEDA O; JOHNSON EW; PTACEK L; STEINBERG GK; OGILVY CS; BERG MJ; CRAWFORD SC; SCOTT RM. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. *Hum Mol Genet.*, 1998, vol. 7, 1851-1858 [0163]

- AKERS AL; JOHNSON E; STEINBERG GK; ZA-BRAMSKI JM; MARCHUK DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. *Hum Mol Genet.*, 2009, vol. 18, 919-930 [0163]
- CHOHANMO; MARCHIOS; MORRISONLA; SID-MAN RL; CAVENEE WK; DEJANAE; YONAS H; PASQUALINIR; ARAP W. Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review. JAMA Neurol., 2018 [0163]
- ZHOU Z; RAWNSLEY DR; GODDARD LM; PAN W; CAO X-J; JAKUS Z; ZHENG H; YANG J; ARTHUR JSC; WHITEHEAD KJ. The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression. *Dev Cell.*, 2015, vol. 32, 168-180 [0163]
- ZHOU Z; TANG AT; WONG W-Y; BAMEZAI S; GODDARD LM; SHENKAR R; ZHOU S; YANG J; WRIGHT AC; FOLEY M. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. *Nature*, 2016, vol. 532, 122-126 [0163]
- CUTTANO R ; RUDINI N ; BRAVI L ; CORADA M ; GIAMPIETRO C ; PAPA E ; MORINI MF ; MADDA-LUNO L ; BAEYENS N ; ADAMS RH. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations. *EMBO Mol Med.*, 2016, vol. 8, 6-24 [0163]
- WESTERFIELD M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). Univ. of Oregon Press, 2000 [0163]
- CHEN JN et al. Mutations affecting the cardiovascular system and other internal organs in zebrafish. *Development*, 1996, vol. 123, 293-302 [0163]
- MABLY JD; CHUANG LP; SERLUCA FC; MO-HIDEEN M-APK; CHEN J-N; FISHMAN MC. santa and valentine pattern concentric growth of cardiac myocardium in the zebrafish. *Development*, 2006, vol. 133, 3139-3146 [0163]
- JIN S-W; BEIS D; MITCHELL T; CHEN J-N; STAINIER DYR. Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. *Development*, 2005, vol. 132, 5199-5209 [0163]
- ROMAN BL; PHAN VN; LAWSON ND; KULIK M; CHILDS S; LEKVEN AC; GARRITY DM; MOON RT; FISHMAN MC; LECHLEIDER RJ. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. *Development*, 2002, vol. 129, 3009-3019 [0163]
- CHI NC; SHAW RM; DE VAL S; KANG G; JAN LY; BLACK BL; STAINIER DYR. Foxn4 directly regulates tbx2b expression and atrioventricular canal formation. *Genes Dev.*, 2008, vol. 22, 734-739 [0163]

- SUGDEN WW ; MEISSNER R ; AEGERTER-WILM-SEN T ; TSARYK R ; LEONARD EV ; BUSSMANN J ; HAMM MJ ; HERZOG W ; JIN Y ; JAKOBSSON L. Endoglin controls blood vessel diameter through endothelial cell shape changes in response to haemodynamic cues. Nat Cell Biol., 2017, vol. 19, 653-665 [0163]
- **HERWIG L et al.** Distinct Cellular Mechanisms of Blood Vessel Fusion in the Zebrafish Embryo. *Current Biology.*, 2011, vol. 21, 1942-1948 [0163]
- PESTEL J; RAMADASS R; GAUVRIT S; HELKER C; HERZOG W. Stainier DYR. Real-time 3D visualization of cellular rearrangements during cardiac valve formation. *Development*, 2016, vol. 143, 2217-2227 [0163]
- DONAT S; LOURENGO M; PAOLINI A; OTTEN C; RENZ M. Abdelilah-Seyfried S. Heg1 and Ccm1/2 proteins control endocardial mechanosensitivity during zebrafish valvulogenesis. *Elife*, 2018, 7 [0163]
- KWAN KM; FUJIMOTO E; GRABHER C; MAN-GUM BD; HARDY ME; CAMPBELL DS; PARANT JM; YOST HJ; KANKI JP. Chien C-B. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. *Dev Dyn.*, 2007, vol. 236, 3088-3099 [0163]
- VILLEFRANC JA ; AMIGO J ; LAWSON ND. Gateway compatible vectors for analysis of gene function in the zebrafish. *Dev Dyn.*, 2007, vol. 236, 3077-3087 [0163]
- SEHNERT AJ; HUQ A; WEINSTEIN BM; WALK-ER C; FISHMAN M; STAINIER DYR. Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. *Nat Genet.*, 2002, vol. 31, 106-110 [0163]
- WEINSTEIN BM; STEMPLE DL; DRIEVER W; FISHMAN MC. Gridlock, a localized heritable vascular patterning defect in the zebrafish. *Nat Med.,* 1995, vol. 1, 1143-1147 [0163]
- LI P; WHITE RM; ZON LI. Transplantation in zebrafish. *Methods Cell Biol.*, 2011, vol. 105, 403-417 [0163]
- LANGE S; SYLVESTER M; SCHÜMANN M; FRE-UND C; KRAUSE E. Identification of phosphorylation-dependent interaction partners of the adapter protein ADAP using quantitative mass spectrometry: SILAC vs (18)O-labeling. J Proteome Res., 2010, vol. 9, 4113-4122 [0163]
- KRISTIANSEN TZ; HARSHA HC; GRØNBORG M; MAITRA A; PANDEY A. Differential membrane proteomics using 180-labeling to identify biomarkers for cholangiocarcinoma. *J Proteome Res.*, 2008, vol. 7, 4670-4677 [0163]
- BLUM Y; BELTING H-G; ELLERTSDOTTIR E; HERWIG L; LÜDERS F; AFFOLTER M. Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the zebrafish embryo. *Dev Biol.*, 2008, vol. 316, 312-322 [0163]

- KLEAVELAND B; ZHENG X; LIU JJ; BLUM Y; TUNG JJ; ZOU Z; SWEENEY SM; CHEN M; GUO L; LU M. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. *Nat Med.*, 2009, vol. 15, 169-176 [0163]
- BOULDAY G; BLÉCON A; PETIT N; CHAREYRE F; GARCIA LA; NIWA-KAWAKITA M; GIOVAN-NINI M; TOURNIER-LASSERVE E. Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. *Dis Model Mech.*, 2009, vol. 2, 168-177 [0163]
- DIETRICH A-C; LOMBARDO VA; VEERKAMP J; PRILLER F; ABDELILAH-SEYFRIED S. Blood flow and Bmp signaling control endocardial chamber morphogenesis. *Dev Cell.*, 2014, vol. 30, 367-377 [0163]
- FISHER OS ; BOGGON TJ. Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology. *Cell Mol Life Sci.*, 2014, vol. 71, 1881-1892 [0163]
- GLADING AJ; GINSBERG MH. Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. *Dis Model Mech.*, 2010, vol. 3, 73-83 [0163]
- GÜNEL M; LAURANS MSH; SHIN D; DILUNA ML; VOORHEES J; CHOATE K; NELSON-WIL-LIAMS C; LIFTON RP. KRIT1, a gene mutated in cerebral cavernous malformation, encodes a microtubuleassociated protein. *Proc Natl Acad Sci USA.*, 2002, vol. 99, 10677-10682 [0163]
- BRAVIL; MALINVERNOM; PISATIF; RUDININ; CUTTANOR; PALLINIR; MARTINIM; LAROCCA LM; LOCATELLIM; LEVIV. Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition. Stroke, 2016, vol. 47, 886-890 [0163]
- MADDALUNOL; RUDININ; CUTTANOR; BRAVI L; GIAMPIETROC; CORADAM; FERRARINIL; ORSENIGOF; PAPAE; BOULDAYG. EndMT contributes to the onset and progression of cerebral cavernous malformations. *Nature*, 2013, vol. 498, 492-496 [0163]
- DEJANA E; LAMPUGNANI MG. Endothelial cell transitions. *Science*, 2018, vol. 362, 746-747 [0163]
- VERMOT J; FOROUHAR AS; LIEBLING M; WU D; PLUMMER D; GHARIB M; FRASER SE. Reversing blood flows act through klf2a to ensure normal valvulogenesis in the developing heart. *PLoS Biol*, 2009, vol. 7, e1000246 [0163]
- VANLANDEWIJCK M; HE L; MAE MA; ANDRAE J; ANDO K; DEL GAUDIO F et al. A molecular atlas of cell types and zonation in the brain vasculature. *Nature*, 2018, vol. 554, 475 [0163]
- **TANG AT et al.** Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. *Nature*, 2017, vol. 545, 305-310 **[0163]**

- DEJANA E ; HIRSCHI KK ; SIMONS M. The molecular basis of endothelial cell plasticity. *Nature Communications*, 2017, vol. 8, 14361 [0163]
- MORINI MF; GIAMPIETRO C; CORADA M; PIS-ATI F; LAVARONE E; CUNHA SI et al. VE-Cadherin-Mediated Epigenetic Regulation of Endothelial Gene Expression. *Circulation Research*, 2018, vol. 122 (2), 231-45 [0163]
- OTTEN, C.; KNOX, J.; BOULDAY, G.; EYMERY, M.; HANISZEWSKI, M.; NEUENSCHWANDER, M.; RADETZKI, S.; VOGT, I.; HAHN, K.; DE LU-CA, C. Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations. *EMBO Mol Med*, 2018, vol. 10 [0163]
- REINHARD, M.; SCHUCHARDT, F.; MECKEL, S.; HEINZ, J.; FELBOR, U.; SURE, U.; GEISEN, U. Propranolol stops progressive multiple cerebral cavernoma in an adult patient. *J. Neurol. Sci.*, 2016, vol. 367, 15-17 [0163]
- ZABRAMSKI, J.M.; KALANI, M.Y.S.; FILIPPIDIS, A.S.; SPETZLER, R.F. Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. *World Neurosurgery*, 2016, vol. 88, 631-639 [0163]